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ABSTRACT 
 
CYTOKINE DYNAMICS, DIAGNOSIS AND TREATMENT OF NEUROINFLAMMATION  
IN CHRONIC CONSTRICTION INJURY RAT MODEL 
 
 
 
By 
Kiran Vasudeva 
July 2015 
 
Dissertation supervised	by	Dr.	John	A.	Pollock 
Chronic neuropathic pain is a serious, worldwide health problem leading to life-long 
treatment and the possibility of significant disability. In this study, neuropathic pain was 
modeled using the chronic constriction injury (CCI) in rats.  The CCI rats exhibited 
hypersensitivity (typical neuropathic pain symptom) to mechanical stimulation of the affected 
paw 11 days post-surgery, at a time when sham surgery animals did not. It is known that immune 
cells play a role in the development of neuropathic pain and to further explore the relationship 
between neuropathic pain and immune cells, we hypothesized that the infiltration of immune 
cells into the affected sciatic nerve can be monitored in vivo by optical imaging. To test this 
hypothesis, an intravenous injection of a novel perfluorocarbon (PFC) nanoemulsion developed 
by J. M. Janjic (PharmD, PhD) and co-workers was used. Post-injection, the nanoemulsion is 
endocytosed by inflammatory cells (e.g. monocytes and macrophages) in a CCI rat. The 
vnanoemulsion carried two distinct imaging agents, a near-infrared (NIR) lipophilic fluorescence 
reporter (DiR) and a 19F magnetic resonance imaging (MRI) tracer (PFC). This study showed 
that in live rats, NIR fluorescence was concentrated in the area of the affected sciatic nerve.  
Furthermore, the 19F MRI signal was observed in the affected sciatic nerve in the perfusion fixed 
rats.  Histological examination of the CCI sciatic nerve sections revealed significant infiltration 
of CD68 positive macrophages.  These results demonstrate that the infiltration of immune cells 
into the sciatic nerve can be visualized in live animals using these methods.  Using the same 
strategy, a theranostic nanoemulsion containing an anti-inflammatory drug, celecoxib, along with 
NIR dye and 19F tracer, was used for the targeted delivery of the drug into the inflammatory cells 
at the site of injury while at the same time providing the ability to track inflammation.  A single 
intravenous injection of the nanoemulsion carrying a low dose of celecoxib (0.24 mg/kg), a 
normally highly insoluble drug, appears to have provided a direct delivery of the drug into the 
inflammatory cells. Single dose intravenous injection of the theranostic nanoemulsion resulted in 
significant relief from the hypersensitivity behavior (mechanical allodynia) that persisted for at 
least four days post-injection.  These findings demonstrated that celecoxib-containing theranostic 
nanoemulsion based therapy is an effective tool for the simultaneous tracking and treatment of 
the neuroinflammation in a CCI rat model. Inflammation is known to be associated with 
peripheral neuropathy, however the interplay among cytokines, chemokines and neurons is still 
unclear. We hypothesized that the neuroinflammatory interaction can be defined by using a 
computational modeling approach, based on the dynamics of the protein expression of various 
inflammatory mediators in the sciatic nerve of the CCI rats. Using Dynamic Bayesian Network 
inference, we identified Interleukin (IL)-18 as a central node associated with neuropathic pain in 
the CCI rat model. Immunofluorescence supported a role for inflammasome activation and 
vi
induction of IL-18 at the site of injury. Combined in-vivo and in-silico approaches may thus 
highlight novel molecular targets associated with peripheral neuropathy that can be the target of 
future theranostic nanoemulsion-based therapy.   
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1Chapter 1 
INTRODUCTION 
1.1 Nociceptive, Inflammatory And Neuropathic Pain 
Pain is “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” [1]. Pain can be broadly 
classified as nociceptive, inflammatory or pathological pain (neuropathic or dysfunctional pain). 
Nociceptive pain is associated with a noxious stimulus and is a protective physiological warning 
to avoid potential tissue damage [2]. Nociceptive pain is acute in nature, occurs only in the 
presence of the stimulus and goes away in the absence of the stimulus. Examples of nociceptive 
pain are pin pricking during an injection and transient intense mechanical pressure on skin. Both 
nociceptive and physiological sensations such as heat, cold, touch and pain are felt via free nerve 
endings of the afferent fibers of the somatosensory nervous system called receptors. The 
receptors that respond specifically to a noxious stimulus are called as nociceptors. They can be 
categorized based upon the type of stimuli they respond to, such as thermal nociceptors for 
sensing heat. There are various types and subtypes of afferent nerve fibers that are responsive to 
different sensations. Painful stimuli are normally felt via Aδ (myelinated) and C (unmyelinated) 
type afferent fibers. These receptors are present on skin, muscles, joints, epithelial tissue and 
internal organs. A stimulus can be innocuous or noxious depending upon the intensity. During 
inflammatory or neuropathic pain, an innocuous stimulus could be perceived as noxious due to 
the presence of inflammatory mediators along with changes in the expression of ion channels and 
neurotransmitters that lead to amplified pain signals [3]. The nerve impulse generated via the 
receptor is transmitted to the dorsal root ganglion (DRG) and the central nervous system (spinal 
cord and brain) by the afferent fibers. The pain perception is not only based upon the neuronal 
2changes in the peripheral nerves, but is greatly dependent upon the impulse transmission and 
neural circuits in the spinal cord and brain [2]. Inflammatory pain, also known as adaptive pain, 
typically occurs due to tissue injury and persists until the inflammation is resolved. Therefore, 
inflammatory pain is protective in nature, as it restricts the movement of the inflamed region and 
helps improve tissue healing. Inflammatory pain is associated with hypersensitivity due to 
increased responsiveness of the nociceptors such as hypersensitivity to thermal stimuli (e.g. 
thermal hyperalgesia). Neuropathic pain, on the other hand, is associated with pathology of the 
neural tissue (i.e. associated with the somatosensory nervous system) [4], which may include 
neuronal demyelination or axonal injury. It could also be defined as “pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system” [5]. There can be 
multiple etiologies for neuropathic pain, such as metabolic, ischemic, toxins, physical trauma and 
infection. Neuropathic pain is also called maladaptive pain [6], because it is not a protective 
response; rather it leads to amplified pain signals due to changes in neurons and neural circuits in 
the peripheral and central nervous system. Axonal injury could be due to complete transection of 
the neuron or changes in the metabolism/ transport of the axoplasm within the axon. Based upon 
the location of the lesion in the nervous system, neuropathic pain could be categorized as 
peripheral, if peripheral nerves are involved, and central, if the brain and/or spinal cord are 
involved. Besides neuronal lesions, there is active participation of the immune cells and 
inflammatory mediators within the nervous system to cause neuropathic pain through 
neuroinflammation [7].  
 
 
 
31.2 Why Use The Chronic Constriction Injury (CCI) Rat Model? 
There are various animal models available to study neuropathic pain. The majority of the 
neuropathic pain conditions in humans involve partial damage to the nerve rather than complete 
transection.  CCI leads to partial damage to the nerve thus simulating commonly found 
neuropathic conditions [8]. The CCI rat model is a well-established and well-characterized 
model in the field of neuropathic pain [9]. CCI of the sciatic nerve is associated with 
hypersensitivity behavior, which is indicative of spontaneous or evoked pain in rats. ‘Positive’ 
symptoms (i.e. hypersensitivity behavior) include spontaneous pain (pain arising without any 
stimuli) and evoked pain such as allodynia or hyperalgesia. Allodynia is pain due to a stimulus 
that is innocuous (i.e. does not normally cause pain). Hyperalgesia is increased response to a 
stimulus that is normally painful [1]. Therefore, the hallmark of neuropathic pain, development 
of hypersensitivity behavior, (i.e. spontaneous or evoked pain-like behaviors) can be studied by 
using the CCI rat model [8] Spontaneous pain-like behavior in rats (post-CCI), is demonstrated 
by paw licking, avoiding weight bearing on the affected limb, limping most likely due to the 
ongoing pain and relatively less movement of the affected hind leg [10]. Evoked pain-like 
behavior is demonstrated in rats by tactile allodynia after the CCI injury and persists for up to 
two months post-CCI. Also, the common sciatic nerve is targeted in the CCI rat model, which is 
easily located and manipulated due to its relatively large size. 
 
 
 
 
 
41.3 CCI Causes Wallerian Degeneration And Neuroinflammation 
 
Figure 1-1 Inflammatory events following Chronic Constriction Injury (CCI)     
                    in rats [11-20]. 
During CCI surgery, four sutures are loosely tied over the common sciatic nerve using 4-
0 chromic gut suture. The chromic gut suture material causes chemotaxis of the immune cells at 
the site of ligation [11] and the pressure applied to the nerve by the ligatures causes epineurial 
edema. The nerve compression and ischemia that initiate axonal degradation distal to the site of 
injury disrupt axon-Schwann cell organization, which activates Schwann cells that leads to 
axonal fragmentation and hence myelin degradation. The beginning of myelin degradation 
further directs the activation of mast cells, neutrophils, and macrophages and exacerbates the 
cascade of inflammation at the site of injury [12, 13].  Additionally, activated Schwann cells are 
an important source of inflammatory cytokines and attract hematogenous monocytes [13]. The 
5resident macrophages become activated and also produce cytokines to attract hematogenous 
monocytes. The macrophages begin to appear around day 3 post-injury and peak at about 2 
weeks post-injury [13, 14]. The function of the macrophages is to remove the degenerating axons 
and myelin debris and also help in axonal regeneration by removal of axon growth inhibitors 
[13]. The accumulation of active immune cells helps to remove the degenerating axons and 
produce inflammatory mediators to enhance the inflammatory cascade [13]. Although all types 
of axons are damaged (i.e. large myelinated, small myelinated and unmyelinated), the majority 
of the axons affected by CCI are large myelinated axons [15].  
This sequence of events initiated due to axonal injury in the peripheral nervous system is 
called Wallerian degeneration. The loss of large myelinated axons (i.e. axonal degeneration) 
peaks around 7-10 days post nerve injury, followed by remyelination around 14-28 days post 
nerve injury [13]. The degenerating axons produce a variety of inflammatory mediators that 
sensitize the peripheral nerve endings by changing the expression of ion channels and 
neurotransmitters [3]. These amplified peripheral nerve impulses are sensed by the DRGs, which 
in turn lead to activation of spinal microglia and re-organization of synapses in the spinal cord 
and brain [3]. Activated satellite glial cells produce nerve growth factor β (NGF-β), tumor 
necrosis factor (TNF) and Interleukin 1β (IL-1β) [16]. In addition, reduced uptake of glutamate 
(excitatory neurotransmitter) is found to occur in the activated glial cells in DRGs, contributing 
to the hyperexcitability during neuropathic pain [16]. Another contributor towards the spread of 
neuroinflammation in the DRGs is the increase in the expression of connexin-43 (Cx-43, gap 
junction protein), which leads to easier trafficking of the inflammatory cytokines within the cells 
[17]. These changes also lead to activation of astrocytes and microglia in the spinal cord and 
brain, which in turn release cytokines that support inflammation and contribute to the 
6maintenance of neuropathic pain [16]. Due to demyelination, axonopathy, and local 
inflammatory response at the site of the lesion, there is an increase in ectopic firing of the 
affected neurons, perceived by the corresponding DRGs, and leading to central sensitization. The 
ectopic activity is observed in both Aδ and C fibers [18-20].  
Wallerian degeneration, therefore, is caused by a combination of innate and adaptive 
responses including both cellular and humoral components [16]. The innate immune response 
includes activation of complement, Toll Like Receptors (TLR2, TLR3 and TLR4), and activation 
of resident immune cells (i.e. mast cells, macrophages and neutrophils), whereas the adaptive 
response includes the activation of T lymphocytes [16]. 
1.4 Inflammatory Mediators During CCI  
Various inflammatory mediators are released during inflammation at the site of nerve 
injury. Inflammatory mediators are in a dynamic state and under strict regulation to maintain a 
balance between the cytokines and chemokines at any given time during the progression of 
inflammation. As shown in figure 1-1 as well as described above, cyclooxygenase 2 (COX-2) 
enzyme and prostaglandin E2 (PGE2) are not the only mediators contributing to the neuropathic 
pain. As mentioned earlier, various types of immune cells participate in the production of 
inflammatory mediators at the site of CCI. The first cells to respond to the injury are the resident 
cells. Besides neurons, the resident cells around the peripheral nerve are the endothelial cells, 
Schwann cells, fibroblasts, mast cells, macrophages and the dendritic cells. Following injury, 
Danger Associated Molecular Patterns (DAMPs) such as ATP, proteins and lipids are released 
outside the cells due to cell damage (neuronal damage).  This leads to the activation of the ATP 
receptors (purinergic receptors; P2X and P2Y) and TLRs that activate neurons and other resident 
cells to produce inflammatory mediators such as TNF-α [3]. P2X receptors (ATP gated calcium 
7ion channels) and P2Y receptors (G protein-coupled receptors) are found in the peripheral or 
central nervous system [21]. Activated Schwann cells produce pro-inflammatory cytokines such 
as TNF, IL-1β, IL-6, PGE2 and monocyte chemotactic protein 1 (MCP1) that promote the 
neuroinflammation [16]. Besides these, Schwann cells also produce nerve growth factor β (NGF-
β) that sensitizes the neurons to cause allodynia and hyperalgesia [22]. 
The underlying mechanism that activates the resident mast cells following nerve injury is 
still unclear. However, it is known that the activated mast cells release various cytokines such 
TNF-α, histamine, serotonin and prostaglandins. These mediators lead to sensitization of the 
nociceptors and also lead to recruitment of hematogenous immune cells, such as neutrophils, to 
the site of the lesion [16]. In response to the amplified nerve signals and the release of 
inflammatory mediators in the peripheral nerve, cells in the DRG become activated.  For 
example, the satellite glial cells and the microglia become activated and exacerbate the 
inflammatory cascade by producing pro-inflammatory mediators themselves [23]. In the spinal 
nerve ligation (SNL) model of neuropathic pain, the satellite glial cell protein, glial fibrillary 
acidic protein (GFAP), had elevated expression from day 1 up to day 10 post-SNL [24]. 
Activated satellite glial cells produce NGF-β, TNF and IL-1β [16]. TNF-α is the first cytokine 
produced at the site of peripheral nerve injury from the mast cells [16]. TNF-α is upregulated 
from 6 hours to 24 hours post-CCI in the injured sciatic nerve and day 1 to day 3 post-CCI in the 
ipsilateral lumbar 4, 5 and 6 (L4, L5 and L6) DRGs [25]. Under the influence of the mediators 
produced by the activated resident immune cells, neutrophils migrate to the site of injury and 
reach their peak numbers at twenty-four hours post-injury [16]. Neutrophils produce cytokines 
such as TNF, IL-1β, IL-2 and IL-6 that can lead to neuronal sensitization as well as neuronal 
death due to the reactive oxygen species released as a result of oxidative burst in the neutrophils 
8[16]. Infiltrating hematogenous macrophages are known to release TNF, IL-1β, IL-6, reactive 
oxygen radicals, PGE2 and PGI2 [16]. T lymphocytes can be found at the affected sciatic nerve 
on day 3 post-CCI and peak in numbers at the site of injury at 3 weeks post-CCI [26]. T 
lymphocytes can be subdivided into helper T cells subtype 1 (Th1), helper T cells subtype 2 
(Th2) or helper T cells subtype 17 (Th17). Th1 cells are known to produce pro-inflammatory 
cytokines Interferon γ (IFN-γ) and TNF, whereas Th2 cells are known to produce anti-
inflammatory cytokines such as IL-4, IL-5, IL-10 and IL-13 [27]. Th17 cells produce pro-
inflammatory cytokine IL-17 [28].  
COX-2 enzyme is induced in the infiltrating (activated) macrophages at the site of the 
neuronal injury.  COX-2 activation leads to production of PGE2 and PGI2, which sensitize the 
neurons [29]. Activated Schwann cells are also known to produce PGE2 [30]. Prostaglandins 
play a central role during Wallerian degeneration and the maintenance of neuropathic pain [29, 
31]. Following peripheral nerve injury, there is elevated production of prostaglandins that are 
derived from arachidonic acid by the activation of COX-1 and COX-2 enzymes in the 
infiltrating, activated macrophages [31]. For example, COX-2 enzyme and eicosanoid PGE2 are 
involved in the pathogenesis of neuropathic pain, contributing to peripheral sensitization of the 
nociceptors and elevated expression of P2X3 and TRPV1 receptors in the associated DRGs [29, 
32, 33]. Local or systemic administration of selective COX-2 inhibitors such as ketorolac, 
indomethacin, etodolac and celecoxib has been shown to be effective in reducing the 
hypersensitivity during neuropathic pain [29, 33-36]. Celecoxib also resulted in improved 
functional recovery after the sciatic nerve crush injury in a rat model [34].  However, sustained 
high dose administration of non-steroidal anti-inflammatory drugs (NSAIDs) can exhibit a range 
of adverse cardiovascular and gastrointestinal effects [29, 33-36].  
91.5 Dual Mode Nanoemulsion 
A dual mode (NIR/19F MRI) nanoemulsion (V-Sense DM NIR) was designed and 
developed by Dr. Jelena M. Janjic, Associate Professor of Pharmaceutics, Department of 
Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University and Dr. Anthony 
Balducci, PhD from Celsense Inc. Pittsburgh PA. Methodology for using this nanoemulsion for 
imaging macrophages and inflammation was adapted from the earlier published work [37, 38]. 
1.6 Theranostic Nanoemulsion 
‘Theranostics’ is a term used to describe the simultaneous diagnosis and therapy for an 
illness [39]. A theranostic nanoemulsion was used in this study for simultaneous visualization 
and treatment of neuropathic pain in a CCI rat model. The theranostic nanoemulsion used in this 
study was originally designed and developed (by Dr. Jelena M. Janjic and Sravan K. Patel; 
Graduate School of Pharmaceutical Sciences, Duquesne University), for the purpose of imaging 
and inhibiting inflammation via targeted delivery of COX-2 inhibitors directly to the activated 
macrophages, These agents were provided to us and were used in-vivo without further 
modifications. Due to proprietary issues, the details of the theranostic nanoemulsion cannot be 
included in this dissertation, while related nanoemulsion designs have been published earlier [40-
43]. 
1.7 Inflammasome 
As previously mentioned, following tissue injury, DAMPs such as heat shock proteins, 
ATP and DNA are released from the injured cells. After phagocytosis by the innate immune cells 
(e.g. macrophages and neutrophils), the DAMPs act as ligands for intracellular nucleotide-
binding oligomerization domain-like receptors (NLRs) that are found in the cytoplasm of the 
innate immune cells [44]. The interaction of the ligand with the NLRs leads to assembly of 
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various inflammasome proteins in the cytoplasm, which activate caspase-1, a pro-inflammatory 
enzyme [44]. Caspase-1 causes maturation and release of IL-1β and IL-18 from the innate 
immune cells via nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κB) 
transcription factor activation. NF-κB activates the promoter region of IL-1β gene, and increases 
the expression of pro-IL-1β. Active caspase-1 further leads to maturation of pro IL-1β and pro 
IL-18 to active IL-1β and IL-18 and their subsequent release [45]. Caspase-1 itself is released 
alongside active IL-1β and IL-18 outside the cells [44]. In this study, we demonstrate using a 
CCI rat model that inflammasome activation may play an important role during peripheral 
neuropathy. 
1.8 Computational Modeling 
The inflammatory diseases/syndromes have complex interactions among various 
inflammatory mediators throughout the course of the disease [46]. It is important to recognize 
that the same mediator can act as pro-inflammatory at one time point and anti-inflammatory at 
another time point. Therefore, it is more relevant to study the associations among various 
cytokines over the entire period of disease progression rather than at a single point in time [47]. 
Studying individual mediators at specific time points during the disease progression may not 
provide an accurate representation of the inflammatory interactions [47]. To overcome this 
problem, data driven computational modeling can be utilized, which is one of the methods used 
to study complex interactions, such as cytokine interactions during inflammation. By using this 
method, the data derived in a laboratory in a specific system (such as inflammation) can be 
analyzed to predict the events during the disease progression in that system [48]. In the current 
study, in collaboration with Dr. Yoram Vodovotz and his co-workers from University of 
Pittsburgh, we have used the data driven computational modeling to identify dependent 
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interactions among various inflammatory mediators/cytokines after the CCI surgery, based upon 
the data derived in the laboratory (cytokine concentrations at the site of nerve injury at multiple 
time points throughout the progression of CCI) as input for the Dynamic Bayesian Network 
(DBN) inference. Similarly, network based models such as DBN have previously been shown to 
reveal interactions among related variables [49]. However, the data driven computational 
modeling provides information about the interactions among different variables and not the 
mechanisms or steps leading to the disease progression [50]. Non-linear time series analysis was 
performed in the current study due to the established fact that the cytokine levels change in a 
non-linear fashion over time (i.e. dynamic/non-linearly) [51]. The cytokine level changes 
occurring during inflammation are non-linear due to involvement of multiple mediators and their 
regulation as multiple feedback loops operating in various directions [51]. Using this approach, 
the concentrations of 14 different inflammatory mediators at various time points at the affected 
sciatic nerve were used as input for the computer software algorithm to define the interactions 
among various cytokines during the CCI induced inflammation progression over a period of 18 
days post-injury. The limitations of the data driven computational approach are its dependence 
on the data collected in the laboratory for a specific condition, data collection time points and the 
parameters chosen, and the limitations of interpreting a small amount of data due to financial or 
other constraints [50].  Also, the conclusion drawn through data driven computational modeling 
is only a prediction based upon a given set of experiments and therefore needs to be biologically 
tested in the laboratory [48].   
1.9 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) 
Anti-inflammatory drugs are broadly classified as steroidal or non-steroidal anti-
inflammatory drugs (NSAIDs). NSAIDs act by inhibiting the cyclooxygenase (COX) enzyme, 
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which is required for the production of eicosanoid family of lipids including prostaglandins, 
prostacyclins and thromboxanes, all derived from arachidonic acid (free fatty acid) [52]. Out of 
these three compounds, only prostaglandins are involved in causing inflammation and pain. 
Thromboxanes and prostacyclins have contrasting physiological functions and participate for or 
against blood clotting respectively, by affecting the platelets to maintain homeostasis in the 
circulatory system [53]. COX enzymes can be further subdivided into two isoforms; COX-1 and 
COX-2. Both COX-1 and COX-2 lead to production of intermediate, highly unstable PGH2 from 
arachidonic acid which is then converted into prostaglandins (PGs) (i.e. PGI2, PGD2, PGE2, 
PGF2), thromboxane A2, and leukotriene products via various synthases [53]. Both COX-1 and 
COX-2 are constitutively expressed differentially in various cell types [54] however COX-2 is 
inducible and is up-regulated in the non-neuronal cells during inflammation, stress or 
tumorigenesis and participates in causing fever, inflammation and pain via prostaglandin 
synthesis [55-57]. Macrophages are the crucial immune cells participating during acute and 
chronic peripheral nerve injury for the generation and maintenance of neuropathic pain [58, 59]. 
COX-2 is up-regulated in the activated macrophages in various types of peripheral nerve injury 
rat models including CCI rat model where COX-2 up-regulation has been observed from around 
two weeks to two months post-CCI, and for days to years in the human patients with acute or 
chronic neuropathic pain [8, 29, 57]. COX-2 and prostaglandins, especially PGE2, have been 
strongly implicated in the development and maintenance of neuropathic pain [29, 56, 60, 61]. 
After its release, PGE2 binds to its receptors (EP1, EP2, EP3 and EP4), which are G protein-
coupled receptors expressed on immune cells and DRG neurons [60]. EP1 and EP4 have been 
specifically reported to be of larger significance during neuropathic pain, contributing to 
peripheral and central sensitization by reducing the threshold for depolarization in injured 
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neurons and blocking glycine (inhibitory neurotransmitter) in the spinal cord [29, 62, 63]. 
Various non-selective COX inhibitors (i.e. ketorolac, ibuprofen) [29, 33, 64]; selective COX2 
inhibitors (i.e. etodolac, celecoxib) [33, 35, 64] and PGE2 receptor antagonists can reduce 
hypersensitivity associated with neuropathic pain [62]. It is well known that prolonged systemic 
administration of non-selective COX inhibitors causes adverse effects such as gastric ulcers [65]. 
On the other hand, selective inhibition of COX-2 has been associated with significantly reduced 
gastric ulcerations as compared to non-selective NSAIDs [65]. Based on these findings, in the 
current study a selective COX-2 inhibitor, celecoxib was chosen for the CCI treatment group.  
Even though, selective COX-2 inhibitors are effective in the pre-clinical neuropathic pain 
animal models; their prolonged use at high therapeutic systemic doses has been associated with 
serious side effect of thrombosis leading to adverse circulatory and cardiac sequelae [53]. High 
systemic doses of celecoxib are required to achieve and maintain its therapeutic effects due to its 
poor water solubility and low bioavailability [66]. Previously, nanoemulsions have been used as 
an efficient drug delivery platform for the drugs with low water solubility such as doxorubicin, 
flurbiprofen and celecoxib [40, 42, 67, 68]. Besides efficient and targeted drug delivery, 
nanoemulsions also protect the drug from enzymatic degradation or hydrolysis during circulation 
and reduce the therapeutic doses of the drugs, thus decreasing the side effects due to high doses 
of the drug otherwise needed [68]. Therefore, in the current study, celecoxib was administered as 
a nanoemulsion designed by Janjic and coworkers [42, 43] for the targeted drug delivery directly 
into the macrophages with a goal to bypass the systemic side effects of the drug.  
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1.10 Specific Aims  
 
Aim 1: To visualize the in-vivo inflammatory changes associated with nerve injury in a CCI rat 
model. 
Hypothesis 1: Based on earlier studies [37, 38], we hypothesized that the neuroinflammation 
will be visualized in-vivo by near infra-red (NIR) imaging and 19F magnetic resonance imaging 
(MRI) by intravenous injection of a dual mode nanoemulsion containing NIR dye and 19F tracer 
[40-43, 69-71].  
Aim 2: To visualize and treat the neuroinflammation by earlier developed nanoemulsion for the 
targeted delivery of celecoxib along with NIR dye and an MRI tracer [40-43] directly into the 
inflammatory cells as a theranostic nanoemulsion in a CCI rat model. 
Hypothesis 2: We hypothesized that the celecoxib-containing theranostic nanoemulsion [40-43] 
will lead to a reduction in the hypersensitivity (mechanical allodynia) in a CCI rat model due to 
COX-2 inhibition in the macrophages at the injured sciatic nerve, along with visualization of the 
neuroinflammation in-vivo. 
Aim 3: To identify a dynamic network of interactions among various inflammatory mediators 
over a period of time and predicting the principle drivers of neuroinflammation by computational 
modeling, based upon the dynamic changes in the cytokine levels at the site of injury in-vivo in a 
CCI rat model over a period of 18 days. 
Hypothesis 3: We hypothesized that the dynamic network of interactions among various 
inflammatory mediators over a period of time and the principle drivers of neuroinflammation can 
be predicted by computational modeling, based upon the dynamic changes in the cytokine levels 
at the site of injury in-vivo in a CCI rat model over a period of 18 days. 
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Imaging Neuroinflammation In Vivo In A Neuropathic Pain Rat 
Model With Near-Infrared Fluorescence And 19F Magnetic 
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 2.1 Introduction 
 
Pain is a public health problem that has deleterious effects on social, mental, physical and 
economic health of its sufferers [72].  Pain caused by injury or disease associated with the 
somatosensory nervous system is called neuropathic pain [4].  Recent studies have estimated that 
at least 6 million Americans suffer from neuropathic pain [73]. Other studies indicate that 
neuropathic pain is usually associated with nerve inflammation [20], which occurs when 
leukocytes such as macrophages infiltrate the nerve.  Understanding the role of key inflammatory 
cytokines and immune cells involved in neuropathic pain could lead to a deeper understanding of 
the signaling mechanisms involved in hypersensitivity as well as better diagnostic and treatment 
strategies.  
The chronic constriction injury (CCI) rat model [8] is a well-characterized example of 
chronic peripheral neuropathic pain [74].  This model is widely used to simulate Complex 
Regional Pain Syndrome type II observed in humans (CRPS II, earlier called causalgia) [8]. 
CRPS II develops when a major peripheral nerve is injured [75] and includes persistent pain and 
mechanical allodynia [76].   
Significant advances have been made in understanding the molecular basis of the diseases 
and conditions of chronic pain and the hypersensitivity associated with CCI.  In many cases, 
hypersensitivity correlates with changes in the expression of specific ion channels [77].  Among 
these are cation channel proteins including the Transient Receptor Potential (TRP), a superfamily 
of receptors [78] that are known for being involved in a variety of sensory processes including 
nociception and pain [79, 80].  In CCI, there is evidence that seven days after the CCI surgery, 
TRPV1 protein, but not mRNA expression increases in the Dorsal Root Ganglia (DRG) [81, 82].  
Furthermore, neuroinflammation has been associated with CCI-induced mechanical 
17
hypersensitivity. Clatworthy and coworkers [83] showed that inflammation plays a key role in 
pathophysiology of neuropathic pain.  Furthermore, macrophages have been shown to play a 
central role in causing the inflammation that contributes to peripheral neuropathies [84].  It has 
also been demonstrated that Wallerian degeneration occurs in CCI rat model [7].  During 
Wallerian degeneration, resident macrophages and the Schwann cells are the first cells to 
respond to the insult and together they initiate the axonal degeneration phase of the distal portion 
of the damaged nerve.  Within the first three days of nerve injury, acute inflammation is evident 
with the infiltration of neutrophils reaching the site of injury via diapedesis [14].  The peak in 
neutrophil infiltration is reached within 24 hours of injury.  From day 4 to day 14 post injury, 
hematogenous macrophages infiltrate the injured nerve area, reaching a peak around 1 week post 
injury [14].  One of the roles of these macrophages is to remove the degenerating nerve tissue 
debris and to cause inflammation [14]. The infiltration of these immune cells into damaged nerve 
tissue is an important component of the inflammatory process.  However, the role of 
inflammatory cell infiltration into the site of neuronal injury and how that initiates chronic pain 
is not well understood.  Understanding this process will ultimately lead to the development of 
new therapeutic agents and better pain management.  
To study infiltrating immune cells in a rat chronic pain model, we used a novel NIR 
(near-infrared) labeled perfluoro-15-crown-5 ether (PCE) nanoemulsion [37], shown to 
preferentially label macrophages in culture and upon intravenous administration.  
Perfluoropolyethers (PFPEs), including PCE, have been used for 19F MRI (magnetic resonance 
imaging) in multiple animal models [85-88].  Specifically, PFPE nanoemulsions  have become a 
powerful tool for imaging inflammation in varied disease models, from acute organ rejection to 
rheumatoid arthritis [89].  PFPE nanoemulsion droplets are taken up from the blood stream by 
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phagocytic cells including monocytes and macrophages and carried by these cells to sites of 
inflammation.  PFPEs in the nanoemulsions are biologically and chemically inert, and are not 
degraded by the phagocytic cells, which gives PFPEs advantage over other imaging modalities 
[90]. The 19F MR signal remains unchanged during the lifetime of the labeled cell and can be 
directly correlated to the immune cell number at the site of interest [91]. Further, 19F MR signal 
is specific for the introduced nanoemulsion and provides an unambiguous signature of 
monocytes and macrophages in vivo. In a recent study [37] we reported in vivo inflammation 
imaging demonstrating that NIR and 19F MRI can be used as complementary imaging modalities 
for identifying underlying cellular mechanisms in inflammation.  
Previously, aspects of the role of inflammation in neuropathic pain have only been 
established by ex vivo techniques [92-95].  To the best of our knowledge, there are no reports on 
visualizing neuroinflammation in live animals using the CCI model of neuropathic pain. While 
19F MRI has been used previously to image in vivo neuroinflammation in the peripheral nervous 
system [96], we are describing for the first time a novel method to visualize the in vivo 
inflammation associated with nerve injury in the CCI rat.  To achieve this, we are using a newly 
developed nanoemulsion-based dual mode imaging probe [37].  We find that NIR and 19F MRI 
can be used to monitor inflammation at the site of injury on the sciatic nerve.  Using multiple ex 
vivo imaging techniques (NIR, 19F MRI and histology), we demonstrate that macrophages have 
infiltrated the sciatic nerve following CCI.  We discuss the implication of a noninvasive 
assessment of neuropathic pain for use in studying pain associated with the hypersensitivity 
caused by CCI. 
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2.2 Materials and Methods 
2.2.1 Ethics Statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institute of Health, and the 
Institutional Animal Care and Use Committee (IACUC) at Duquesne University approved the 
animal protocol (Protocol 1109-10).  All surgical procedures were performed under isoflurane 
anesthesia.  Male Sprague-Dawley rats weighing 250-350 g were used in this study (Hilltop Lab 
Animals, Inc., Scottdale, PA).  Rats were maintained on a 12:12 hour light-dark cycle and were 
given ad libitum access to water and purified chow.  Purified chow has been demonstrated to 
reduce non-specific fluorescence caused by plant materials in basic chow in the LI-COR 
Bioscience Application Note: In Vivo Animal Imaging Diet Consideration [97]   
2.2.2. Chronic Constriction Injury  
The chronic constriction injury (CCI) method developed by Bennett and Xie [8] was used 
to induce neuropathic pain in the sciatic nerve of rats (Figure 2-1A).  Animals were divided into 
three groups; CCI, sham and naïve un-operated control.  Briefly, under general anesthesia, the 
common sciatic nerve of the CCI animals was exposed by making an incision through the skin 
and carefully separating the muscles in the mid thigh region of right hind limb.  Four ligatures 
were tied around the common sciatic nerve using 4-0 chromic gut suture.  Care was taken to 
ensure that the ligatures were secured in place without restricting epineurial blood flow.  The 
muscle layer was closed using 4-0 chromic gut suture followed by skin closure using 9 mm 
stainless steel wound clips. Sham rats underwent identical surgery except that the ligatures were 
not tied around the nerve.  Naïve control rats did not undergo any surgical procedures and are 
referred to as un-operated controls. 
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2.2.3 Behavioral Testing 
On the day of surgery, prior to commencement of any surgical procedures, CCI, sham 
and control rats underwent baseline assessment for mechanical sensitivity.  Behavioral testing 
was repeated on day 8 and day 11 post-surgery.  Following previously established methods, 
mechanical pain threshold was assessed by applying calibrated Semmes-Weinstein 
monofilaments to the plantar surface of both the left and right hind paw, specifically in the 
cutaneous region that is innervated exclusively by the sciatic nerve [98, 99].  
A linear regression was used to estimate each rat’s 50% withdrawal threshold.  As 
previously described [98], rats were placed on a metal grid and covered with a Plexiglas cover. 
The lowest-caliber filament (0.41g) was pushed onto the plantar surface of the right hind paw 5 
times until the filament bent; 2 to 3 seconds separated each push. Five minutes later, the left paw 
of the same rat was similarly assessed. Not less than 5 minutes after the left paw was assessed, 
the entire procedure was repeated. In this way, the right and left paws were probed with the 0.41 
g filament 10 times, and the number of withdrawals was recorded. In ascending order, each 
filament was so tested until the rat withdrew from all 10 pushes of a single-sized filament or until 
the largest-caliber filament was tested. 
To estimate the force from which the rat withdrew 50% of the time, force (in grams) was 
regressed on withdrawal frequency for all 5 filaments by using simple linear regression. The 
force at which the rat withdrew a paw on 5 of 10 pushes (50% withdrawal threshold) was 
predicted by using the regression equation. If the 50% withdrawal threshold so calculated was 
greater than 15.13g, the highest-caliber filament used (15.13g) was recorded as the gram force. If 
the rat failed to respond to any of the filaments, 15.13g was recorded as the 50% withdrawal 
threshold. The same investigator always performed this test.  Threshold levels were then 
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expressed as a difference score between the pain threshold for the right and left hind paws.  
These values were normalized to differences that existed between the 2 paws at baseline. 
Statistics were performed using SPSS V12.0 software.  We observed significant difference 
between the CCI condition and the un-operated control rats (Kruskal-Wallis 1-way ANOVA by 
ranks; P≤0.05).  All behavioral testing was done by an experimenter blinded to the surgical 
treatment.  Rats used for the detailed behavioral testing consisted of a separate cohort from those 
used for the DRG analysis and in vivo imaging.  All CCI animals were observed to exhibit 
guarding, paw licking and or paw lifting behaviors by day 8 post-surgery.  However, only normal 
grooming behaviors were seen in the sham and un-operated controls. 
2.2.4 Dorsal Root Ganglia Dissection 
Nine days post-surgery, bilateral L3, L4 and L5 DRG were dissected from CCI rats via 
laminectomy.  These ganglia were chosen because neurons within them provide the sensory 
component of the sciatic nerve [100, 101].  Ganglia were rapidly removed and stored in RNA 
later solution (Qiagen) for later use.  Rats were sacrificed after completion of DRG extraction. 
2.2.5 RNA Isolation And qPCR Analysis 
 Quantitative PCR (qPCR) and the comparative cycle threshold (CT) method [102] were 
used to determine if the CCI altered the mRNA expression of TRPV1, Neuropeptide Y (NPY) 
and Growth-associated Protein 43 (Gap43) relative to Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) in L5 DRG 12 days post-surgery (see Supplemental Table 2-S1 for 
primers).  GAPDH, an important enzyme in glycolysis, serves as a control transcript for 
comparisons to transcripts from other genes expressed within the same tissue [103].  Tissue 
samples were removed from the RNA later solution, processed over QiaShredder columns and 
RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA). To prevent any genomic DNA 
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contamination, each RNA sample was treated with DNase I (Invitrogen, Grand Island, NY).  
Supplemental Table 2-S1. Primer Sequences used for this study. 
GAPDH      
 Tm (C) GC content 
(%) 
Sequence (5’-3’) Amplicon length 
Forward 55.4 55.0 CACAGTCAAGGCTGAGAATGG  
Reverse 54.7 55.0 CGATGCCAAAGTTGTCATGG  
    300bp 
TRPV1     
 Tm (C) GC content 
(%) 
Sequence Amplicon length 
*Forward 56.2 55.0 GTGATCGCTTACAGCAGCAG  
*Reverse 55.0 55.0 CGGTGACTCGGAAATAGTCC  
    238bp 
NPY     
 Tm (C) GC content 
(%) 
Sequence Amplicon length 
Forward 49.6  47.4 GACAGAGATATGGCAAGAG  
Reverse 48.9 47.4 CTAGGAAAAGTCAGGAGAG  
    148bp 
Gap43     
 Tm (C) GC content 
(%) 
Sequence Amplicon length 
Forward 51.0 50.0 CCTAAACAAGCCGATGTG  
Reverse 49.7 44.0 TTTGGCTTCATCTACAGC  
    150bp 
 
* primer sequences acquired from Charrua A, Reguenga C, Paule CC, Nagy I, Cruz F, Avelino 
A. (2008). Cystitis is associated with TRPV1b-downregulation in rat dorsal root ganglia. 
Neuroreport 19(15): 1469-1472.  
 Using RNA as the template, one-step qPCR was performed with gene specific primers.  
Reverse-transcription was performed on the StepOnePlus machine using the Power SYBR® 
Green RNA-to-CT™ 1-Step Kit (Applied Biosystems).  RNA extracted from each rat was 
analyzed separately in triplicate.  Analysis of amplified cDNA products by agarose gel and 
subsequent DNA sequencing confirmed the identity of the intended PCR product.  All statistical 
tests were performed using SPSS software. Assumptions of ANOVA were met as indicated by 
Mauchly’s Test of Sphericity and Levine’s Test for Equality of Variances. Significance of the F 
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statistic was defined as p ≤ 0.05.  TRPV1 mRNA levels in right (ipsilateral to the nerve injury) 
DRG of CCI rats was compared to right DRG of control (pooled) rats by performing a 1-Way 
ANOVA with treatment as the between-subjects factor. 
2.2.6 Immunohistochemistry And Confocal Microscopy 
 Dorsal root ganglia from control and CCI rats were used for immunohistochemistry to 
explore the protein expression levels of TRPV1.  Under general anesthesia, prior to any surgical 
procedures, the CCI and control rats were injected with DiD Dye (V-22887, Invitrogen, 
Carlsbad, CA) in the plantar region of the right hind paw.  DiD is a lipophilic retrograde tracer 
that will stain all neuronal cells innervating the hind paw.  Post-treatment, all DRGs were 
removed and immediately fixed in 4% paraformaldehyde 1X Phosphate Buffer Saline (PBS) 
solution.  The tissue samples were cryoprotected in 30% sucrose 1X PBS solution for 4 hours. 
After four hours of incubation, 1/3 of the cryoprotectant solution was replaced with Optimal 
Cutting Temperature (OCT) compound (Sakura-Finetek, Torrance, CA) and incubated on a 
rocking shaker overnight. After overnight incubation, samples were embedded in OCT and 20μm 
thick sections were made on a cryostat.  Sections were then fixed in 4% paraformaldehyde 
solution 1X PBS, permeabilized with 0.3% Triton X-100 solution and stained with primary and 
secondary antibodies. The following primary antibodies were used: 1:50 mouse anti-rat 
Neurofilament-M (Neuromics, Edina, MN), 1:50 rabbit anti-rat TRPV1 (Santa Cruz 
Biotechnology, Dallas, TX). The sections were then washed and incubated overnight with anti-
mouse secondary antibodies conjugated to Alexa-546 (Invitrogen, Carlsbad, CA), and anti-
rabbit-FITC (Santa Cruz Biotechnology, Dallas, TX), diluted 1:100 in PBS.  Sections were 
washed in 1X PBS and mounted in Prolong-Gold (Invitrogen, Carlsbad, CA).  Relative 
expression of TRPV1 was determined by comparing the fluorescence intensity for TRPV1 to the 
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fluorescence intensity of DiD, whose fluorescence intensity is not affected by the CCI surgery.  
This was done for labeled neurons from naïve control DRG and CCI DRG using the Leica TCS 
SP2 software version 2.3.  For a double-labeled cell, the overall TRPV1 mean amplitude was 
divided by the overall mean DiD amplitude.  The results of an unpaired t-test showed t= -6.45, 
SD= 0.758E-01 degrees of freedom = 6. The probability of this result, assuming the null 
hypothesis, is 0.0007.  An experimenter blind to treatment did staining and quantification of 
immunohistochemistry. 
 In separate immunohistochemical experiments using comparable protocols, the recovered 
control, sham and CCI sciatic nerves were prepared for examination using mouse anti rat CD68 
antibody (MCA341R, AbD Serotech, Raleigh, NC) and Alexa fluor-488 donkey anti-mouse 
secondary antibody (A-21202, Invitrogen, Carlsbad, CA) to assess the presence of macrophages 
that infiltrate the nerve.   
Cellular uptake of nanoemulsion was performed in the mouse leukemic monocyte 
macrophage cell line RAW 264.7 (ATCC, Manassas VA) as described by Patel et al [42].  
Approximately, 0.3 million cells were seeded on cover slips in 6-well plates in 2 mL culture 
medium per well and grown as adherent macrophages. After 48 h incubation at 37 °C and 5% 
CO2, medium was aspirated and cells washed with 1X PBS. Cells were exposed to 2 mL of 
either fresh culture medium alone or dispersed nanoemulsion-containing medium (10 µL/mL).  
Following 5 h incubation, 1 mL medium was aspirated and cells fixed with 1 mL 4% 
paraformaldehyde in 1X PBS. After 30 minutes at room temperature, the cells were washed with 
1X PBS three times.  Each coverslip with and without nanoemulsion labeled cells was 
transferred to glass slides containing a drop of ProLong® Gold mounting medium. The 
nanoemulsion labeled with DiR (Invitrogen, Carlsbad, CA) was detected with 633 nm laser 
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excitation and emission window of 700 nm to 850 nm. Confocal microscopy was performed on a 
Leica SP2 spectral Laser Scanning Confocal microscope.  A transmission DIC image was 
acquired with each confocal scan. 
2.2.7 NIR Labeled PFPE Nanoemulsion 
 NIR labeled PFPE Nanoemulsion (V-Sense DM NIR) was produced and provided by 
Celsense Inc (Pittsburgh, PA, USA) and was used without further modifications.  Previous 
studies have demonstrated that the nanoemulsion droplets are on the order of 180 - 200 nm in 
size [37]. 
2.2.8 Live Animal Imaging (NIR) 
To follow the localization of emulsion labeled circulating monocytes (monocytes in the 
blood, macrophages in tissue), NIR imaging of the fluorescent label in live rats was performed 
on a LiCOR® Pearl Impulse (LI-COR Biosciences, Lincoln, NE) small animal imaging system. 
For the live animal imaging, rats were fed purified chow (D10012G Research Diets, Inc. New 
Brunswick, NJ), which helps to reduce non-specific fluorescence in the abdominal and thoracic 
region of the animal caused by certain foods. Tail-vein injection of 300 µL of V-Sense DM 
nanoemulsion was performed 8 days after surgery under general anesthesia. Within minutes, the 
injected animals were imaged in the LiCOR imager to establish that the intravenous injection 
was successful and that the nanoemulsion was not leaking subcutaneously within the tail. On day 
11 post surgery, maximum neuroinflammation was predicted based on previous results, and 
another set of NIR imaging was performed under general anesthesia (xylazine, 7 mg/kg / 
ketamine, 80 mg/kg) given intraperitoneally. Simultaneous image acquisition of white light 
(body view) and 785 nm excitation for 820 nm emission were merged and processed in the 
LiCOR Pearl Impulse Software (version 2.0) with linked look-up-tables (LUT). Relative 
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fluorescence was measured from a region of the same size over the sciatic nerve for both left and 
right legs for the naïve, sham and CCI conditions.  This involved identifying a region of interest 
(ROI) around the fluorescent signal evident in the CCI.  That ROI perimeter was then copied to 
the other legs for a given experiment.  In this way, nearly the same number of pixels of area for 
the signal is compared within a given paired experiment.  The ROI images for each rat 
(Supplemental Figure 2-S1) and the tabulation of relative fluorescence from the LiCOR Pearl 
Impulse software (Table 2-S2) are shown in Supplemental Data.  Prism software version 5.0 was 
used to perform analysis of variance (ANOVA) for the entire set of conditions revealing a p 
value < 0.0001 (Supplemental Table 2-S3).  Furthermore, a t-test specifically comparing the 
sham right leg to the CCI right leg reveals a p value <0.0001. Dissected sciatic nerves were 
similarly imaged for NIR fluorescence on a flatbed LiCOR Odyssey Infrared Imaging system.  
An experimenter blinded to experimental conditions did the analysis of NIR Pearl images. 
2.2.9 MRI (1H & 19F) Methods 
1H and 19F MRI was performed on rat legs using a Bruker Biospec Avance III 7-T/21-cm 
system (Bruker Biospin MRI, Billerica MA) and a 35-mm (1H/19F) double resonance birdcage 
coil (Rapid MR International, Columbus OH).  Following perfusion fixation, dissected legs were 
placed in a 50 mL conical tube and positioned in the magnet.  Following pilot scans, the 
anatomical images were collected using a RARE (Rapid Acquisition with Relaxation 
Enhancement) sequence with both axial and a double oblique (parallel to the femur/tibia plane) 
coronal views.  The following acquisition parameters were used: TR/TE 4000/7 ms, RARE 
Factor = 8, NA = 4, 6 x 6 cm FOV, 256 x 256 matrix, 2-mm slice thickness, and 22 or 14 
contiguous slices for axial or coronal views, respectively.  19F MRI was performed at 282 MHz 
with the same slice geometry and the following parameters: TR/TE 3000/7 ms, RARE Factor = 
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4, 6 x 6 cm FOV, 128 x 128 matrix, and NA= 256 or 384 for axial or coronal views, respectively.  
Since the resonance frequencies were centered precisely on the water and the perfluorocarbon 
resonances, 19F and 1H anatomical images were co-registered without additional image 
processing. 
19F NMR spectra for the PFPE nanoemulsion in the dissected sciatic nerves were 
acquired following standard protocols with trifluoroacetic acid (TFA) as the internal standard 
[42].  Nerves were inserted into borosilicate NMR tubes (5 mm diameter) and spectra recorded 
(Bruker, 470 MHz). 19F NMR peak around -92.5 ppm corresponding to fluorine nuclei was 
measured with TFA (set at -76.0 ppm) as reference (Supplemental Figure 2-S2). 
2.3 Results 
In this study, we demonstrate that CCI rats exhibit symptoms of mechanical 
hypersensitivity, which is a hallmark of chronic pain. We also show that dual mode PFPE 
nanoemulsion can be used to reveal the focal point of neuroinflammation by both NIR imaging 
and 19F MRI. Furthermore, we demonstrate that the NIR and 19F signal is arising from CD68 
positive macrophage cells carrying the nanoemulsion that infiltrate the CCI injured nerve.  Due 
to anatomical barriers for free nanoemulsion delivery to the site of injury and considering the 
supporting histological findings, the NIR and 19F MRI signal shown arise from infiltrating cells.  
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Figure 2-1.  Chronic Constriction Injury (CCI) affects behavior, as well as mRNA and 
protein expression. 
A.  Sketch of the sciatic nerve with the chronic constriction injury sutures in place.  
B. Mechanical hypersensitivity in the right hind paw. Bars represent the mean ± SEM 
normalized 50% withdrawal threshold from calibrated Semmes-Weinstein monofilaments (g) for 
each of the treatment groups; un-operated control (Con), sham-operated control (Sham), and 
chronic constriction injury (CCI). The more negative a mean difference score, the lower the pain 
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threshold in the right hind paw. *Significant difference from un-operated control rats (Kruskal- 
Wallis 1-way ANOVA by ranks; P≤0.05). Un-operated and sham-operated control rats did not 
differ in normalized pain thresholds at day 8 or day 11 post-operative. Sample size representing 
each mean indicated on the graph. 
C. Relative Expression of mRNA assessed by qPCR (one step direct priming of mRNA).  mRNA 
extracted from dissected L5 ipsilateral dorsal root ganglia for non-surgical control (Con), sham 
and CCI were used to compare the expression levels of TRPV1, Growth associated protein 43 
(Gap43) and Neuropeptide Y (NPY).  All three genes exhibit elevated levels of transcript 
expression in the CCI condition that were significantly different from control, indicating 
peripheral nerve trauma and neuropathic pain.  For TRPV1, these data show that the CCI-
treatment group was significantly different from the control groups (one-way ANVOA, p<0.05).  
 뼆 뼈 뼔 뼖 뼟 뼡 뼱 럃곃럃 ꇃ 胃雃诃 쎷 胃胃疀 럃럃櫃럃Ã           ᔔ ᘀ쩨 Ȕ
伀儀 J J ᔔ ᘀ쩨 睨 伀㔨 儀Ȕ J J ᔔ ᘀ쩨 偨╅伀儀Ȕ J J ᔔ쩨Ȕᘀ ᕨ堷伀J儀J ᔔ쩨Ȕᘀ㍨㰠伀J儀J ᔔ쩨
Ȕᘀ 깴伀J儀J ᔔ쩨Ȕᘀ桨㑹伀J儀J ᔗ쩨Ȕᘀ恨둺䠀Ī䩏䩑 ᔔ쩨Ȕᘀ恨둺伀J儀J ᔔ쩨Ȕᘀ롨
t group was significantly different from the control groups (one-way ANOVA, p<0.05). The 
sham-treatment group was not significantly different from the control group (one-way ANOVA, 
p>0.05).  For NPY, these data show that the CCI-treatment group was significantly different 
from both the sham-treatment group and the control group (one-way ANOVA, p<0.001). Sample 
size representing each mean indicated on the graph. D. DiD retrogradely labeled neurons from the right footpad of a CCI surgical animal.  Cell 
bodies in the L5 dorsal root ganglia were processed for multi-stain confocal microscopy with 
anti-TRPV1 and anti-Neurofilament antibodies. The results reveal that some neurons co-label 
with TRPV1 and DiD, while other neurons identified with anti-Neurofilament antibody (*) lack 
both DiD and TRPV1. Scale Bar = 80 µm.  
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E. Using Leica confocal software, the relative fluorescence of TRPV1 to DiD in co-expressing 
cells for representative CCI and comparably stained tissue sections from control DRG is shown. 
Sample size representing each mean indicated on the graph. TRPV1 protein expression is 
elevated in the CCI condition. 
Figure 2-1 B illustrates that in the CCI rat, mechanical hypersensitivity is evident 11 days 
post-surgery. Guarding behavior and other behaviors that are indicators of increased sensitivity 
were evident in all CCI animals. We also demonstrate that under these conditions, the mRNA 
expression levels of TRPV1, NPY and Gap43 are elevated on day 12 post-surgery (Figure 2-1 
C). For TRPV1, the mean fold change values for the CCI-treatment, sham-treatment, and control 
groups were 2.60±0.352, 2.06±0.30, and 1.11±0.18, respectively.  These data show that the CCI-
treatment group was significantly different from the control groups (one-way ANOVA, p<0.05).  
The CCI-treatment group was not significantly different from the sham group (one-way 
ANOVA, p>0.05).  For GAP43, the mean fold-change values for the CCI-treatment, sham- 
treatment, and control groups were 2.42±0.32, 1.52±0.51, and 1.00±0.07, respectively. These 
data show that the CCI-treatment group was significantly different from the sham-treatment and 
control groups (one-way ANOVA, p<0.05).  The sham-treatment group was not significantly 
different from the control group (one-way ANOVA, p>0.05).  For NPY, the mean fold change 
values for the CCI-treatment, sham-treatment, and control groups of 64.20±33.79, 6.49±6.21, 
and 1.44±1.34, respectively.  These data show that the CCI-treatment group was significantly 
different from both the sham-treatment group and the control group (one-way ANOVA, 
p<0.001). 
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To demonstrate that the expression of the TRPV1 protein is similarly elevated in the L5 
dorsal root ganglia of CCI animals as compared to control, we analyzed tissue sections with 
antibodies against TRPV1 and Neurofilament-M (a neuronal marker).  Additionally, the plantar 
region of the right rear paw of each rat was injected with DiD, a retrograde fluorescent dye that 
identifies the neurons innervating that specific region of the foot.  Not all large diameter neurons 
in the dorsal root ganglia were positive for the DiD retrograde tracer since only a discrete 
number of neurons reach that region of the footpad.  However, several DiD positive neurons are 
found and of those, some co-express TRPV1 in both control and CCI tissue.  In the control, the 
immunofluorescent ratio of TRPV1/DiD is 0.787 indicating that under these conditions the DiD 
signal is brighter than the TRPV1 signal.  However, in the CCI the TRPV1/DiD ratio is 1.12 
(Figure 2-1 E), indicative of elevated TRPV1 protein expression in these neurons of the dorsal 
root ganglion.  
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Figure 2-2.  Near Infrared imaging (NIR) of live rats merged with white light images of 
their body, 2 days post intravenous injection of labeled emulsion on day 11 post surgery.  
All of these images were acquired on the LiCOR Pearl Live animal imager and processed in the 
same experiment with linked look-up tables.  The control (A, B, C) and sham (D, E, F) rats 
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exhibit only autofluorescence over the thoracolumbar region, which is evident prior to injection 
(A, D, G).  The inset in F exhibits a ventral view of the wound, which lacks any fluorescent 
signal. The CCI affected right leg (I) exhibits a clear band of fluorescent signal aligned with the 
position of the sciatic nerve (arrow), which runs parallel to the femur.  No signal is evident on 
the CCI animal’s unaffected left leg (H).  Note – supplemental data (Supplemental Figure 2-S3) 
of a comparable experiment reveals only autofluorescence in sham and naïve controls, while 
only the CCI exhibits extensive signal along the length of the thigh, parallel to the position of the 
right sciatic nerve.  Bar = 1 cm. 
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Figure 2-S3. Near Infrared imaging (NIR) of live rats merged with white light images of 
their body, 2 days post intravenous injection of labeled emulsion on day 11 post surgery. 
All of these images were acquired on the LiCOR Pearl Live animal imager and processed in the 
same experiment with linked look-up tables.  The control, sham and CCI (A-F) exhibit auto 
fluorescence over the thoracolumbar region, which is also evident prior to injection (Note Figure 
2-2).  The control animal (A) does not exhibit any fluorescence over the right leg.  The sham (B) 
similarly does not exhibit any fluorescence in the area of the surgical wound (surgical staples). 
The CCI animal (C) exhibits a wide area of fluorescent signal over much of the thigh.  The left 
side of the control, sham and CCI (D, E, F) exhibit only the auto fluorescence in the 
thoracolumbar region. Bar = 1 cm. 
Figure 2-2 reveals that after the intravenous injection of the NIR labeled PFPE 
nanoemulsion, CCI injured rats exhibits NIR fluorescence that is focally localized parallel to the 
thigh (Figure 2-2 I) at 11 days post-CCI. This is in contrast to the autofluorescence evident in 
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sham (Figure 2-2 F) and control (Figure 2-2 C) in the thoracolumbar regions, which is similar to 
that seen prior to the nanoemulsion injection (Figure 2-2 A, D, G).  In a separate experiment, the 
surgical wound was occasionally found to exhibit low-level NIR fluorescence (Figure 2-3 B, C).  
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Figure 2-3.1 Near Infrared imaging (NIR) of live rats merged with white light images of 
their body, 2 days post-intravenous injection of labeled emulsion on day 11 post-surgery 
compared to day 18 post-surgery.  All of these images were acquired on the LiCOR Pearl Live 
animal imager and processed in the same experiment with linked look-up tables. Bar = 1cm.  
Bars in the graph represent Mean ± SEM. The sham surgical control (A, B, C) exhibits auto 
fluorescence over the thoracolumbar region, which is also evident prior to injection. In the sham 
animal, a superficial fluorescence signal is detected precisely on the surgical wound.  That 
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surgical wound signal is dramatically reduced by day 18 (C) in the same sham animal.  The CCI 
experimental animal (D, E, F) exhibits auto-fluorescence over the thoracolumbar region, which 
is also evident prior to injection.  The CCI affected right leg (E) exhibits a clear band of 
fluorescent signal aligned with the position of the sciatic nerve (black arrow) along the entire 
length of the thigh.  No signal is evident on the CCI animal’s unaffected left leg (D).  On day 18, 
the signal in the Sham attributed to the wound has nearly completely resolved and no signal is 
apparent along the sciatic nerve (C).  The CCI sciatic nerve associated signal persists in at day 18 
(F). Bar = 1 cm.  G. The relative fluorescence of a region over the sciatic nerve is compared.  For 
each condition ROI measurements were made (Supplemental Figure 2-S1, Table 2-S2) for the 4 
sets of data giving a sample number of 4 to 5.  The results of the one-way ANOVA test 
(Supplemental Table 2-S3) show that the relative fluorescence in the CCI right is significantly 
different from the remainder of the samples with a p value <0.0001.  Separately, a t-test analysis 
of the Sham right versus the CCI right revealed a p value of <0.0001. Sciatic nerve dissected 
from comparable animals imaged simultaneously in the same field of view for NIR fluorescence 
on the LiCOR Odyssey Flatbed Imager (H, I).  The CCI sciatic nerve (I) exhibits a strong 
fluorescent signal in comparison to the sham sciatic nerve (H).   
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 Figure 2-3.2 Two-way ANOVA analysis of Near Infrared imaging (NIR) of live rats 
merged with white light images of their body, 2 days post-intravenous injection of labeled 
emulsion on day 11 post-surgery. The relative fluorescence of a region over the sciatic nerve is 
compared.  For each condition ROI measurements were made (Supplemental Figure 2-S1, Table 
2-S2) for the 4 sets of data giving a sample number of 4 to 5.  The results of the two-way 
ANOVA test show that the relative fluorescence in the CCI right hind limb is significantly 
different from the remainder of the samples with a p value <0.05 using Sidak’s multiple 
comparison’s test. Separately, a t-test analysis of the sham right versus the CCI right revealed a p 
value of <0.0001. Bars in the graph represent Mean ± SEM. There was a significant main effect 
of rat condition (p = 0.0021) and hind limbs (p = 0.0012) with a significant interaction between 
variables (p = 0.0023). 
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Figure 2-S1.  Near Infrared imaging (NIR) of live rats merged with white light images with 
the Region of Interest (ROI) indicated. All of these images were acquired on the LiCOR Pearl 
Live animal imager and processed in the same linked look-up tables.  The ROI was set for the 
right leg CCI condition and then copied to a similar relative position on each of other legs for 
that experimental set.  The LiCOR software tabulates the relative fluorescent signal and area 
(note Table 2-S2). 
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Table 2-S2. LiCOR total relative fluorescence for each ROI.  The Mean (Total Relative 
Fluorescence/Area) for each ROI is used for the analysis of variance (ANOVA) and t-test. 
 
 Image ID Name Polygon Total Mean 
(total/area) 
Std. Dev. Min Max Area 
(pixels) 
          
Ex
pe
rim
en
t #
1 0000331_02 Ctr Right 1 2.72E2 6.28E-3 2.02E-3 1.45E-3 1.95E-2 43369 
0000333_02 Ctr Left 1 2.46E2 5.67E-3 2.22E-3 1.05E-3 2.14E-2 43369 
0000335_02 Sham Right 1 3.78E2 8.73E-3 4.22E-3 5.50E-4 3.31E-2 43369 
0000337_02 Sham Left 1 4.78E2 1.10E-2 5.79E-3 1.95E-3 3.49E-2 43369 
0000348_02 CCI Right 1 1.75E3 4.05E-2 1.18E-2 1.80E-3 7.41E-2 43369 
0000349_02 CCI Left 1 3.95E2 9.10E-3 3.44E-3 1.30E-3 2.68E-2 43369 
Ex
pe
rim
en
t #
2 0000454_02 Ctr Right 1 3.04E2 1.84E-2 4.78E-3 9.60E-3 4.14E-2 13271 
0000455_02 Ctr Left Ctr LF 2.34E2 1.42E-2 4.34E-3 6.00E-3 3.53E-2 12347 
0000460_02 Sham Right ShamRT 3.75E2 2.28E-2 8.34E-3 9.80E-3 5.91E-2 12653 
0000461_02 Sham Left ShamLF 1.92E2 1.17E-2 4.41E-3 5.10E-3 3.39E-2 13739 
0000464_02 CCI Right CCI RT 7.21E2 4.37E-2 6.77E-3 2.02E-2 6.43E-2 16486 
0000466_02 CCI Left CCI LF 1.94E2 1.18E-2 3.35E-3 4.65E-3 3.07E-2 11751 
Ex
pe
rim
en
t #
3 
0000470_02 Ctr Right Ctr RT 3.71E2 2.15E-2 4.24E-3 1.24E-2 3.88E-2 16498 
0000471_02 Ctr Left Ctr LF 3.24E2 1.88E-2 3.81E-3 9.85E-3 3.63E-2 16478 
0000478_02 Sham Right ShamRT 2.66E2 1.55E-2 4.73E-3 7.55E-3 4.25E-2 16798 
0000479_02 Sham Left ShamLF 2.62E2 1.52E-2 4.29E-3 8.00E-3 4.06E-2 16489 
0000487_02 CCI Right CCI RT 5.87E2 3.41E-2 8.07E-3 1.30E-2 6.74E-2 13708 
0000488_02 CCI Right CCI RT 5.72E2 3.32E-2 7.12E-3 1.30E-2 6.14E-2 17210 
0000490_02 CCI Left CCI LF 2.22E2 1.29E-2 2.44E-3 5.90E-3 2.31E-2 17210 
Ex
pe
rim
en
t #
4 0000715_02 Ctr Left Ctr LF 5.54E1 8.08E-3 1.74E-3 3.20E-3 1.64E-2 6861 
0000718_04 Ctr Right 1 6.70E1 9.76E-3 1.92E-3 4.85E-3 1.91E-2 6861 
0000725_02 Sham Left ShamLF 4.38E1 6.39E-3 3.01E-3 7.50E-4 1.64E-2 6861 
0000727_02 Sham Right ShamRT 4.31E1 6.28E-3 1.45E-3 2.00E-3 1.22E-2 6861 
0000739_02 CCI Left CCI LF 8.01E1 1.17E-2 4.33E-3 4.05E-3 2.47E-2 6861 
0000742_02 CCI Right 1 1.65E2 2.41E-2 7.35E-3 2.05E-3 4.40E-2 6861 
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Table 2-S3.   One-Way ANOVA of Relative NIR Fluorescence in Live Rats. 
 
 
 
  
Naïve 
Left 
 
Naïve 
Right 
 
Sham 
Left 
 
Sham 
Right 
 
CCI 
Left 
*** 
CCI 
Right 
Expt #1 0.0057 0.0063 0.0110 0.0087 0.0091 0.041 
Expt #2 0.0140 0.0180 0.0120 0.0230 0.0120 0.044 
Expt #3 0.0190 0.0220 0.0150 0.0160 0.0130 0.034 0.033 
Expt #4 0.0080 0.0098 0.0064 0.0063 0.0120 0.024 
       
n 4 4 4 4 4 5 
Mean 0.01168 0.0140 0.0111 0.0135 0.01153 0.0352 
Std. 
Deviation 
0.0060 0.0073 0.0036 0.0076 0.0017 0.0078 
Std. Error 0.0030 0.0036 0.0018 0.0038 0.0008 0.0035 
      p <0.0001  
 
t test of Sham Right versus CCI Right p value <0.0001 
 
This indicated that there was some superficial inflammation at the surgical wound as 
compared to the deeper sciatic nerve signal, which exhibits more scattering along the length of 
the sciatic nerve Figure 2-3.1 (E, F). Using the Li-COR Pearl Impulse software version 2.0 
image analysis tools, we identified regions of interest (ROI) over the affected sciatic nerve for 
the CCI, sham and control animals (Supplemental Figure 2-S1 and Table 2-S2).  By averaging 
the normalized fluorescence (total relative fluorescence/total area) of the right and left legs, we 
demonstrate in Figure 2-3.1 (G) and Figure 2-3.2, that the CCI fluorescence is significantly 
brighter than the controls.  Two-way ANOVA analysis of the entire data set comparing the 
relative fluorescence detected in the naïve right and left legs, the sham right and left legs and the 
CCI right and left legs reveals a difference for the CCI affected right leg with a p value < 0.05 
using Sidak’s multiple comparison’s test (Figure 2-3.2 and Supplemental Table 2-S3).  There 
was a significant main effect of rat condition (p = 0.0021) and hind limbs (p = 0.0012) with a 
significant interaction between variables (p = 0.0023). A t test specifically comparing the 
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affected CCI right leg to the sham surgical right leg reveals a significant difference with a p 
value < 0.0001 (Supplemental Table 2-S3).  However, given that NIR imaging cannot 
unequivocally provide spatial localization of the fluorescence, we continued the analysis by 
assessing the fluorescence of the dissected sciatic nerve from the sham as compared to the CCI 
animal Figure 2-3.1 (H, I).  With CCI and sham nerves lying side-by-side and imaged 
simultaneously on the flatbed LiCOR Odyssey imaging system, only the CCI shows positive 
signal. 
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Figure 2-4. 1H and 19F MRI of the hind limbs for the rats shown in Figure 2-2 F and 2-2 I.  
Panel A shows an anatomical (1H) image of the leg for the animal shown in 2-2 I.  The black 
arrow indicates the sutures used for the chronic constriction injury. The long white arrows 
indicate the position of the tibia, fibula and femur. The inset image shows the adjacent image 
slice, giving a clearer view of the tibia (T) and the femur (F).  The white arrow in inset panel A 
points to the sciatic nerve, which appears as a white line.  Panel B shows a composite 1H/19F 
image.  The 19F image is rendered in pseudo color (red) and is overlaid on the anatomical image 
shown in A.  A significant amount of 19F signal is observed at the sutured sciatic nerve.  A small 
amount of fluorine signal is also evident at the head of the tibia and slight in the femur.  The 
inset shows an axial view of the thigh revealing the femur in cross section.  A small amount of 
fluorine signal is observed at the surface aligning with the surgical wound, where minor 
superficial inflammation is still evident (arrow head). The (F) indicates the femur in cross 
sections with a low level of 19F signal. The white arrow indicates the sciatic nerve with 19F 
signal.  The asterisk (*) is near the femoral artery.  Panel C shows a 1H/19F composite image of 
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the sham right leg from the animal shown in Figure 2-2 F.  No fluorine signal was observed at 
the sciatic nerve, however a weak signal was observed in the femur, presumably in the bone 
marrow (arrow). The inset shows an axial view at the level of the arrow near the head of the 
femur (F) with 19F signal in the bone marrow.  The black arrow points to the femur and the 
asterisk (*) is near the femoral artery. Bar = 1 cm. 
In preparation of the MRI analysis of the tissues, we assessed the NMR spectra of the 
dissected sciatic nerves to ascertain that the only fluorine signature to be detected was arising 
from the nanoemulsion and not any contribution that may come from natural sources or from 
anesthesia.  The NMR spectra (Supplemental Figure 2-S2) show that the only detectable fluorine 
in the sciatic nerve arises from the PFPE nanoemulsion. Analysis of the same right legs as those 
shown in Figure 2-2 F for the Sham and Figure 2-2 I for the CCI condition by proton and 19F 
MRI show that the PFPE signal is coincident with the ligation of the sciatic nerve (Figure 2-4).  
Figure 2-4 A shows that the four suture knots associated with the constriction injury are visible 
by proton MRI along the sciatic nerve, which is running parallel to the femur.  The sciatic nerve 
(white arrow inset), tibia (T) and femur (F) are clearly visible in the adjacent image slice (Figure 
2-4 A – inset).  Fluorine signal is evident along the sciatic nerve in the region of the sutures 
(Figure 2-4 B) as well as in the bone marrow of the proximal head of the tibia. Viewed in cross 
section (Figure 2-4 B – inset), 19F signal is evident in the sciatic nerve, the femur as well as a 
slight signal where some minor inflammation persists at the site of the surgical wound.  The clips 
had been removed on day 7 post-surgery.  In the sham, a lower level of 19F signal is evident only 
in the bone marrow near the head of the femur (Figure 2-4 C).  A comparable experiment 
revealed PFPE nanoemulsion labeled inflammation in the region of the CCI sciatic nerve 
(Supplemental Figure 2-S3 C) as compared to control and sham.  
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Figure 2-S2.  NMR 19F spectra for nanoemulsion in dissected CCI sciatic nerve. 
Exhibits 19F NMR spectrum of dissected right sciatic nerve from CCI animal.  TFA (−76.00 
ppm) reference standard is shown along with the tissue signal for the nanoemulsion in the sciatic 
nerve (-92.5ppm). 
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Figure 2-5. Cryosection of sciatic nerve. A, B show the affected right sciatic nerve from the 
CCI leg shown in Figure 2-2 I stained with anti-CD68 antibody to reveal the presence of 
macrophages infiltrating the nerve. C, D CD68 positive cells are not present in the left leg 
(contralateral to surgery Figure 2-2 H) of the same CCI animal.  E, F shows a nerve from a 
separate CCI animal that also exhibits infiltration of CD68 positive cells. The boxed area is 
enlarged to reveal the granular cytoplasm (black arrow) of the macrophages, indicative of the 
presence of the nanoemulsion.  Sham surgical sciatic nerve and non-surgical control sciatic nerve 
do not exhibit any CD68 positive cells (G, H) and (I, J).  The fluorescent images A, C, G, and I 
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were all acquired at the same sitting with the exact same image acquisition parameters.  
Macrophages grown in cell culture take up the nanoemulsion, exhibited as particles evident by 
both confocal fluorescence emissions 700 – 850nm of NIR label (DiR) (K, M) as well as 
transmitted light (L, N). 
To confirm that the PFPE signal is localized to the site of neuroinflammation by 
infiltration of macrophages into the actual nerve, we sectioned the recovered sciatic nerve from 
the CCI right leg and the left leg of the same animal shown in Figure 2-2 H, I and Figure 2-4 A, 
B and stained the nerve with anti-CD68 antibody (Figure 2-5 A-D).  Similarly, the sciatic nerves 
from the un-operated control and the sham were also recovered for analysis (Figure 2-5 G-J). 
The results clearly demonstrate that macrophages have infiltrated into the CCI nerve, but not any 
of the controls.  In duplicate experiments, examination of the macrophages revealed that they 
exhibit granular cytoplasm (Figure 2-5 E, F). The nanoemulsion droplets in these cells are 
consistent with the nature of nanoemulsion droplets detected in macrophages grown in cell 
culture, which measure at the limit of spatial resolution for the light microscope with a size of 
200 – 300 nm (Figure 2-5 K, L, M, N), which is consistent with the analytic size measurement of 
180-200 nm in diameter [37]. 
2.4 Discussion  
Here we report the first live imaging of neuroinflammation in the CCI neuropathic pain 
model with NIR and 19F labeled nanoemulsion taken up by circulating monocytes that infiltrate 
into the damaged sciatic nerve and present as macrophages. 
Chronic neuropathy in the CCI rat model leads to mechanical hypersensitivity [104]. 
Figure 2-1B demonstrates significant induction of mechanical hypersensitivity in ipsilateral hind 
paw of CCI rat. We note that the role of TRPV1 as a nociceptor has been widely documented in 
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a variety of acute, chronic, and neuropathic pain models and diseases such as diabetic 
neuropathy, chronic pancreatitis, cancer pain, osteoarthritis, and gastrointestinal diseases [105-
108].  NPY is a peptide neurotransmitter released by primary afferent neurons located in the 
dorsal root ganglia and received by neurons located in the substantia gelatinosa region of the 
spinal cord [109].  In animal models of neuropathic pain, NPY has been shown to be upregulated 
[110, 111], and can be used as an indicator that trauma to the nerve has occurred. During 
development, Gap43 is a growth-associated protein that is highly expressed in the growth cones 
of elongating axons.  Its expression decreases after the target has been innervated [112].  In 
addition to its developmental role, Gap43 is also differently expressed following neuronal tissue 
damage or inflammation, which has been demonstrated in several animal neuropathy models 
[112-114] and can be used to verify that trauma has occurred in peripheral nerve tissue.   
We have demonstrated that in the CCI pain model, changes in mRNA expression levels 
of TRPV1 as well as NPY and Gap43 are evident in lumbar level five dorsal root ganglia using 
one-step qPCR analysis (Figure 2-1 C).  TRPV1 is known to play a role in inflammatory as well 
as neuropathic pain models [115].  The increased expression of NPY, a neurotransmitter, is 
known to play a role in modulating both innate and adaptive immune response [116], including 
modulating the phagocytic uptake by neutrophils and macrophages [117]. Furthermore, NPY has 
been shown to modulate neuronal signaling in acute pain, neuropathic pain and inflammatory 
animal pain models and induces anti-nociceptive effects [109].  The increase in NPY expression 
provides indirect evidence to support the interpretation that nerve trauma has been induced on 
the sciatic nerve. We find that mRNA expression of TRPV1 was increased in the ipsilateral 
dorsal root ganglia level 5 as compared to the control rat (Figure 2-1 C). Furthermore, neurons in 
the dorsal root ganglia that are retrograde labeled with DiD from the plantar foot pad injection 
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exhibit a relative increase in TRPV1 protein expression in the CCI condition as compared to un-
operated control rats (Figure 2-1 D, E). Collectively, these results demonstrate that CCI is 
inducing a hypersensitivity associated with changes in gene expression for the nerves of the 
affected DRG and sciatic nerve.   
We also reported the in vivo imaging of neuroinflammation in the CCI sciatic nerve using 
dual mode (NIR and 19F MRI) nanoemulsion. Both resident and hematogenous immune cells are 
involved in causing neuroinflammation at the site of injury in CCI rat model [14]. The 
infiltration of immune cells into the site of injury results in the release of inflammatory 
mediators, which then cause changes in the gene expression profile of the affected neurons and 
leads to peripheral sensitization [118].  In vivo imaging of granulomatous inflammation has been 
previously reported via labeling of macrophages with fluorescent NIR dye [119].  However, 
optical imaging is compromised due to the absorption and scattering of both the excitation and 
emitted light [120]. 19F MRI has an advantage in that it is not limited by depth and has no 
background noise in tissues [121]. 19F MRI has also been successfully used for in vivo imaging 
and quantification of inflammation in various animal disease models [85, 96, 122].  Previously, 
we demonstrated in vitro phagocytic uptake of a dual labeled nanoemulsion by macrophages in 
culture [42].  Here, we again demonstrate that a perfluorocarbon nanoemulsion containing both 
NIR dye and 19F [42] is taken up by macrophages in culture as an assessment of toxicity and 
uptake as previously measured [37, 42], which gave us confidence that we could achieve 
adequate sensitivity in vivo by both imaging modalities (Figure 2-5 K-N). This nanoemulsion is 
then used in order that we might achieve maximum sensitivity and specificity in vivo, in the 
analysis of neuroinflammation in CCI. 
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On day 8 post-surgery, an intravenous injection of the nanoemulsion was given to the rats 
followed immediately by NIR fluorescence assessment to ensure that the injection was not 
inadvertently released subcutaneously. In the bloodstream, the phagocytic cells evidently engulf 
these nanoemulsion droplets through a still undetermined mechanism. These labeled immune 
cells naturally migrate to the site of injury to participate in the inflammatory response. NIR 
fluorescence emission from the labeling was observed only on the ipsilateral side of the CCI rat 
overlying the site of sciatic nerve ligation (Figure 2-2 I and Figure 2-3 E, F, I). Fluorescence was 
absent on hind limbs of sham rat, control rat and the contralateral hind limb of CCI rat (Figure 2-
2 B, C, E, F, Hand Figure 2-3 A-D).  NIR imaging was used to reveal the accumulation of 
immune cells at the site of sciatic nerve injury in live animals. Macrophages are the primary 
immune cells that phagocytize perfluorocarbon nanoemulsion droplets and they represent the 
majority of all the labeled cells [85].  The results from our in vivo NIR imaging suggest that the 
fluorescence signal is associated with neuroinflammation at the site of sciatic nerve injury in CCI 
rats. To confirm that the observed fluorescence originated in the sciatic nerve, ex vivo NIR 
imaging of the recovered injured sciatic nerves was performed. Fluorescence emission for NIR 
dye was observed only in the CCI ipsilateral sciatic nerve and not the ipsilateral nerve of the 
sham animal (Figure 2-3 H, I). The results complement the findings from the in vivo imaging and 
show that a fluorescence signal is present in the dissected nerve from the CCI rat, which is 
indicative of the accumulation of labeled macrophages. 
To confirm that the fluorescence signal at the site of CCI injury was due to accumulation 
of nanoemulsion labeled macrophages, highly sensitive19F NMR spectroscopy and 19F MRI were 
performed.  NMR spectroscopy (supplemental data Figure 2-S2) demonstrates that in the 
dissected sciatic nerve, the only fluorine signature arises from the 19F in the PFPE.  
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The 19F signal localizes at the site of sciatic nerve injury in the CCI rats and no such 
signal was observed in the sham rat (Figure 2-4).  The presence of 19F signal was also observed 
in the femur and tibia of CCI and sham rats. Complex regional pain syndrome has previously 
been associated with osteoporotic changes in human subjects [123].  Furthermore, it has been 
demonstrated that osteoporotic changes in the ipsilateral tibia bone occur after CCI surgery. 
These changes are also associated with an increased number of osteoclasts in the bone [124].  
Hence, the 19F signal we observed in the bone marrow (Figure 2-4) could be indicative of the 
osteoporotic changes in the femur and tibia of CCI rats and is a result of the peripheral nerve 
injury. It has also been shown that a subset of blood monocytes could serve as osteoclast 
precursors [125]. Overall, our interpretation is that the 19F signal evident in the bone marrow is 
due to migration of labeled monocytes to the bone. 
Immunohistochemistry performed on the ipsilateral sciatic nerve of CCI rat clearly 
demonstrates infiltration of macrophages in the sciatic nerve (Figure 2-5).  No such infiltration 
was observed for the left leg contralateral to the CCI, the ipsilateral sham and the control nerves 
(Figure 2-5). Therefore, the 19F signal and the fluorescence observed during in vivo and ex vivo 
NIR imaging is due to infiltration of labeled macrophages at the site of injury.    
2.5 Conclusion 
This study demonstrates that the infiltration of immune cells into the CCI affected sciatic 
nerve can be monitored in live animals.  Furthermore, the neuroinflammation caused by the CCI 
surgery can be imaged using the dual mode nanoemulsion such that both live animal NIR 
imaging and post-mortem perfluorocarbon 19F MRI generates complementary results 
demonstrating that this neuroinflammation contributes to the pain associated with CCI surgery.  
In rats, specifically targeting the immune cells in vivo may serve as a treatment for 
52
neuroinflammation. The same technique could be used to monitor the effect of therapeutic drugs 
by assessing the extent of inflammation at the site of injury and to diagnose neuroinflammation 
without the need for surgical intervention involving a nerve biopsy.  
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Chapter 3 
Pain Management With Low Dose Celecoxib Delivered By Targeted 
Nanoemulsion 
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3.1 Introduction 
Neuropathic pain is caused by direct or indirect injury to the somatosensory nervous 
system [4]. It affects millions of people globally and heavily impacts the physical, social, mental 
and economic status of its sufferers [73]. Neuropathic pain is difficult to diagnose and is mostly 
refractory to the prevailing treatment options [126]. It is now accepted that besides nerve injury, 
neuropathic pain is almost always associated with inflammation due to nerve and tissue injury 
[118]. Macrophages are the major effector cells that cause neuroinflammation and neuropathic 
pain as a result of Wallerian degeneration following peripheral nerve injury [14]. Immediately 
after the nerve injury, resident immune cells are activated and produce a variety of inflammatory 
mediators to cause the migration and accumulation of hematogenous immune cells at the site of 
injury. Although Schwann cells and resident immune cells participate during early phases of 
nerve injury, major contribution towards inflammation and maintenance of neuropathic pain 
come from the infiltrating macrophages at the site of nerve injury [127].  
During neuroinflammation, prostaglandins are one of the mediators produced by the 
macrophages and play an important role during Wallerian degeneration and maintenance of 
neuropathic pain [29, 31]. Following peripheral nerve injury, there is elevated expression and 
over production of prostaglandins that are derived from arachidonic acid by the activation of 
cyclooxygenase (COX) enzymes COX-1 and COX-2 in the infiltrating macrophages [31]. COX-
2 enzyme and eicosanoid PGE2 are involved in the pathogenesis of neuropathic pain to cause 
peripheral sensitization of the nociceptors and increased expression of P2X3 receptors in the 
associated DRGs during peripheral nerve injury [29, 32, 33]. Previous studies have reported that 
the systemic administration of selective COX-2 inhibitors such as celecoxib, ketorolac, and 
indomethacin reduce hypersensitivity after the nerve injury. These same treatments can lead to 
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improvement in functional recovery in various animal models of neuropathic pain.  However, 
COX-2 inhibitors have the limitation of causing adverse secondary effects due to sustained and 
high dose systemic administration of non-steroidal anti-inflammatory drugs (NSAIDs) [29, 33-
36].  
To study the neuroinflammatory pain, we used a well-established rat model of CCI 
developed by Bennett and Xie in 1988 [8].  In our previous study, we had used a nanoemulsion 
containing a near infrared (NIR) dye and a perfluorocarbon (PFC) tracer to label the 
hematogenous immune cells in-vivo in the rats that underwent CCI.  Subsequently, we could 
successfully image the immune cell accumulation at the site of injury using NIR fluorescence in 
live animals and also the 19F fluorine signal by magnetic fluorescence imaging (MRI) [128]. 
Previous studies using similar sized PFC nanoemulsions have revealed that majority of the 
nanoemulsion is endocytosed by the circulating monocytes [38]. We have also demonstrated that 
the theranostic nanoemulsion containing selective COX-2 inhibitor, celecoxib, was endocytosed 
by the macrophages and significantly reduced the expression of PGE2 in the activated 
macrophages during in-vitro cell culture [42].   
In this study, we performed the in-vivo experiments to demonstrate that the new 
theranostic nanoemulsion formulation can provide direct delivery of the celecoxib drug into the 
macrophages in live rats, causing a reversal of mechanical allodynia (hypersensitivity) associated 
with the CCI condition.  We also demonstrate that the same drug loaded theranostic 
nanoemulsion was useful to monitor the inflammation at the site of nerve injury and thus proving 
true to its name (i.e. simultaneous therapy and diagnostics).  Furthermore, immunohistological 
analysis of the affected CCI sciatic nerve revealed that the drug loaded nanoemulsion resulted in 
a statistically significant reduction (t test, p< 0.0001) in the relative number of activated 
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macrophages along with a significant reduction in the COX-2 and PGE2 expression (t test, p< 
0.0001) in the macrophages at the affected sciatic nerve. 
3.2 Methods 
3.2.1 Experimental Groups 
CCI rats were divided into treated and untreated groups. These groups have also been 
referred to as drug and no drug conditions. The treated CCI group received a single intravenous 
injection of the theranostic nanoemulsion containing celecoxib drug on day 8 post-CCI. The 
untreated CCI group was injected with the vehicle nanoemulsion, without containing the 
celecoxib. The other controls used during this study were sham or naïve rats that were injected 
with either the vehicle or the theranostic nanoemulsion.  
3.2.2. Chronic Constriction Injury  
Please refer to the appendix (Materials and methods) 
3.2.3 Behavioral Testing (Up-down method, performed and analyzed by Muzamil 
Saleem) 
Mechanical allodynia testing was performed on the CCI rats injected with the 
nanoemulsion containing celecoxib (with drug/theranostic nanoemulsion), CCI rats injected with 
the vehicle nanoemulsion (without drug) and sham rats injected with the vehicle nanoemulsion. 
Baseline behavior testing was performed on two consecutive days before the CCI/sham surgery 
to obtain the baseline withdrawal threshold values for all the experimental groups.  To prevent 
any undue discomfort to the rats, the rats were rested and no behavior testing was performed for 
two days (i.e. on the day of surgery and the day after). Beginning day 3 post-surgery, daily 
behavioral testing was resumed for up to day 12 post-surgery. The behavior testing was 
performed using the up-down method adapted from [129] on freely moving rats in a perspex 
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chamber with a wire mesh floor that allowed access to the paws. During the light phase of their 
circadian cycle, rats were allowed to acclimatize in the mechanical allodynia testing apparatus 
for at least 15 minutes prior to the behavior testing, when there was an apparent decrease in their 
cage exploration and grooming behavior. Tactile hypersensitivity was tested by applying von 
Frey filaments to the plantar surface of their hind paw for duration of 3 seconds until there was a 
flex of approximately 20 degrees. The gram forces of the filaments ranged from 1 g to 15 g. 
Positive withdrawals were counted during or immediately following the stimulus. The thickness 
of the von Frey filament was increased or decreased following a negative or positive response 
respectively. At this point four more stimuli were applied and the responses recorded. There is a 
latency of one minute between presentations of stimuli. The 50% paw withdrawal threshold was 
calculated and treatment groups were analyzed by repeated-measures two-way ANOVA and the 
Bonferney post-hoc test. Data are presented as mean ± SD.	
Similarly, behavioral testing was carried out for two consecutive days preceding sham 
surgery to establish a baseline withdrawal threshold. The rats were then allowed a day of rest and 
then tested on consecutive days until 12 days post-surgery, at which point the rats were 
euthanized and perfusion fixed.  
3.2.4 Theranostic Nanoemulsion 
The theranostic nanoemulsion was provided to us by Dr. Jelena M. Janjic, Associate 
Professor, Department of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne 
University, Pittsburgh. Due to proprietary issues, details of the theranostic nanoemulsion cannot 
be included in the dissertation and will be included in the final publication. 
3.2.5 Live Animal Imaging (NIR) 
Please refer to the appendix (Materials and methods) 
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3.2.6 MRI (1H & 19F) Methods 
Performed by Dr. T. Kevin Hitchens, as described in Chapter 2. 
3.2.7 Histology And Confocal Microscopy 
Double immunofluorescence staining was performed for COX-2 and PGE2 along with 
CD68 staining. For detailed methodology, please refer to the appendix (Materials and methods). 
3.3. Results 
3.3.1 Reduction In Mechanical Allodynia With Single Injection Of Celecoxib 
Containing Nanoemulsion 
To determine the effect of the drug-loaded nanoemulsion on the hypersensitivity 
behavior, mechanical allodynia testing was performed on all the experimental groups of rats, 
CCI injected with celecoxib-loaded theranostic nanoemulsion (with drug), CCI injected with 
vehicle nanoemulsion (nanoemulsion without drug), and sham rats injected with vehicle 
nanoemulsion only. Similar to our previous results [128], Figure 3-1 shows the development of 
mechanical allodynia on the ipsilateral hind paw around day 7 post-CCI in both the CCI groups 
(no injection given up to day 7 post-CCI). As expected, sham rats did not exhibit the 
development of hypersensitivity throughout the period of study (Figure 3-1). However, after a 
single intravenous injection of the celecoxib-loaded nanoemulsion (0.3 ml) on day 8 post-CCI, 
the CCI group treated with the theranostic nanoemulsion exhibited reversal of mechanical 
allodynia on day 9 post-CCI (i.e. 24 hours post injection), with a statistically significant (Two-
way ANOVA and Bonferney post-hoc test) decline in mechanical allodynia on day 10 post-CCI 
that persisted throughout the period of study up to day 12 post-CCI, as compared to the CCI 
group injected with the vehicle nanoemulsion. There was a significant main effect of rat 
condition (p < 0.0001) and time (p < 0.0001) with a significant interaction between variables (p 
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< 0.0001) and a significant main effect of matching (p < 0.0001). Persistent mechanical allodynia 
/ hypersensitivity was observed on the ipsilateral hind paw of the untreated CCI group (i.e. 
injected with the vehicle nanoemulsion), (Figure 3-1) beginning around day 7 post-CCI until day 
12 post-CCI. The contralateral hind paw did not reveal mechanical hypersensitivity in any of the 
experimental groups (data not shown). 
 
Figure 3-1. Mechanical allodynia testing.  Mechanical allodynia develops on the ipsilateral 
hind paw around day 7 post-CCI in both the CCI groups, treated with either the celecoxib 
containing theranostic nanoemulsion (shown in blue) or the vehicle nanoemulsion (shown in 
red). Significant reduction (matched two-way ANOVA and Bonferney post-hoc test, p <0.0001) 
in mechanical allodynia is exhibited on the ipsilateral side of the CCI group treated with 
celecoxib-loaded nanoemulsion on day 10 post-CCI (two days after the intravenous 
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nanoemulsion injection) as compared to the ipsilateral side of the CCI group treated with vehicle 
nanoemulsion. There was a significant main effect of rat condition (p < 0.0001) and time (p < 
0.0001) with a significant interaction between variables (p < 0.0001) and a significant main 
effect of matching (p < 0.0001). The decline in hypersensitivity on the ipsilateral side of the CCI 
group treated with theranostic nanoemulsion, persists throughout the period of study (up to day 
12 post-CCI). Sham rats do not exhibit development of mechanical allodynia on the ipsilateral 
side of the sham surgery (shown in gray). The bars in the graph represent mean	±	SD. 
3.3.2 Reduction In Neuroinflammation Observed By Live Animal Imaging 
(NIRF) 
To determine the effect of the drug-loaded nanoemulsion on the near infrared (NIR) 
fluorescent signal at the site of injury, that acts as an indirect indicator of neuroinflammation 
[128], NIR fluorescence imaging was performed on all the experimental groups of rats. Similar 
to our previous report [128], Figures 3-2 and 3-3 show NIR fluorescence band on the ipsilateral 
thigh region of both the treated (i.e. injected with theranostic nanoemulsion) and the untreated 
(i.e. injected with vehicle nanoemulsion) CCI groups on day 11 post-CCI (Figure 3-2 A, B; 
Figure 3-3 A, B). Sham rats exhibited a low level fluorescence due to the wound caused by skin 
and muscle incision during the sham surgery (Figure 3-2 C; Figure 3-3 C, D). For the 
quantification of NIR fluorescent signal among four experimental groups (i.e. CCI injected with 
celecoxib-loaded nanoemulsion, CCI injected with vehicle nanoemulsion, sham rats injected 
with celecoxib-loaded nanoemulsion and sham rats injected with vehicle nanoemulsion), 
normalized fluorescence (total fluorescence/total area) at the sciatic nerve region was compared 
using LiCOR Pearl Impulse software version 2.0 link look-up tables.  
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Figure 3-3 A, B, C, D displays the regions of interest (ROIs) chosen to compare the 
relative NIR fluorescence among the various groups. The NIR imaging analysis did not reveal 
any significant difference in the NIR fluorescence intensity among any of the three groups (i.e. 
CCI injected with theranostic nanoemulsion, CCI injected with vehicle nanoemulsion and sham 
rats injected with theranostic nanoemulsion) (Figure 3-3 E and Table 3-1) (One way ANOVA 
and Tukey’s multiple comparisons test, p = 0.2346). However, a trend of decline in the NIR 
fluorescence was apparent for the CCI group treated with the theranostic nanoemulsion as 
compared to the CCI group treated with the vehicle nanoemulsion (Figure 3-3 E). Similar to our 
previous observation [128], both the sham groups represent a reduced NIR fluorescence as 
compared to both the CCI groups (Table 3-1). Sham rat without the drug was not included in the 
one-way ANOVA analysis because only one rat was available in this group that received good 
intravenous injection, and for ANOVA at least two rats were required in each group. 
Nonetheless, the NIR fluorescence value for sham rat without the drug is included in the NIR 
fluorescence data (Table 3-1).  
 
 
 
Figure 3-2. Near infrared (NIR) imaging of live rats merged with white light images of their 
body, 2 days post-intravenous injection of labeled emulsion on day 11 post-surgery.  
A CCI without drug B CCI with drug C Sham without drug 
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Images were acquired on the LiCOR Pearl Live animal imager and the acquired images were 
processed in the same experiment with linked look-up tables. The CCI affected right legs (A, B) 
exhibit a clear band of fluorescent signal aligned with the position of the sciatic nerve, which 
runs parallel to the femur. Low-level fluorescent signal is evident on the sham rat right leg (C). 
Autofluorescence in the thoracolumbar region is exhibited by all the experimental groups (A, B, 
C). 
 
 
 
 
E 
B C D 
CCI with drug CCI no drug Sham no drug Sham with drug 
A 
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Figure 3-3.  Near Infrared imaging (NIR) of live rats merged with white light images with 
the Region of Interest (ROI) indicated. All of these images were acquired on the LiCOR Pearl 
Live animal imager and processed in the same linked look-up tables.  NIR fluorescence is 
evident at the sciatic nerve region in all the experimental groups (A, B, C, D). However, the CCI 
group treated with theranostic nanoemulsion (A) exhibits apparent reduction in the NIR 
fluorescence at the sciatic nerve region as compared to the CCI group treated with the vehicle 
nanoemulsion (B). Both the sham groups, treated with either the theranostic or vehicle 
nanoemulsion (C, D) reveal low-level NIR fluorescence due to skin and muscle incision. The 
ROI was set for the right leg CCI group treated with theranostic nanoemulsion (A) and the same 
ROI was copied to a similar relative position on each of the other right hind legs of various 
experimental groups (B, C, D). The LiCOR software tabulates the relative fluorescent signal and 
the area (Table 3-1). A trend of reduced NIR fluorescence signal is revealed by the CCI group 
treated with the theranostic nanoemulsion as compared to the CCI group treated with the vehicle 
nanoemulsion, however, a statistically significant difference is not seen (E and Table 3-1) (One-
way ANOVA, p = 0.2346). Autofluorescence in thoracolumbar region is present in all the 
experimental groups (A, B, C, D). Bars represent mean  ± SEM. 
Table 3-1. LiCOR relative NIR fluorescence for each ROI.  The Mean (Total Relative 
Fluorescence/Area) for each ROI is used for the analysis of variance (one-way ANOVA). 
Name Image ID Channel Total Mean (Total/Area) Std. Dev. Min Max Area (pixels) Shape
CCI with drug 0001792_02 800 2.10E+03 2.19E‐01 1.28E‐01 5.48E‐02 7.25E‐01 5809 Polygon
CCI with drug 0001851_02 800 1.91E+03 2.00E‐01 1.19E‐01 1.63E‐02 6.48E‐01 8744 Polygon
CCI without drug 0001799_02 800 1.96E+03 2.05E‐01 1.28E‐01 3.67E‐02 8.44E‐01 8733 Polygon
CCI without drug 0001845_02 800 2.74E+03 2.88E‐01 1.86E‐01 1.91E‐02 1.04E+00 7039 Polygon
Sham with drug 0001805_02 800 1.74E+03 1.83E‐01 9.17E‐02 5.03E‐02 5.43E‐01 9514 Polygon
Sham with drug 0002009_02 800 1.07E+03 1.12E‐01 5.02E‐02 3.81E‐02 3.76E‐01 8515 Polygon
Sham without drug 0001812_02 800 7.63E+02 8.02E‐02 4.52E‐02 2.41E‐02 2.52E‐01 9514 Polygon  
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3.3.3. Reduction In Neuroinflammation Observed By 19F MRI  
In a separate experiment, to see if there was any difference in the 19F signal in the treated 
and untreated CCI groups at the site of injury, a highly specific and sensitive 19F MRI was 
performed on the dissected ipsilateral hind limbs by Dr. Kevin Hitchens, similar to our previous 
study along with regular 1H MRI [128]. Overlay of regular 1H MRI and 19F MRI images revealed 
the presence of 19F signal at the sciatic nerve, parallel to the femur bone in both treated and 
untreated CCI groups with a notable reduction in the 19F signal for the CCI rat treated with 
celecoxib-containing nanoemulsion as compared to the untreated CCI rat injected with the 
vehicle nanoemulsion (Figure 3-4 A, B). Comparative analysis for the 19F signal [86] in the 
sciatic nerve was performed (by Dr. Kevin Hitchens) between the two CCI groups (with identical 
parameters) and approximately 50% reduction in the 19F signal was observed in the sciatic nerve 
retrieved from the CCI rat treated with the theranostic nanoemulsion (Figure 3-4 C). Statistical 
analysis for 19F quantification could not be performed due to one rat in each CCI group. It was 
not feasible to perform the highly expensive 19F MRI on a larger number of rats due to economic 
constraints. Thus, the in-vivo 19F MRI results indicate a reduction in the neuroinflammation at 
the site of injury in the CCI group treated with the theranostic nanoemulsion as compared to the 
CCI group injected with the vehicle nanoemulsion. Similar to our previous study [128], the 19F 
fluorine signal is also evident in the femur bones of both the CCI groups.  
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Figure 3-4. 1H and 19F MRI overlay of the ipsilateral rat hind limbs. A, B show an overlay of 
an anatomical (1H) image of the leg (gray) and 19F MRI image (red). The white arrows indicate 
the site of ligation of sutures at the sciatic nerve. The inset image shows the adjacent image slice, 
giving a clearer view of the femur bone running parallel to the sciatic nerve, which appears as a 
white line. 19F signal is observed at the sutured sciatic nerve in both the CCI groups (A, B).  
Apparent reduction in the 19F signal is evident at the sciatic nerve of the CCI group treated with 
the celecoxib-containing nanoemulsion (A) as compared to the CCI group injected with the 
vehicle nanoemulsion (B). The comparative 19F signal at the sciatic nerve in both the CCI groups 
is depicted graphically which shows approximately two-fold reduction in the 19F signal at the 
ipsilateral sciatic nerve in the CCI rat treated with the celecoxib-loaded nanoemulsion (with 
drug) as compared to the CCI rat treated with the vehicle nanoemulsion (no drug) (C).  
With drug Without drug 
A  B C  
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3.3.4 Celecoxib Loaded Nanoemulsion Reduces Macrophage Infiltration Along 
With Reduction In COX-2 And PGE2 Expression In The Macrophages 
Double immunofluorescence studies were performed to investigate whether the 
differences in the 19F fluorine signals in the CCI treated and untreated groups were also 
associated with changes in the macrophage infiltration and COX-2 or PGE2 expression changes 
at the site of injury. Figure 3-5 A, B reveals expression of COX-2 and PGE2, along with the 
presence of CD68 positive cells in both treated (B) and untreated (A) CCI groups. The 
expression of COX-2 or PGE2 and infiltration of CD68 macrophages was not seen in the control 
groups (i.e. contralateral sciatic nerves from CCI rat treated with vehicle nanoemulsion, 
ipsilateral sciatic nerves from sham and naïve rats injected with vehicle nanoemulsion) (Figure 
3-5 C, D, E).  
 
 
 
 
 
 
 
 
 
 
 
 
67
 
 
 
Figure 3-5. Double immunofluorescence for COX-2 and PGE2 along with CD68 positive 
macrophages. A, B shows infiltration of CD68 positive macrophages along with COX-2 and 
PGE2 expression in the ipsilateral sciatic nerve sections of the CCI group injected with the 
vehicle nanoemulsion (A) and the CCI group injected with the theranostic nanoemulsion (B). An 
apparent reduction in the expression of CD68, COX-2 and PGE2 is revealed in the CCI group 
injected with the theranostic nanoemulsion (B). Ipsilateral sciatic nerve sections from the sham 
(D) and naïve control rats (E) injected with the vehicle nanoemulsion and contralateral sciatic 
nerve sections from the CCI rats injected with the vehicle nanoemulsion (C) do not exhibit 
CD68, COX-2 and PGE2 expression. Double immunofluorescence staining for COX-2 and 
CD68 macrophages was performed in the same experiment and confocal microscopy was 
performed in the same sitting with the same image acquisition parameters. Similarly, double 
immunofluorescence staining for PGE2 and CD68 macrophages was performed in the same 
A B C D E
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experiment and confocal microscopy was performed in the same sitting with the same image 
acquisition parameters. Bar = 150 µm 
 
 
 
 
 
Figure 3-6. Quantification of relative fluorescence. Significant reduction in mean fluorescence 
intensity per unit area was observed for CD68 macrophages (A), COX-2 expression in 
A B 
C 
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macrophages (B) and PGE2 expression in macrophages (C) in the CCI group treated with 
celecoxib-containing nanoemulsion (t test, p<0.0001). n= total number of regions of interest 
(ROIs) in (A) and number of macrophages chosen in (B, C) from a total of three rats in either of 
the CCI groups. Bars represent Mean ± SEM. 
To determine any differences in the relative number of macrophages in the treated 
(injected with theranostic nanoemulsion) and untreated (injected with vehicle nanoemulsion) 
CCI groups, mean fluorescence intensity of CD68 positive cells / area was compared. A 
significant reduction (t-test, p<0.0001) in the mean fluorescence intensity of CD68 positive 
macrophages per unit area was observed in the CCI group treated with a single dose of 
celecoxib- containing nanoemulsion as compared to the CCI group injected with a single dose of 
the vehicle nanoemulsion (Figure 3-6 A). CD68 fluorescence intensity of the individual 
macrophages was not significantly different between the macrophages in the treated and 
untreated CCI groups (data not displayed graphically, please see appendix for values, Table A-1, 
A-2 and A-3). Therefore, significantly reduced CD68 fluorescence/area in the CCI group treated 
with the theranostic nanoemulsion implies that there is relative reduction in the number of 
macrophage infiltration in the CCI group treated with the theranostic nanoemulsion. Finally, to 
see if a single dose of celecoxib-loaded nanoemulsion was effective enough to change COX-2 or 
PGE2 expression in the macrophages, the normalized mean fluorescence intensity of COX-2 and 
PGE2 (ratio of mean fluorescence intensity of COX-2 or PGE2 / CD68 fluorescence intensity, 
please see the appendix for detailed methodology) was compared for both the CCI groups using 
Leica SP2 spectral Laser Scanning Confocal microscope software analysis. A significant 
reduction (t-test, p < 0.0001) in the relative expression of COX-2 and PGE2 was found in the 
CCI group injected with the theranostic nanoemulsion as compared to the vehicle injected CCI 
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group (Figure 3-6 B, C). These results show that a single dose of celecoxib-loaded nanoemulsion 
was sufficient to significantly reduce the relative expression of COX-2 and PGE2 in the 
infiltrating macrophages at the site of injury. 
3.4 Discussion  
As mentioned earlier, nerve injury leads to immunological activation of resident cells as 
well as chemotaxis of hematogenous macrophages to the site of injury. The activated 
macrophages at the site of injury release PGE2, a prostaglandin that contributes to the cause and 
maintenance of neuropathic pain [60].  Furthermore, these activated immune cells release other 
inflammatory mediators as described earlier in the introduction (Chapter 1). PGE2 is 
predominantly produced via the COX-2 oxygenation of arachidonic acid to PGH2, which is 
enzymatically metabolized to PGE2 during inflammatory conditions. Autoregulatory feedback 
leads to an increase in COX-2 expression in the macrophages in the injured peripheral nerve 
[60].  
Released PGE2 binds to four EP (Prostaglandin E) receptors, EP1, EP2, EP3 and EP4 
expressed on the injured afferent neurons [130]. The EP receptors are G protein coupled 
receptors with seven transmembrane domains. Binding of PGE2 on EP1 receptor leads to 
intracellular increase in calcium ions that mediates increased release of neurotransmitters at the 
synapse in the spinal cord [131]. Binding of PGE2 to the EP2 and EP4 receptors on the afferent 
neurons causes increase in cAMP concentrations intracellularly due to activation of adenylyl 
cyclase. EP3 receptors cause anti-nociception by inhibiting the adenylyl cyclase activation in the 
neurons [132]. Therefore, binding of PGE2 to its receptors on the primary afferent neurons 
causes peripheral sensitization by reducing the activation threshold of tetradotoxin-resistant 
sodium channels as well as inhibition of voltage-gated potassium currents [131]. Both these 
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events are mediated by protein kinase A (PKA) signaling that causes an increase in the number 
of action potentials per stimulus known as sensitization [131]. PGE2 also causes prolonged 
action potential firing in the injured afferent neurons due to activation of voltage-gated calcium 
channels that in turn leads to an increase in intracellular calcium and inhibition of the potassium 
channels that ultimately contributes to the peripheral sensitization. Furthermore, PGE2 
potentiates the transient receptor potential vanilloid type 1 (TRPV1) channel through EP1 
receptor along with the bradykinin-induced release of substance P and CGRP in the DRG 
neurons [60]. Increased intracellular calcium flow in the DRG neurons leads to enhanced release 
of neurotransmitters (excitatory amino acids), such as glutamate and aspartate, excitatory 
peptides, such as substance P and calcitonin gene-related peptide (CGRP) at the post-synaptic 
neurons in the spinal cord [131]. The release of these excitatory molecules at the post-synaptic 
neurons in the dorsal horn of spinal cord is the beginning of central sensitization [133] .  
Central sensitization can be broadly divided into two phases, a transcription-independent 
(i.e. phosphorylation-dependent) and a transcription-dependent phase. The phosphorylation 
phase is the early phase of central sensitization that occurs due to binding of the excitatory 
molecules (neurotransmitters) to their specific receptors on the post-synaptic neurons in the 
spinal cord. Activation of glutamate receptors (i.e. amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA), N-methyl-D-aspartate (NMDA), kainate (KA) or mGluR metabotropic 
receptor subtypes) and CGRP receptors lead to massive inflow of calcium ions, activation and 
recruitment of PKA, protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II 
(CAMKII) to cause strengthening of the excitatory synapse in the spinal cord [133]. Activation 
of PKA, PKC and CAMKII causes phosphorylation of ERK 1/2 that further causes trafficking of 
AMPA receptors at the posy-synaptic membranes in the spinal cord and phosphorylates 
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potassium channel to further increase the membrane excitability [133]. In addition, ERK1/2 
causes activation of various transcription factors, including CREB that leads to further 
transcription of various genes such as COX-2 (as mentioned previously), and c-FOS among 
others and therefore, begins the transcription-dependent long-lasting central sensitization phase 
[133]. In this way, COX-2 and PGE2 are up regulated at the site of injury and in the spinal cord 
in the CCI rat model of neuropathic pain [29]. For excellent illustrations of peripheral and central 
sensitization, please refer to [133] and [134]. 
In this study, we have demonstrated a significant relief in mechanical allodynia behavior 
upon injection with a single intravenous dose of the celecoxib-containing theranostic 
nanoemulsion using the CCI rat model (Chapter 3, Figure 3-1, Two-way ANOVA, p< 0.0001). 
The exact mechanism of action for this observation was not investigated in this study and further 
experimentation is required. We have demonstrated a significant reduction in the relative 
expression of COX-2 and PGE2 in the macrophages at the site of nerve injury (Chapter 3, Figure 
3-6, t test, p< 0.0001). Based upon the literature described above, it is predicted that after the 
release of celecoxib in the cytoplasm of the theranostic nanoemulsion-containing macrophages, 
celecoxib selectively inhibits the COX-2 enzyme in the activated macrophages at the site of 
nerve injury and therefore hampers the synthesis of PGE2 in the macrophages. Reduced PGE2 
synthesis and thereby a decline in the PGE2 release at the site of injury is predicted to affect the 
peripheral sensitization due to the reduced availability of PGE2 to bind to the EP receptors at the 
injured afferent neurons. Reduced activation of EP receptors at the afferent neurons is predicted 
to cause a decline in the release of neurotransmitters (i.e. glutamate, aspartate, substance P and 
CGRP) at the post-synaptic neurons in the spinal cord. A decline in the peripheral sensitization is 
predicted to indirectly affect the central sensitization and may prevent the transcription-
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dependent events responsible for long-term central sensitization. Therefore, the reversal of 
mechanical allodynia demonstrated in this study could be due to a decline in the peripheral 
sensitization or a reversal of both peripheral sensitization and transcription-independent 
(phosphorylation-dependent) central sensitization events.  
 It is also known that prostaglandins are also produced by the injured neurons themselves, 
referred to as neurogenic inflammation [60]. Prostaglandins released from the injured neurons, 
bind to the EP4 receptors on the activated macrophages at the site of injury and mediate the 
release of metalloproteases and CGRP from the macrophages [135]. It is predicted that the 
theranostic nanoemulsion does not directly affect the neurogenic inflammation, as the 
nanoemulsion is endocytosed by the inflammatory cells only and not the neurons. These are the 
predictions based on the literature available. The actual mechanism of action of the theranostic 
nanoemulsion to cause reversal of the mechanical allodynia in the CCI rat model needs to be 
substantiated by further experimentation. 
3.5 Conclusion 
Significant reduction in mechanical allodynia was observed for at least three days (day 10 
to day12 post-CCI) after the intravenous delivery of a single dose of celecoxib-loaded 
theranostic nanoemulsion.  This change in behavior occurs along with significant reduction in 
inflammation as measured by in the number of infiltrating macrophages as well as a reduction in 
the relative expression of COX-2 and PGE2 at the site of injury. These data show that the 
successful delivery of low dose celecoxib in the activated macrophages leads to sustained pain 
relief.  Furthermore, the data exhibits the therapeutic potential of selective COX-2 inhibitors 
injected as theranostic nanoemulsion to treat chronic neuropathic pain via delivery of the drug 
directly into the macrophages. 
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In Vivo and Systems Biology Studies Implicate IL-18 as a Central 
Mediator in Chronic Pain 
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4.1 Introduction 
 
Pain arises with multiple etiologies and when pain persists beyond the natural course of 
tissue healing, it is considered to be chronic pain [1]. Chronic pain is now considered of public 
health importance due to its wide impact on society. Chronic pain affects around 100 million 
American adults and leads to economic loss of approximately $600 billion annually [73]. 
Neuropathic pain is one of the causes of chronic pain, and affects more than 6 million Americans 
[73]. Neuropathic pain occurs in response to injury of the somatosensory nervous system [4], and 
may cause pain in the joints, muscles, internal organs, or skin. Furthermore, neuropathic pain 
may occur in the central or peripheral nervous system based upon the site of lesion. 
 Following nerve injury, Wallerian degeneration or anterograde degeneration of the 
neurons occurs leading to disintegration of the myelin and the axons distal to the injury causing 
inflammation and neuropathic pain [14]. This axonal degeneration causes disorientation of the 
axon-Schwann cell organization, which initiates activation of the Schwann cells [136],  as well 
as resident immune cells including mast cells, and macrophages. Activated Schwann cells as 
well as the immune cells secrete chemokines and cytokines that accelerate the recruitment of 
other immune cells from the bloodstream. These recruited cells accumulate at the site of injury 
and include neutrophils, monocytes, lymphocytes, and natural killer cells [12, 13, 137], likely in 
an attempt to promote tissue healing [138]. However, this inflammatory response often becomes 
self-sustaining and thus a deleterious part of the process of post-injury pain [139]. Indeed, due to 
demyelination, axonopathy, and the local inflammatory responses at the lesion, neuronal firing 
for the affected peripheral nerves is increased at the site of injury (peripheral sensitization).  This 
leads to hypersensitivity or reduced threshold to a given stimuli also known as allodynia [18-20]. 
In the past few years, various studies have been performed to explore the molecular dialogue 
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during inflammation following peripheral nerve injury (neuroinflammation) [9, 16, 138, 140-
142] including chronic constriction injury (CCI) rat model as developed in the 1980’s [8]; 
however, details about the interaction among various inflammatory mediators and neurons 
during neuroinflammation still need to be elucidated.  
 Numerous immune cells and inflammatory mediators are involved at different anatomical 
levels in the pain axis, and hence various strategies targeting inflammation have been employed 
to dampen neuropathic pain [16]. One strategy is to diminish the infiltration or activation of 
immune cells such as mast cells, Schwann cells, neutrophils, macrophages, and microglia in an 
effort to reduce the over-exuberant and self-sustaining production of inflammatory mediators 
[16]. Even though this strategy has shown some success in limiting neuropathic pain associated 
hypersensitivity in animal models, doing so poses a major side effect of causing a delay in the 
nerve repair and regeneration [143-145]. An alternative strategy is to specifically target the pain 
stimulating mediators from the immune cells without disrupting the beneficial functions of other 
inflammatory mediators [13, 138]. In recent years, multiple studies have documented dynamic 
changes in various inflammatory mediators post-CCI, including cytokines (TNF-α, IL-2, IL-6, 
IL-1β, IL-4) and chemokines (MCP-1/CCL2 and KC/CXCL1).  The expression of these 
mediators is elevated in the sciatic nerve after CCI in rats, and induces peripheral 
hypersensitivity post injury [16, 26, 137, 146-149].  Cytokines such as IL-1β and TNF-α 
contribute to inflammation and pain during early stages of nerve injury, but later they exhibit a 
beneficial role and are expressed during nerve repair/regeneration [46]. Therefore, studying the 
complex interplay among various inflammatory mediators at different time points during the 
disease progression is more relevant than studying the discrete mediators as singular products 
functioning at one time point in the disease [47].  
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 One method for studying the changes of complex pathophysiological responses in a time 
series experiment is to employ data driven computational modeling.  Such an approach does not 
rely on an a priori understanding of the biological system, but rather only the input and the data 
measured over time [48, 50].  Among several different approaches, network-centric models such 
as Dynamic Bayesian Network (DBN) inference can be used to identify dependent interactions. 
Furthermore, network-based models may reveal how related variables interact with one another 
[48, 49]. For example, DBN inference has recently been used to study the interactions among 
various inflammatory mediators in multiple clinical and pre-clinical settings [150-152].   
 In the present study, we utilized a combination of in vivo and DBN modeling approaches 
to predict an inflammatory network that is active during chronic neuropathic pain as evident in 
chronic constriction injury (CCI). The expression of 14 different cytokines/chemokines in the 
CCI sciatic nerve was assayed using multiplex ELISA, over a period of 18 days post-surgery. 
These protein expression levels were used to calculate the interplay of inflammatory mediators 
based on DBN inference. Immunohistological examination of the CCI sciatic nerve for several 
inflammasome markers supports the DBN prediction. To the best of our knowledge, this is the 
first study to define an inflammatory target using computational modeling in the setting of 
chronic neuropathic pain. 
4.2 Materials and Methods 
4.2.1 Animals 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institute of Health, and Institutional 
Animal Care and Use Committee (IACUC) at Duquesne University approved the protocol (# 
1109-10). Male Sprague-Dawley rats weighing 250-350 g were used in this study (Hilltop Lab 
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Animals, Inc., Scottdale, PA). Rats were maintained on 12:12 hour light dark cycle and were 
given ad libitum access to food and water. 
4.2.2 Surgery And Anesthesia 
 Surgery was performed as described by Bennett and Xie [8, 128], which induces 
neuropathic pain in rats. Rats were divided into three groups, CCI, sham controls and naïve non-
surgical control rats. Briefly, under isoflurane anesthesia, sciatic nerve was exposed via incision 
through skin followed by muscle separation and then four ligatures approximately 1 mm apart 
were tied around the common sciatic nerve of the CCI rat, using 4-0 chromic gut suture. The 
ligatures were neither tight nor loose. The muscle layer was closed using 4-0 chromic gut suture 
followed by skin closure using stainless steel wound clips. Sham rats underwent identical surgery 
except that the ligatures were not applied to the sciatic nerve. Naïve control rats did not undergo 
any surgical procedures and are referred to as non-surgical controls. 
4.2.3 Behavioral Analysis 
Naïve control, sham surgical control and CCI were tested for mechanical allodynia a day 
before surgery and day 11post-surgery as described previously [128].  Briefly, the calibrated 
Semmes-Weinstein monofilaments were applied to the plantar surface of the right hind paw in 
the region of sciatic nerve innervation. The filaments were applied in the ascending order of 
gram force ranging from 0.41-15.13 gram force. Each filament was applied 10 times and the 
withdrawal responses were recorded. The force at which the rat withdrew a paw on 5 of 10 
pushes (50% withdrawal threshold) was predicted by using the regression equation. Normalized 
50% withdrawal threshold (WT) for the ipsilateral hind paw was calculated by using the formula: 
Normalized 50% WT = Post-Surgery 50% WT– Baseline 50% WT. The normalized withdrawal 
latencies were averaged for CCI, sham and naïve non-surgical controls, and their means were 
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compared using Kruskal-Wallis 1-Way ANOVA by Ranks Test (Graphpad PRISM version 
6.0c). Differences were considered significant at p≤ 0.05. 
4.2.4 Tissue Dissection 
The ipsilateral sciatic nerves were collected at the region of injury from CCI, sham and 
naïve control rats. The tissue collection was performed at four time points spanned over the 
period of 18 days post-surgery i.e. 2-3 hours post-surgery and day 8, 11 and 18 post surgery for 
the CCI and sham rats, along with the naïve non-surgical control rats. Four rats were used for 
every given time point. Immediately post-dissection, the tissue was preserved in RNA later 
solution (AM7024, Ambion) and stored at 4°C for 24 hours and thereafter stored at  
-20 °C freezer until further processing. For histology, the tissue was preserved in PBS buffered 
(pH 7.4) 4% paraformaldehyde solution. 
4.2.5 Histology And Confocal Microscopy 
The fixed nerves from control, sham and CCI rats were sliced into 20 μm thick 
longitudinal cryosections.  Double immunofluorescence studies were performed to examine the 
infiltration of macrophages (CD68) along with the presence of caspase-1, IL-18, IL-1β and IL-1α 
using mouse anti-CD68, 1:100 (MCA341R, AbD Serotech), rabbit anti-caspse-1, 1:50 (caspse-1 
p10 (M20) sc514, Santa Cruz Biotechnology), rabbit anti-IL-18, 1:100 (R1186, Acris 
Antibodies), rabbit anti-IL-1β, 1:100 (ab9787, abcam) and goat anti-IL-1α, 1:100 (ab9875, 
abcam) primary antibodies. The secondary antibodies used were Alexa fluor-488 donkey anti- 
mouse, 1:200 (A-21202, Invitrogen), Alexa fluor-546 donkey anti-goat, 1:200 (A-11056, 
Invitrogen) and Alexa fluor-647 donkey anti-rabbit, 1:200 (A-31573, Invitrogen). All the 
antibody dilutions were prepared using 1:20 normal donkey serum in 1X PBS, pH 7.4. Antigen 
retrieval was performed using sodium citrate buffer (10 mM sodium citrate, 0.1% Tween 20, pH 
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6.0 and pH 8.5). Confocal microscopy was performed on a Leica SP2 spectral Laser Scanning 
Confocal microscope. 
4.2.6 Processing Of Rat Sciatic Nerve 
Sciatic nerve sections were obtained from rats (Hilltop lab animals, Scottdale, 
Pennsylvania) and immediately preserved in RNA later® solution (Ambion).  Nerve tissue was 
then homogenized in a 2X lysis buffer (Cell Signaling, Danvers, MA) with 1 mM PMSF using a 
handheld homogenizer.  Samples were then centrifuged at 12,000g for 10 min at 4°C.  After 
centrifugation, collected supernatant was measured for total protein concentration using a 
Pierce™ BCA Protein Assay Kit (Pierce, Rockford, IL). Next, 100 g of total protein in a 
volume of 100l per sample were subjected to analysis of rat cytokines and chemokines as 
described below.   
4.2.7 Analysis Of Inflammatory Mediators 
Prepared nerve sample protein extracts were added to a Millipore (Rat 
cytokine/chemokine 14-plex, cat. #RECYTMAG-25K (Billercia, MA) assay kit as per 
manufacturer’s specifications, for use on a Luminex™ 100 instrument (Luminex Corp., Austin, 
TX). Briefly, 14 cytokines and chemokines, granulocyte-macrophage colony stimulating factor 
[GM-CSF], interferon [IFN]-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-18, 
GRO/KC, monocyte chemotactic protein-1 [MCP-1], and TNF-α, were assessed using the 
MiraiBio CT/QT multiplexing software platform (MiraiBio, Alameda, CA) as per 
manufacturer’s specifications. Reported values in pg/ml were then normalized to pg analyte/mg 
total protein.  The cytokine concentrations obtained (pg/mg) were averaged for each group of rat 
at a given time point and their means were compared among different groups at various time 
points using Two- way ANOVA. Differences were considered significant at p≤ 0.05. 
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4.2.8 Dynamic Bayesian Network Inference  
It was assumed that the cytokine levels obtained at four different time points are the 
result of ongoing neuroinflammation post CCI. The time course of cytokines/chemokines at four 
different time points over a period of 18 days after CCI was first averaged across experimental 
repeats and then used as input for a Dynamic Bayesian Network (DBN) inference algorithm, 
implemented in Matlab® essentially as described previously [150-153]. Briefly, the algorithm 
assumes the data to be drawn from a multivariate normal distribution, with interactions between 
nodes modeled as piece-wise linear Gaussian distributions. Network structures were sampled 
using a Gibbs sampling scheme and scored according to their fit with experimental data. The 
Gibbs sampling procedure was run for 25 steps, and marginal posterior probabilities for each 
edge were then averaged over these networks, and reported as an indicator of the confidence in 
the inferred interactions.  Only edges with marginal probabilities greater than 0.5 were included 
in the reported network structure [154]. 
4.3. Results  
 
4.3.1 Mechanical Allodynia And Inflammatory Mediators During CCI 
Mechanical allodynia is one of the classic signs of neuropathic pain development [8]. In 
the current study, an experimental paradigm of Chronic Constriction Injury (CCI) was used to 
induce neuropathic pain in rats [8, 128]. Similar to prior reports [8, 128], CCI resulted in a 
significant increase (Kruskal-Wallis one-way ANOVA and Tukey’s multiple comparisons test, p 
< 0.0001) in tactile pain sensitivity (mechanical allodynia) during the second week after CCI 
surgery as compared to sham and control rats (Figure 4-1, tactile sensitivity measured on day 11 
post-surgery). The increased sensitivity to the tactile stimulus was observed only on the affected 
ipsilateral side (right hind limb) of the rat and no such signs were observed on the unaffected 
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contralateral side (left hind limb, data not shown). Animals subjected to CCI also exhibited 
guarding behaviors for their right hind limbs.  These findings confirmed the development of 
hypersensitivity, which is an indication of neuropathic pain in the rats post-CCI.  
 
 
 
FIGURE 4-1: Mechanical allodynia develops on ipsilateral hind paw post CCI surgery: The 
mechanical allodynia is represented as normalized difference scores between the baseline values 
before the surgery and day 11 post-surgery for three treatment groups; Naïve control, Sham 
control and CCI rats. More negative scores represent higher mechanical sensitivity towards 
Semmes-Weinstein filaments. CCI rats developed mechanical allodynia and were significantly 
different from both sham and naïve control groups. Bars represent the mean ± SD and * 
represents significant difference p < 0.0001 (Kruskal-Wallis 1-way ANOVA by ranks and 
Tukey’s multiple comparisons test). Sample size for each treatment group is indicated on the 
graph. 
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As mentioned earlier, inflammation at the site of nerve lesion contributes to the 
development of peripheral sensitization [128, 142]. To investigate the dynamics of 
neuroinflammation in this animal model, fourteen different inflammatory mediators were 
assayed simultaneously at multiple time points using Luminex™ assessment of protein extracts 
from the dissected sciatic nerve (Extended Data Table 4-1). 
Extended Data Table 4-1: Cytokine concentrations for 14 different inflammatory mediators in 
three treatment groups; naïve control, sham control and CCI rats at four time points; day 0, day 
8, day 11 and day 18 post surgery.  
 
Results$in$pg/mg$protein
Sample$ID Sample
Time$Point$of$tissue$
collection$(hrs.) IL?5 MCP?1 TNF? IL?1 IL?6 GM?CSF GRO/KC IFN? IL?1 IL?10 IL?12p70 IL?18 IL?2 IL?4
Baseline Baseline?1& 0 26.02 86.8 6.06 272.13 164.04 10.58 8.16 277.18 31.72 38.32 32.29 207.14 114.97 174.14
Baseline?2 0 20.86 129.14 1.11 164.04 214.59 0 4.76 422.55 18.06 5.08 31.04 176.91 86.98 50.51
Baseline?3& 0 23 208.26 14.95 264.41 333.79 11.85 30.12 543.56 28.39 30.89 33.52 249.61 121.2 44.38
Baseline?4 0 19.73 86.8 1.11 189.08 214.59 9.3 9.82 298.79 37.44 3.46 31.04 132.45 126.58 22.82
Sham Sham&(0)1 2&hr. 21.95 2533.15 10.15 546.64 6841.53 14.35 901.84 243.7 19.83 20.07 28.45 203.36 107.94 49.64
Day&0 Sham&(0)2 2&hr. 19.73 1454.84 0 240.43 7285.84 3.9 3208.15 228.9 34.19 50.31 31.04 93.37 144.85 117.41
Sham&(0)3 2&hr. 26.02 1490.07 6.83 530.11 5466.47 14.35 1658.14 392.1 21.57 61.76 32.29 262.91 117.19 47.04
Sham&(0)4 2&hr. 20.86 2736.26 9.84 588.89 5485.88 8.65 1482.66 253.41 22.44 42.41 29.76 320.89 101.86 68.44
Sham Sham&(8)1& 192&hr. 24.03 86.8 7.56 384.93 124.44 13.11 3.22 201.76 35.82 17.99 32.29 381.52 123.43 55.16
Day&8 Sham&(8)2 192&hr. 19.73 0 3.27 332.05 137.84 0 4.35 225.56 42.65 20.84 32.29 478.26 86.56 117.08
Sham&(8)3& 192&hr. 21.95 116.43 1.98 251.36 251.26 10.58 8.11 463.04 39.05 40.62 31.66 252.65 124.78 31.2
Sham&(8)4 192&hr. 27.11 0.00 11.04 317.08 181.68 0.00 4.88 404.68 26.37 33.83 45.32 355.55 178.25 58.17
Sham Sham&(11)1& 264&hr. 27.88 0.00 8.47 448.57 170.92 17.03 3.55 312.23 194.99 58.91 38.49 519.00 114.64 41.75
Day&11 Sham&(11)2& 264&hr. 20.86 129.14 0 220.11 226.92 9.3 11.5 301.84 36.63 50.31 32.29 292.24 118.97 27.11
Sham&(11)3 264&hr. 18.57 44.22 5.22 195.5 124.44 0 4.19 251.8 30.89 32.95 29.76 267.1 173.13 62.11
Sham&(11)4& 264&hr. 20.86 68.32 0 106.73 164.04 0 3.8 280.3 37.44 4.54 28.45 217.74 106.2 94.99
Sham Sham&(18)1& 432&hr. 19.73 44.22 11.59 261.73 151.03 0 4.85 322.89 11.19 11.2 32.29 161.82 69.36 32.19
Day&18 Sham&(18)2 432&hr. 16.09 102.49 1.11 207.21 82.64 0 4.17 191.28 18.94 0 27.11 221.53 79.51 41.67
Sham&(18)3& 432&hr. 14.76 0 0 112.51 67.99 0 3.45 187.74 11.67 0 27.11 159.18 56.41 26.06
Sham&(18)4& 432&hr. 23 140.91 8.41 125.8 226.92 11.85 6.73 423.92 24.16 27.81 32.29 195.04 108.81 48.78
CCI CCI&(0)1 2&hr. 17.35 1159.21 0 405.17 9125.13 11.85 2300.08 201.76 71.41 34.74 25.74 64.85 36.82 17.04
Day&0 CCI&(0)2 2&hr. 18.57 841.11 0 189.95 3613.15 0 558.11 319.91 39.05 0 30.4 124.93 50.33 11.93
CCI&(0)3 2&hr. 20.86 1633.73 0 501.66 15927.95 11.22 13484.15 167.87 29.23 65.57 31.04 105.38 34.72 10.54
CCI&(0)4 2&hr. 18.57 1480.39 0 247.52 9016.66 6.66 2698.09 152.92 54.38 30.64 29.76 100.88 32.63 18.24
CCI CCI&(8)1 192&hr. 51.95 311.08 0 167.53 176.89 0 13.19 274.05 59.36 9.61 32.29 556 34.02 213.69
Day&8 CCI&(8)2 192&hr. 99.25 140.91 0 103.26 124.44 0 4.63 208.65 13.53 0 29.76 378.83 41.11 137.94
CCI&(8)3 192&hr. 111.15 116.43 0 93.44 82.64 0 7.65 70.16 31.72 0 29.76 209.04 36.12 258.99
CCI&(8)4 192&hr. 86.89 140.91 0 152.43 52.81 0 6.16 8.06 30.89 0 27.11 384.22 28.54 123.94
CCI CCI&(11)1 264&hr. 67.79 68.32 0 73.18 52.81 0 3.45 115.2 13.53 0 27.11 194.28 27.21 111.44
Day&11 CCI&(11)2 264&hr. 110.13 208.26 0 261.73 96.89 0 8.03 98.05 81.74 39.6 32.29 441 36.82 178.79
CCI&(11)3 264&hr. 51.31 216.51 0 246.93 52.81 0 9.53 0 63.91 0 25.74 449.91 29.89 139.19
CCI&(11)4 264&hr. 59.6 190.95 0 214.83 96.89 0 10.4 119.35 47.78 0 29.76 703.95 29.89 150.91
CCI CCI&(18)1 432&hr. 18.57 190.95 0 123.78 52.81 0 6.24 43.57 27.55 0 28.45 461.55 27.21 155.15
Day&18 CCI&(18)2 432&hr. 29.73 129.14 0 78.39 67.99 0 2.55 115.2 9.76 16.69 32.29 667.72 31.26 104.34
CCI&(18)3 432&hr. 107.06 102.49 0 80.71 82.64 0 3.51 127.51 15.36 0 28.45 249.61 31.26 304.08
CCI&(18)4 432&hr. 82.61 349.58 0 309.18 96.89 0 15.03 79.81 83.93 2.64 32.29 408.12 30.23 136.06  
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FIGURE 4-2: Cytokine and chemokine protein levels at ipsilateral sciatic nerve suggest 
sustained inflammasome activation in CCI rats. Protein concentration measured on ipsilateral 
sciatic nerves by multiplex ELISA for three treatment groups; naïve control, sham-surgery 
control and CCI rats at four time points; day 0 (2-3 hrs. post surgery), day 8, 11 and 18 post 
surgery. a. IL-4 protein is elevated in a statistically significant manner (Tukey’s multiple 
comparisons test) in the CCI condition as compared to sham and naïve rats from day 8 through 
day 18 (Two-way ANOVA; there was a non-significant main effect of rat condition (p = 0.1723) 
and a significant effect of time (p = 0.0119) with a significant interaction between variables (p = 
0.0004). b. For CCI, IL-18 concentration increased from day 8 through day 18 and was 
significantly different from day 0 values at all time points (Tukey’s multiple comparisons test). 
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Significant difference between CCI & sham rats was observed on day 18 (Tukey’s multiple 
comparisons test). Significant difference for CCI and naïve control rats was observed on day 8, 
11 and 18 (Tukey’s multiple comparisons test). For sham rats, the IL-18 levels increased from 
day 8 to day 11, however unlike CCI rats, the levels returned to baseline levels by day 18 post- 
surgery (Tukey’s multiple comparisons test). (Two-way ANOVA; there was a significant main 
effect of rat condition (p = 0.0351) and time (p = 0.0315) with a significant interaction between 
variables (p = 0.0139). c. MCP-1 protein is elevated in a statistically significant manner (Tukey’s 
multiple comparisons test) similar to what was observed for IL-18 in the CCI condition as 
compared to sham and naïve rats (Two-way ANOVA; there was a significant main effect of rat 
condition (p = 0.0374) and time (p = 0.0084) with a significant interaction between variables (p 
= 0.0334). d. IFN-γ protein drops in the CCI condition in a statistically significant manner 
(Tukey’s multiple comparisons test) over the time course of the experiment as compared to sham 
and naïve rats (Two-way ANOVA; there was a significant main effect of rat condition (p = 
0.0171) and non-significant main effect of time (p = 0.1844) with a non-significant interaction 
between variables (p = 0.5332). Bars represent the mean ± SD and * represents significant 
difference at p ≤ 0.05 (Tukey’s multiple comparisons test). Four rats were used in each treatment 
group at every given time point. 
Inflammatory mediators whose expression was determined to be significantly different 
between CCI and sham rats included IL-1β, IL-2, IL-4, IL-5, IL-6, IL-18, IFN-γ, TNF-α, MCP-1 
and IL-12p70. Four mediators exhibited significant difference (Tukey’s multiple comparisons 
test) across the entire time course of the experiment (Figure 4-2). For example, in CCI rats, the 
expression of IL-4 was significantly elevated (Tukey’s multiple comparisons test) by day 8 and 
high expression persisted through day 11 and day 18 as compared to both sham-surgery rats and 
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the naïve control (Figure 4-2A). For IL-4, there was a non-significant main effect of rat condition 
(p = 0.1723) and a significant main effect of time (p = 0.0119) with a significant interaction 
between variables (p = 0.0004) using Tukey’s multiple comparisons test. In sham-surgery rats, 
IL-18 expression was significantly higher (Tukey’s multiple comparisons test) than naïve control 
from day 8 to day 11 post-surgery, followed by a return to baseline levels on day 18. In contrast, 
the CCI rats exhibited IL-18 expression that was significantly higher (Tukey’s multiple 
comparisons test) than normal on day 8 and that persisted at a significantly high level (Tukey’s 
multiple comparisons test) through day 18 (Figure 4-2B). For IL-18, there was a significant main 
effect of rat condition (p = 0.0351) and time (p = 0.0315) with a significant interaction between 
variables (p = 0.0139) using Tukey’s multiple comparisons test. Similar to IL-18, MCP-1 
expression was elevated at day 8 for both the sham-surgery and CCI rats. In contrast, at day 11 
and day 18 MCP-1 expression trajectories of the sham and CCI animals diverged: MCP-1 
expression in the sham animals returned to baseline levels, while MCP-1 expression in CCI 
animals persisted at a significantly high level (Tukey’s multiple comparisons test) (Figure 4-2C). 
For MCP-1, there was a significant main effect of rat condition (p = 0.0374) and time (p = 
0.0084) with a significant interaction between variables (p = 0.0334) using Tukey’s multiple 
comparisons test. IFN-γ levels were significantly lower in CCI rats (Tukey’s multiple 
comparisons test) as compared to sham and naïve rats starting on day 8, and remained low 
through day 18 (Figure 4-2D). For IFN-γ, there was a significant main effect of rat condition (p = 
0.0171) and a non-significant main effect of time (p = 0.1844) with a non-significant interaction 
between variables (p = 0.5332) using Tukey’s multiple comparisons test.  
4.3.2 Dynamic Bayesian Network (DBN) Inference  
Based on the tissue-level protein expression data (extended data Table 4-1), DBN 
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inference [150-152] was utilized to calculate the most likely central nodes and regulatory 
interactions (Figure 4-3). 
 
 
FIGURE 4-3: Dynamic Bayesian Network (DBN) inference suggests a central role for the 
inflammasome in CCI: Data on inflammatory mediators from CCI (A) and Sham (B) rats (see 
Figure 4-2 & Extended Data Table 4-1) were used to carry out DBN inference. Inflammatory 
mediators are represented as network nodes. The thickness of connections among nodes or to 
themselves (edges) is based on how often they are represented in individual experiments. Nodes 
with auto-regulatory feedback and connections to other nodes are considered central. 
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This analysis suggested that elevated pain sensitivity in CCI rats occurs in parallel to 
changes in the tissue expression of key inflammatory mediators. In CCI animals (Figure 4-3A), 
this analysis suggested a network in which IL-18 serves as a central node exhibiting auto-
regulatory feedback. Furthermore, IL-18 was inferred to affect the expression of multiple 
inflammatory mediators including IL-5, MCP-1, IL-1β, IL-6, IFN-γ, and IL-4. In sham-surgery 
animals (Figure 4-3B), DBN inference suggested a network centered on IFN-γ, IL-1β, and IL-18, 
with each exhibiting auto-regulation.   
4.3.3 Immunohistochemical Analysis 
 Figure 4-3 raised the hypothesis that inflammasome activation – known to drive the post-
translational processing of pro-IL-18 and pro-IL-1 to IL-18 and IL-1, respectively [44, 155] – 
occurred in the setting of CCI. To test this hypothesis, multi-target immunofluorescence was 
performed on the ipsilateral sciatic nerve tissue sections from CCI, sham, and naïve control rats. 
The analysis of CCI tissue sections demonstrated the elevated expression of prostaglandin E2 
(PGE2), IL-18, IL-1β, IL-1α, and the inflammasome product caspase-1 in CCI, whereas these 
proteins were not detected in sham or naïve control nerve sections (Figure 4-4).  
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FIGURE 4-4: Double immunofluorescence for macrophages and cytokines on ipsilateral sciatic 
nerve cryosections suggests inflammasome activation in CCI rats: IL-18 A shows infiltration of 
CD68 positive macrophages and presence of IL-18 in CCI sciatic nerve. Sham and Naïve control 
sciatic nerves did not exhibit presence of macrophages and IL-18 (B, C).  IL-1α Ipsilateral CCI 
sciatic nerves exhibit presence of macrophages and IL-1α (D), which are both absent from Sham 
and Naïve control tissue (E, F).  IL-1β Macrophages and IL-1β are evident in the affected sciatic 
nerve (G), but are absent from Sham and Naïve control tissue (H, I).  Caspase-1 Macrophages 
and caspase-1 are evident in the CCI sciatic nerve (J), but are not evident in the Sham and Naïve 
control tissue (K, L).   PGE2 Macrophages and PGE2 are evident in the affected CCI sciatic 
nerve (M). No macrophages or PGE2 expression are evident in the Sham and Naïve control 
tissue (N, O).   For each experiment group (A, B, C), (D, E, F), (G, H, I), (J, K, L) and (M, N, 
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O), the confocal images were acquired in the same sitting with the same image acquisition 
parameters. Bar = 150 µm. 
4.4. Discussion  
 
Within hours following the peripheral nerve injury, several physiological responses can be 
observed including involvement of innate and adaptive immune responses [16]. Within days of 
the peripheral nerve injury, the physiological changes become manifested as hyperexcitability of 
nociceptive neurons in response to innocuous tactile stimuli. This phenomenon becomes evident 
as mechanical allodynia, as described by Bennett and Xie in 1988. Similar to our previous report 
[128], we have confirmed the development of mechanical allodynia in this study. Inflammation 
begins at the site of injury, and later involves the dorsal root ganglia (DRG), spinal cord and 
brain [16]. Conventional immune cells such as mast cells, neutrophils, macrophages and T 
lymphocytes, along with other resident cells such as Schwann cells, microglia and astrocytes, 
exhibit activated profiles of gene expression producing a variety of inflammatory mediators that 
contribute to the initiation and maintenance of neuropathic pain [16, 23, 118, 136]. Based upon 
previous studies, the cytokines that are consistently elevated in expression following peripheral 
nerve injury are TNF-α, IL-1β, and IL-6 [3].  
Neuroinflammation is a complex physiological response. While extensive research on 
inflammatory mediators has led to some useful clinical therapies, satisfactory treatment of 
neuropathic pain remains elusive [156]. Under experimental conditions of neuroinflammation, 
neutralizing antibodies have been used to attack several inflammatory mediators including TNF-
α, IL-1β, IL-6, IL-15, IL-18, and MCP-1 resulting in limited success in reducing neuropathic 
pain [16]. Furthermore, stimulation of nominally anti-inflammatory cytokines (IL-4, IL-10, TGF-
β1) was reported to reduce hypersensitivity in various animal models of neuropathic pain [16].  
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In the present study, we hypothesized that a better understanding of the dynamic 
interconnections among tissue inflammatory mediators would facilitate the search for 
inflammation-modulating therapies in the setting of neuropathic pain. In clinical settings, 
neuropathic pain is mostly diagnosed in its chronic stages. Therefore, we determined the tissue 
levels of inflammatory mediators at both acute (2-3 hours post-CCI) and subacute as well as 
chronic stages (day 8 to day 18 post-CCI). Based on DBN inference carried out with these data, 
we hypothesize key interactions among inflammatory mediators that are operant in CCI-induced 
neuroinflammation, as well as the transition from acute to chronic pain. Specifically, we infer a 
central role for IFN-, IL-1, and IL-18 following general tissue injury, since these mediators 
appeared as central nodes (those which are feeding back on themselves as well as affecting the 
expression of other mediators) in the sham surgical acute inflammatory network. In contrast, IL-
18 was inferred as the central node in the CCI animals, appearing to control its own expression 
along with affecting other mediators involved in neuroinflammation.  This IL-18-centered 
network correlates with the maintenance of neuropathic pain (mechanical allodynia) throughout 
the period of study.  
 The inflammasome is a caspase-activating complex that serves critical roles in innate 
immunity [44, 155, 157-159].  It is known that inflammasome induction in macrophages leads to 
secretion of IL-18 as well as IL-1. Both IL-18 and IL-1 are cleaved proteolytically from their 
respective precursors via activation of caspase-1 enzyme. Both IL-18 and IL-1 can induce 
cyclooxygenase and PGE2 [155, 160-164]. Both IL-18 and IL-1 are elevated in the spinal cord 
(central nervous system) following CCI [9, 157]. Similarly, we found IL-18 expression to be 
elevated consistently at the site of injury (peripheral nervous system) from day 8 to day18 post-
CCI. However, no consistent difference was found for IL-1 baseline and post-CCI protein 
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levels at the site of injury (data not shown). Immunofluorescence analysis carried out on 
ipsilateral sciatic nerve sections further confirmed the expression of IL-18, caspase-1, and PGE2 
after the CCI surgery.  
 Among the many inflammatory pathways induced by inflammasome activation, the 
cyclooxygenase pathway and attendant production of PGE2 play a key role in the setting of 
inflammatory pain following peripheral nerve injuries [29, 118]. Separate studies have also 
demonstrated that IL-18 can induce both cyclooxygenase and PGE2 from macrophages and 
chondrocytes [160, 162].  Our immunohistological studies confirm the expression of IL-18 in the 
sciatic nerve, supporting our Luminex™ data and supporting the hypothesis that inflammasome 
activation occurs in damaged nerves in the setting of CCI.  
DBN inference along with our other data suggests that as a consequence of CCI, besides 
driving its own expression, IL-18 also drives the expression of IL-4 and MCP-1 along with the 
down regulation of IFN-γ.  In the context of nerve injury, IFN-γ has been shown to exhibit 
elevated expression in the central nervous system, and contribute to central sensitization [148]. 
However in the present study, we observed a gradual decline in IFN-γ at the site of chronic 
constriction injury on the sciatic nerve over the entire duration of the study.  IFN-γ is induced in 
macrophages either by the synergistic action of both IL-18 and IL-12 or in the presence of active 
IL-12p70 homodimer [97, 165-168].  We did not observe an up regulation in the IL-12p70 levels 
for the CCI rats.  With regard to IL-4, this cytokine can play an anti-inflammatory role in many 
settings of inflammation, as well as exerting anti-nociceptive properties in the setting of 
neuropathic pain [169]. Moreover, IL-4 is a known inhibitor of IFN-γ production by the 
macrophages [165].  Here, we observed a consistent up regulation of IL-4 in the CCI rats from 
day 8 to day 18 post-CCI. Importantly, IL-18 is also known to perform other immune functions 
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that are not directly related to the IFN-γ production. Furthermore, IFN-γ production is not 
dependent entirely on IL-18 [170].  Therefore, even though IL-18 (which was initially named as 
‘IFN-γ inducing factor’) is up regulated, this does not necessarily cause an up regulation of IFN-
γ in all circumstances.  
 Dynamic Bayesian Network inference also suggested that IL-18 might drive the 
expression of the chemokine MCP-1/CCL2 during peripheral neuropathy. Consistent with 
previous studies [171], we found elevated MCP-1 expression as a consequence of CCI, and it is 
likely that MCP-1 expression also contributes to the development of mechanical allodynia. These 
findings further support the activation of inflammasome pathways post-CCI injury, leading to 
activation of caspase-1 and the production of IL-18 and IL-1β.  Similar observations have been 
made for neuropathic pain models and a model of complex regional pain syndrome [157, 172]. 
4.5. Conclusion 
This study highlights the potential for computational modeling as a tool to infer key 
interactions among inflammatory mediators at the tissue level in the context of chronic 
neuropathic pain. The results of this combined in vivo / in silico study suggest a central role for 
inflammasome activation and subsequent production of IL-18 in the induction and maintenance 
of neuropathic pain during peripheral nerve injury. Furthermore, our analyses suggest that the 
response to general tissue injury in this context involves interactions among IFN-γ, IL-1β and IL-
18. Recent studies have demonstrated that spinal blockade of IL-18 led to improvement in 
mechanical allodynia and thermal hyperalgesia during CCI in rats [9]. Therefore, these results 
raise the possibility that IL-18 or inflammasome inhibition may lead to significant neuropathic 
pain relief; however, these studies must be extended and the exact underlying mechanisms still 
need to be revealed. Finally, these studies demonstrate the power of combined in-vivo / in-silico 
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studies in the setting of chronic neuropathic pain.   
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Chapter 5 
DISCUSSION 
5.1 In-Vivo Inflammation Imaging Using Near Infra Red (NIR) Fluorescence 
And 19F Magnetic Resonance Imaging (MRI) In CCI Rat Model 
The accurate diagnosis of neuropathic pain associated neuroinflammation relies upon the 
nerve biopsy, which is not feasible in all the cases of neuropathic pain [173]. In addition, the 
procedure is invasive and the etiology may remain elusive even after the biopsy due to a 
mismatch between the region of biopsy and the site of actual inflammation in the injured nerve. 
Therefore, neuroinflammation imaging matched with an analysis of symptoms exhibited by the 
patients may guide the clinicians to personalized and targeted treatment for a given set of 
patients. Today, the focus is on mechanism-based treatment of neuropathic pain rather than 
following a common regimen of treatment for various neuropathic pain disorders [156]. 
Therefore, it would be of great value if we can image neuroinflammation in-vivo using non-
invasive techniques. 
Multiple imaging modalities are available to image the structures and/or physiological 
functions in the body. Examples of imaging modalities for medical purposes include plain 
radiography (using X-rays only), fluoroscopy (using X-rays and contrast agents such as Barium 
sulphate), computed tomography (CT scan using X-rays), magnetic resonance imaging (MRI 
using radio frequency waves), positron emission tomography (PET using positron emitting 
radionuclide tracers) and single photon emission computed tomography (SPECT using gamma 
rays). Radionuclide based scans have limited resolution [174] and have to be combined with 
MRI or CT to achieve the resolution of anatomic details [175].  These techniques have done 
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wonders to guide clinicians in making accurate diagnoses. However, diagnosing early stages of 
inflammation in soft tissues is still a bottleneck when using conventional imaging techniques 
available, due to poor contrast between the inflamed and healthy tissue and low signal-to-noise 
ratio [176]. In-vivo neuroinflammatory events are difficult to be captured by these conventional 
imaging techniques, unless the inflammation is flared-up to the extent of causing morphological 
changes in the nerve, such as a significant change in the diameter of the nerve due to edema or a 
high contrast between the pathological and a healthy tissue. 
5.2 Imaging Reagents  
Contrast of MRI scan can be drastically improved with the use of contrast tracers such as 
gadolinium, super paramagnetic iron-oxide particles and 19F tracers. Recently, iron-oxide 
particles and 19F tracers have been successfully used in biomedical research in various animal 
models, such as organ transplant rejection [38], experimental allergic encephalomyelitis [85], 
inflammatory bowel disease [122], pulmonary inflammation [177], inflammation post cardiac 
and cerebral ischemia [176], Staphylococcus aureus abscess [178], renal graft rejection [179], 
and cardiac allograft rejection using iron-oxide particles [180].  Phase I clinical trial in humans 
have employed a 19F tracer to track ex-vivo labeled dendritic cells, injected as dendritic cell 
vaccine against colorectal adenocarcinoma in human patients [175]. 19F is a stable and a natural 
isotope found in abundance. Also, 19F has a nuclear spin of ½ and is highly responsive to NMR 
analysis providing a high signal-to-noise ratio with no background noise [42]. Even though iron 
oxide labeling provides higher sensitivity as compared to a 19F tracer during MRI [38], 19F signal 
directly correlates to the amount of labeled cells. On the other hand, metal ion-based MRI agents 
indirectly change the relaxation times of water in their surroundings and therefore the alteration 
in signal contrast (increase or decrease) is ambiguous and indirectly related to the amount of 
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labeled cells present [38]. Also, 19F MRI has no background signal in the soft tissues and thus is 
highly specific and more advantageous than metallic tracers [87]. Gadolinium, another metallic 
labeling agent, labels the region of inflammation, due to its leakage through the leaky capillaries 
with increased permeability due to the undergoing inflammatory events. Therefore, the 
specificity can be compromised by other biological phenomena, such as a circulatory disease, 
rather than due to the inflammatory disease under study [176]. 
Another advantage of 19F imaging is that both 1H and 19F MRI can be obtained with the 
same scanner in one experiment and both the scans can be superimposed to precisely locate the 
19F signal within the anatomical structures. Natural fluorine found in the body (19F) is present in 
bones and teeth. It stays fixed and moves negligibly and therefore the signal achieved elsewhere 
due to 19F is highly sensitive of the tracer [181]. 
Our collaborator Jelena M. Janjic, Pharm D, PhD has designed a novel nanoemulsion 
containing a NIR dye and a 19F tracer for tracking inflammation with dual imaging modalities of 
optical imaging and 19F MRI. Previously, optical imaging and bioluminescence have been used 
in animal models, such as cutaneous granuloma model using DiR dye labeled macrophages 
[119].  Dyes with excitation wavelength below 700 nm are strongly absorbed and scattered by 
hemoglobin in the body and the dyes with excitation wavelength above 820 nm are also strongly 
absorbed as well as scattered by water molecules in the body. Thus, NIR dyes with excitation 
window between 700 nm and 800 nm are best suited for optical imaging in animal tissues [97], 
(LiCOR Biosciences http://biosupport.licor.com/docs/pearlBrochure2010.pdf). Therefore, in this 
study, a NIR dye was used to label the circulating immune cells along with the 19F tracer, 
formulated as a nanoemulsion. Even though NIR imaging has high sensitivity [42], it also has 
tissue penetration depth limitations, due to scattering and absorption issues, which results in poor 
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resolution, rendering NIR imaging only as a semi-quantitative technique [182]. To overcome this 
limitation, MRI was performed along with NIR fluorescence imaging [42].  
MRI has infinite tissue depth penetration with high resolution of 10-100 μm [38, 183]. 
Thus, the use of 19F tracer led to enhanced specificity and sensitivity of the inflammatory signal 
detection. Therefore, the NIR dye and the 19F tracer containing dual mode nanoemulsion was 
used in this study with the goal of imaging of neuroinflammation using dual imaging modalities 
of NIR fluorescence and 19F MRI.  
5.3 Animal Model  
There are various animal models available to study neuropathic pain, such as the chronic 
constriction injury rat model [8], spinal nerve ligation [184] and partial sciatic nerve ligation 
[185].  A majority of the neuropathic pain conditions in human patients involve partial damage to 
the nerve rather than a complete nerve transection.  CCI in rats causes partial damage to the 
sciatic nerve, thus simulating commonly found neuropathic conditions in humans [8]. CCI rat 
model is a well-established and well-characterized rat model in the field of neuropathic pain [9]. 
The hallmarks of neuropathic pain include thermal hyperalgesia, cold allodynia and tactile 
allodynia. These signs develop readily after the CCI injury and persist for about two months 
post-CCI [8]. The common sciatic nerve is readily located and easily manipulated due to its 
relatively larger size. Another advantage is that in this model, both spontaneous and evoked pain-
like behaviors can be studied. Spontaneous pain-like behavior is demonstrated by paw licking, 
avoiding weight bearing, limping and relatively less movement of the affected limb [10]. Evoked 
pain-like behavior is caused as a response to noxious or non-noxious external stimuli.  
After about one week post-CCI, the signs of hypersensitivity develop that indicate the 
onset of neuropathic pain in rats. Hypersensitivity is enhanced responsiveness to a normal 
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innocuous stimulus or an exaggerated response to a noxious stimulus [1]. We observed the 
development of hypersensitivity to a normally innocuous mechanical stimulus, constituting 
mechanical allodynia.  Behaviorally, mechanical allodynia begins to develop in the ipsilateral 
hind paw from day 8 post-CCI and persists for approximately 7 weeks post-CCI [186].  In the 
current study, the development of neuropathic pain was confirmed by the presence of mechanical 
allodynia on the ipsilateral hind paw, observed on day 11 post-CCI. Literature suggests that CCI 
rats exhibit the signs of neuropathic pain-like behavior at least 2 months post-CCI surgery [8]. 
5.4 Nanoemulsion  
Nanoemulsions are oil-in-water emulsions that are stabilized with surfactants or 
emulsifiers. Nanoparticles can be of various sizes, and for biomedical purposes, the most 
commonly used size ranges from 100-500 nm [187]. Most immune cells participating during 
inflammation are known to be phagocytic, and can engulf the intravenously injected 
nanoemulsion [90]. Given that during inflammation, the inflammatory cells migrate from blood 
to the site of injury, one of the methods to track inflammation is to follow the migration of these 
labeled immune cells (i.e. labeled with nanoemulsion) from blood to the site of injury [38, 188]. 
Hence, with the purpose of labeling the immune cells in-vivo, slow intravenous injection of the 
nanoemulsion (0.3 ml) was given to the rats under general anesthesia on day 8 post-CCI. The 
average size of the nanoemulsion droplets used in this study was around 180 nm [42].  
It is important to recognize that the larger size nanoparticles (> 500 nm) are phagocytized 
by the circulating phagocytic cells whereas the smaller size nanoparticles (<500 nm) are 
engulfed by receptor mediated endocytosis or pinocytosis [189]. In-vitro studies have shown that 
PFC nanoemulsions can be engulfed either by phagocytic or non-phagocytic cells via 
endocytosis [69, 70, 190]. PFC based nanoemulsions can be phagocytized by phagocytic cells, 
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such as monocytes, macrophages, neutrophils, dendritic cells and T lymphocytes [174, 191, 192]. 
Flogel and coworkers have shown that following the intravenous injection, the PFC containing 
nanoemulsion droplets are engulfed preferentially by circulating monocytes/macrophages 
(~80%), followed by B and T lymphocytes [176, 191]. During in-vitro characterization, it has 
also been shown that the PFC nanoemulsion is non-toxic and does not affect the viability of 
macrophages [40, 42, 71]. Post-intravenous injection blood clearance half-life of a similar PFC 
nanoemulsion (~145 nm diameter) has been found to be approximately 9 hours [38]. In allograft 
rejection rat model, it has been shown that the labeled immune cells reach the site of rejection 
within 24 hours [38] and in another study, ex-vivo labeled dendritic cells took around 18 hours to 
drain the regional lymph node in human subjects [175]. As mentioned earlier, we observed the 
development of significant mechanical allodynia on day 11 post-CCI, which is an indirect 
indicator of the development of neuroinflammation at the sciatic nerve [193]. Therefore, based 
upon the given fact and the brief review of literature given above, in this study, the nanoemulsion 
was injected on day 8 post-CCI and the NIR fluorescence imaging was performed on day 11 
post-CCI. A time period of 72 hours between the time of injection and NIR imaging allowed for 
the uptake of the nanoemulsion by the immune cells in circulation and their migration to the site 
of injury (sciatic nerve). 
Based upon the literature [37, 38, 40, 42, 69] and the size of the nanoparticles used in this 
study (<160 nm, [42], it was predicted that after the intravenous injection of the nanoemulsion, 
the nanoparticles containing NIR dye and 19F tracer would be endocytosed by the circulating 
monocytes and then migrate to the sciatic nerve post-CCI, causing neuroinflammation. To 
resolve a specific NIR signal above tissue background and to reveal that NIR fluorescence was 
evident on the thoracolumbar region of the rats, NIR fluorescence images were acquired 
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immediately before the injection of the nanoemulsion in all the experimental groups of rats 
(Chapter 2, Figure 2-2). Pre-injection NIR fluorescence in the thoracolumbar region of the rats 
suggested autofluorescence in the liver and abdominal areas, possibly due to rat diet contents in 
the gastrointestinal tract (LiCOR Biosciences). Similar to hemoglobin and water, chlorophyll, 
along with other components in a regular rat diet, absorbs NIR wavelength and scatters light in-
vivo (LiCOR Biosciences). Therefore, purified diet (D10012G Research Diets, Inc. New 
Brunswick, NJ) was used during NIR imaging because it significantly reduces autofluorescence 
during in-vivo NIR fluorescence imaging (LiCOR Biosciences). Even though the use of purified 
diet did lead to reduced autofluorescence, it was not completely eliminated and was consistently 
observed before or after the nanoemulsion injection on day 8 post-CCI (Chapter 2, Figure 2-2, 2-
3.1). To ensure the precise intravenous delivery of the nanoemulsion, all the rats were imaged on 
the LiCOR imager immediately after the injection to observe a fluorescent spot on the tail that 
represented the site of injection (Chapter 2, Figure 2-2 G). Slight leakage of the fluorescent 
nanoemulsion at the injection site was inevitable due to puncture of the tail vein by the needle at 
the injection site. However, the presence of a strong fluorescent signal from the site of injection 
towards the base of the tail or a big clump of strong fluorescent signal localized in the tail 
indicated a subcutaneous injection. The rats injected with unintentional subcutaneous delivery of 
the nanoemulsion were excluded and only the rats injected with accurate intravenous delivery of 
the nanoemulsion were included in this study. Overall, based upon the LiCOR imaging, the 
success rate of intravenous injections in the lateral tail vein of young-adult rats was 
approximately 70% in this study.  
In the CCI rat, a sharp band of fluorescent signal visible on the ipsilateral thigh on day 11 
post-CCI (Chapter 2, Figure 2-2 I) indicated presence of inflammation at the site of injury, which 
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was significantly different (t test, one-way ANOVA, two-way ANOVA) from the contralateral 
CCI hind limb and the naïve or sham conditions (Chapter 2, Figure 2-3.1 G, Figure 2-3.2). With 
the goal of finding out the exact source of NIR fluorescence in the thigh region of the CCI rat, 
LiCOR Pearl imaging was performed on a perfusion fixed rat on day 12 post-CCI. And it was 
found that the NIR fluorescence at the ipsilateral thigh region of a CCI rat was contributed by the 
regional lymph node and the femur bone in addition to the injured ipsilateral sciatic nerve (data 
not included in the dissertation). On the contralateral hind limb, the NIR fluorescence was 
observed only on the lymph node and the femur bone, however no fluorescence was visible on 
the contralateral sciatic nerve. The presence of NIR fluorescence in the lymph node and femur 
bone is possibly due to physiological circulation of the labeled immune cells through the 
reticuloendothelial (RE) system. RE system is the other name for mononuclear-macrophage 
system where the macrophages are scattered throughout the reticular connective tissue in liver, 
spleen, lymph nodes, bone marrow and lungs. The clearance of PFC nanoemulsions is assumed 
to occur via RE system and expiration through lungs [87, 90]. Sham rats exhibited a sharp NIR 
fluorescence at the site of incision (Chapter 2, Figure 2-3.1 B) on day 11 post-surgery. Since the 
fluorescence was not scattered and had very sharp boundaries, it indicated a superficial injury 
due to the skin and muscle incision during sham surgery rather than a deep injury like in a CCI 
rat that showed a scattering effect leading to an irregular band of fluorescence (Chapter 2, Figure 
2-3.1 B). Also, on day 18 post-surgery, the fluorescent signal had almost disappeared in sham 
rats, whereas it persisted in the CCI rats (Chapter 2, Figure 2-3.1 C,F). This confirmed that the 
sham surgery was superficial and that the skin and muscle incisions had been nearly healed by 
day 18 post-surgery, whereas CCI rats still exhibited a strong fluorescent signal on day 18 post-
CCI that indicated persistent inflammation on the injured sciatic nerve (Chapter 2, Figure 2-3.1 
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C, F). To further confirm the origin of NIR fluorescence in the sciatic nerve, the ipsilateral 
common sciatic nerve was dissected out from the CCI and the sham rats and was imaged on 
LiCOR Odyssey imager. LiCOR Odyssey imager is a two dimensional scanner with 700 nm and 
800 nm excitation lasers for ex-vivo NIR imaging (LiCOR Biosciences). A strong fluorescent 
signal was observed for the CCI rat sciatic nerve that confirmed the presence of NIR dye in the 
injured sciatic nerve and hence complemented the in-vivo NIR imaging data to suggest that the 
NIR fluorescence in the sciatic nerve was indeed due to the presence of NIR dye containing 
immune cells participating in the neuroinflammation at the injured sciatic nerve (Chapter 2, 
Figure 2-3.1 H, I). Since the nanoemulsion labeled cells contained both NIR dye and a 19F tracer, 
to trace the presence of 19F tracer in the sciatic nerve, 19F MRI was performed in the ipsilateral 
hindleg of the perfusion fixed CCI and sham rats, along with 19F Nuclear Magnetic Resonance 
NMR spectroscopy on the dissected ipsilateral and contralateral sciatic nerves. Superimposed 1H 
and 19F scans of axial and coronal slices of the rat hind leg revealed the presence of 19F signal 
(red) superimposed with the knots at the ipsilateral sciatic nerve of the CCI rat (Chapter 2, Figure 
2-4). The 19F signal was not present at the ipsilateral sciatic nerve of the sham rat or the 
contralateral sciatic nerve of the CCI rat. Hence, the in-vivo (LiCOR Pearl) and ex-vivo (19F MRI 
and LiCOR Odyssey) imaging data strongly suggested the presence of inflammation at the 
injured sciatic nerve in the CCI rats due to the accumulation of nanoemulsion labeled immune 
cells at the site of injury. 19F NMR revealed the confirmatory peak of PFC nanoemulsion in the 
ipsilateral sciatic nerve post-CCI and no 19F signal was evident in the contralateral sciatic nerve 
of the CCI rats or the ipsilateral nerves from the sham or naive control rats (Chapter 2, 
Supplementary Figure 2-S2). Besides the presence of 19F signal at the sciatic nerve, the 19F signal 
was also observed in the ipsilateral femur and tibia bones of the CCI and sham rats (Chapter 2, 
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Figure 2-4). 19F signal in the bones could be due to the fact that the PFC nanoparticles are 
engulfed by the monocytes and macrophages and are cleared-up by the RE system of the bones 
[189]. Suyama and coworkers showed the development of osteoporosis in the ipsilateral tibia 
bone associated with the CCI of the common sciatic nerve in rats [124]. Similarly in humans, 
patchy osteoporosis has been linked with complex regional pain syndrome [123]. Therefore, 
another reason for the presence of 19F signal in the bones of CCI rats could be the inflammatory 
changes associated with the regional peripheral nerve injury (i.e. common sciatic nerve). Since 
the 19F signal was observed in both the CCI and sham rats, and apparently the intensity of the 19F 
signal in the femur bone of the CCI rat was much higher than the femur bone of the sham rat 
(Chapter 2, Figure 2-4), it is very likely that the 19F signal in the femur bone is due to a 
combination of both physiological (clearing by the RE system of the femur bone) and 
pathological reasons (osteoporosis of the ipsilateral femur bone). However, these interesting 
findings need to be substantiated and further explored in future studies.  
To validate the results obtained from the imaging techniques, immunofluorescence was 
performed on thin cryosections of the fixed sciatic nerves to find out the infiltration of activated 
macrophages in the sciatic nerve. In Chapter 2, Figure 2-5 showed the infiltration of CD68+ 
macrophages in the ipsilateral sciatic nerves of the CCI rats whereas no such infiltration was 
apparent for the sham or naïve control rats. This finding confirmed that the NIR fluorescence 
signal and 19F signal in the ipsilateral thigh of the CCI rats was indeed due to the presence of 
nanoemulsion labeled macrophages at the site of injury. Therefore, the first hypothesis that 
“neuroinflammation will be visualized in-vivo by NIR imaging and 19F MRI by intravenous 
injection of a dual mode nanoemulsion containing NIR dye and 19F tracer” is accepted. We have 
demonstrated that the NIR fluorescence imaging and the 19F MRI techniques were 
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complementary to each other and that it was feasible to capture neuroinflammation with a 
positive contrast signal and high resolution at the common sciatic nerve in a CCI rat model. 
Following successful imaging of neuroinflammation in CCI rat model [128], the theranostic 
nanoemulsion originally designed and developed by Dr. Jelena M. Janjic and Sravan K. Patel 
[41, 42] was used to track the inflammation at the site of injury before and after the drug 
administration. The goal of this study was to track the therapeutic effect of the theranostic 
nanoemulsion [41, 42] on the CCI induced neuropathic pain by measuring mechanical allodynia 
in rats along with tracking inflammation by using NIR fluorescence imaging and 19F MRI 
techniques. The nanoemulsion injection with celecoxib (theranostic nanoemulsion) or 
nanoemulsion without celecoxib (vehicle nanoemulsion) (0.3 ml each), was given on day 8 post- 
surgery. Similar to our previous study [128], and based upon the size of the nanoemulsion used 
(< 160 nm, [42]), upon intravenous delivery, the nanoemulsion is engulfed by the circulating 
monocytes and hence the anti-inflammatory drug (celecoxib) is delivered directly into the 
monocytes in circulation. As mentioned earlier, nanoemulsion loaded monocytes then migrate 
and accumulate at the site of injury to participate in the inflammation at the injured sciatic nerve 
[128]. In-vitro drug kinetics and in-vivo pharmacodynamics and pharmacokinetics of the 
theranostic nanoemulsion were beyond the scope of this dissertation and should be pursued in 
future studies. 
5.5 Reduced Hypersensitivity Using Celecoxib Containing Theranostic 
Nanoemulsion In CCI Rat Model 
As mentioned earlier, mechanical allodynia is one of the classic signs of neuropathic pain 
[194]. Therefore, to observe the development of neuropathic pain-like behavior in rats, 
mechanical allodynia was recorded everyday, up to day 12 post-CCI (performed and analyzed by 
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Muzamil Saleem). Similar to our previous results, mechanical allodynia developed around day 7 
post-CCI and persisted through the entire period of study, up to day 12 post-CCI for the CCI 
group injected with the vehicle nanoemulsion (i.e. nanoemulsion without celecoxib) (Chapter 3, 
Figure 3-1). Similar to the previous results and as expected, hypersensitivity development was 
not observed for the sham or naïve control rats. Similar to our previous study [128], rats were 
given the nanoemulsion injection (theranostic nanoemulsion or vehicle) on day 8 post-surgery. 
For both the CCI groups, injected with theranostic or vehicle nanoemulsion, mechanical 
allodynia profile was similar, up to the day of nanoemulsion injection (i.e. day 8 post-CCI). 
Unlike the CCI rats injected with vehicle nanoemulsion, there was reversal of hypersensitivity 
behavior (i.e. mechanical allodynia) in the CCI group injected with celecoxib-containing 
nanoemulsion on day 9 post-CCI (the day following the theranostic nanoemulsion injection). A 
statistically significant (Two-way ANOVA) reduction in the hypersensitivity behavior 
(mechanical allodynia) was observed from day 10 post-CCI up to day 12 post-CCI (Chapter 3, 
Figure 3-1). On the other hand, as mentioned earlier, the vehicle injected CCI group exhibited 
persistent mechanical allodynia from around day 7 post-CCI up to day 12 post-CCI. COX-2 and 
PGE2 are important contributors to the hypersensitivity associated with neuropathic pain [29, 56, 
60-62]. In earlier studies, prolonged administration of celecoxib has been effective in reducing 
the hypersensitivity in pre-clinical models of neuropathic pain [33, 35, 64]. Hypersensitivity in 
neuropathic pain is majorly contributed by the macrophage infiltration, and also the subsequent 
PGE2 release at the site of injury [62]. Therefore, a significant reduction in mechanical allodynia 
in the treated CCI group (i.e. injected with theranostic nanoemulsion) indicated either a reduction 
in macrophage infiltration and/or reduced COX-2 and PGE2 levels in the macrophages present at 
the site of nerve injury. In-vitro characterization of the theranostic nanoemulsion, using an 
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ELISA assay, has revealed a significant reduction in PGE2 levels in the activated macrophages 
in cell-culture studies [42]. Based upon the previous in-vivo studies using PFC nanoemulsions of 
similar size, the majority of the nanoemulsion is engulfed by the circulating monocytes and a 
smaller proportion by other circulating immune cells [37, 38]. Possible molecular events for 
reduced hypersensitivity upon injection of a single dose of celecoxib-containing theranostic 
nanoemulsion have been discussed in Chapter 3, discussion. (Please refer to Chapter 3 for further 
details). 
5.6 In-Vivo Inflammation Imaging Using Near Infra Red (NIR) Fluorescence 
And 19F Magnetic Resonance Imaging (MRI) In CCI Rat Model 
Similar to our previous study [128] and as described earlier in Chapter 3, rats were 
injected with the nanoemulsion on day 8 post-CCI, followed by NIR fluorescence imaging on 
day 11 post-CCI. All the rats were also imaged immediately after the intravenous injection of the 
nanoemulsion to ensure intravenous delivery of the nanoemulsion. NIR fluorescence imaging on 
LiCOR Pearl imager revealed a clear difference between the rats injected via the intravenous 
route and an erroneous subcutaneous injection. As mentioned earlier, a successful intravenous 
tail-vein injection was evident as a small fluorescent spot at the site of injection and the vein was 
cleared of the nanoemulsion immediately after the injection. On the other hand if the 
nanoemulsion was erroneously injected into the subcutaneous tissue of the tail, a strong NIR 
fluorescence was evident in an extended area from the site of injection towards the base of the 
tail and the fluorescence persisted at the same spot in the tail throughout the period of study (up 
to day 12 post-surgery). The nanoemulsion was always delivered based upon seeing a flash of 
blood in the hub of the 24g x ¾ inch, over-the-needle catheter (Fisher Scientific), movement of 
the syringe plunger without resistance and feel of the needle penetrating the vein. Even though 
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every effort was made to deliver the nanoemulsion precisely into the vein, based upon the NIR 
fluorescence imaging, the overall success rate of intravenous delivery of the nanoemulsion was 
about 70% in this study. Therefore, in the current study, stringent screening of the rats was 
performed and only those cases where the nanoemulsion injection was given successfully 
through the intravenous route (based on the LiCOR Pearl imaging) were included in the data 
analysis. 
As described in our previous study [128], the presence of NIR fluorescence in the sciatic 
nerve region is an indicator of macrophage accumulation at the site of nerve injury. Similar to 
our previous study [128], Chapter 3, Figures 3-2, 3-3 depicted NIR fluorescence signal in the 
ipsilateral thigh of the CCI and sham rats injected with either theranostic or vehicle 
nanoemulsion. The fluorescence signal appeared due to the presence of NIR dye at the site of 
injury in both CCI and sham groups (Chapter 3, Figure 3-2). Even though the NIR fluorescence 
signal was present in both CCI and sham groups, unlike CCI rats, the sham rats revealed a low-
level NIR signal at the site of surgery (Chapter 3, Table 3-1). Based upon the NIR fluorescence 
quantification analysis, it was determined that there was a trend of reduced NIR fluorescence in 
the CCI group injected with the theranostic nanoemulsion, in comparison to the untreated CCI or 
sham groups (Chapter 3, Figure 3-3 E). Since the NIR fluorescence was not significantly 
different (One-way ANOVA) among any of the rat groups (Chapter 3, Figure 3-3 E), based on 
the previous study [128], it was predicted that there may not be any significant difference in the 
macrophage infiltration at the site of injury for the treated or untreated CCI groups. However, the 
trend of reduced NIR fluorescence in the treated CCI group (i.e. injected with theranostic 
nanoemulsion) indicated reduced infiltration of NIR dye labeled macrophages at the site of nerve 
injury. And as mentioned earlier, it is not advisable to completely rely on the NIR fluorescence, 
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due to its tissue penetration depth issues [182], which make it a semi-quantitative technique and 
therefore less sensitive to subtle differences in the NIR fluorescence intensity. Besides the tissue 
penetration depth issues, the NIR autofluorescence signal was also evident at the thoracolumbar 
region of rats in all the experimental groups, irrespective of the nanoemulsion injection (i.e. 
before as well as after the injection). We made the same observation in our previous study [128], 
and the autofluorescence was due to rat diet components in the gastrointestinal tract of the rats 
(LiCOR Biosciences). Autofluorescence could not be resolved completely, even though rats 
were fed a purified diet as per the LiCOR diet recommendations to reduce autofluorescence 
(LiCOR Biosciences). 
Therefore, to overcome the limitations of NIR fluorescence imaging, complementary 19F 
MRI was performed (by Dr. Kevin Hitchens). As described earlier, 19F signal is highly specific 
due to absence of background noise in the animal tissue. The 19F MRI was performed on the 
perfusion fixed ipsilateral hind legs of the CCI rats injected with theranostic or vehicle 
nanoemulsion and 19F signal differences were recorded precisely in both the treated and 
untreated CCI groups. Superimposed scans of 1H and 19F MRI revealed a clear 19F signal at the 
ligatures that were tied over the common sciatic nerve in both the CCI groups (Chapter 3, Figure 
3-4). The presence of 19F signal at the sciatic nerve confirmed the presence of PFC nanoparticles 
at the site of injury (Chapter 3, Figure 3-4). 19F quantification performed (by Dr. Kevin Hitchens) 
on 19F MRI scans for the treated and untreated CCI groups, revealed approximately two-fold 
reduction in the 19F signal for the CCI group treated with celecoxib-containing theranostic 
nanoemulsion (Chapter 3, Figure 3-4). 19F MRI quantification (performed by Dr. Kevin 
Hitchens) was based upon the number of 19F nuclei spins per voxel, using trifluoroacetic acid 
(TFA) as a standard reference with known number of 19F nuclei [86]. Statistical analysis could 
110
not be performed for the 19F MRI scans because one rat was used per condition (due to economic 
constraints). Similar to our previous findings (Chapter 2, Figure 2-4), besides the presence of 19F 
signal in the sciatic nerve, the 19F signal was also evident in the femur bone of both the CCI 
groups, which could be attributed to both physiological and pathological reasons as described 
earlier in discussion. It is well known that inflammatory mediators cause vasodilation of the 
capillaries at the site of inflammation, leading to their enhanced permeability. Hence, some 
nanoparticles in circulation (after intravenous delivery of the nanoemulsion) may bypass 
endocytosis by the circulating immune cells and pass directly through the leaky capillaries at the 
site of the injured sciatic nerve (also known as blood-nerve barrier dysfunction, [195]) and 
accumulate at the site of injury, thus contributing to NIR fluorescence and 19F signal. These 
nanoparticles may continue to reside at the site of injury or later on, may get engulfed by the 
resident immune cells at the site of injury. Based upon the previous study [128], reduced 19F 
signal in the CCI rat sciatic nerve, treated with the celecoxib-loaded nanoemulsion, was 
predicted to be due to a lower number of nanoemulsion labeled macrophages at the site of injury. 
Therefore, to determine the actual differences in the infiltration of activated macrophages and 
expression levels of COX-2 and PGE2, double immunofluorescence was performed on the 
ipsilateral sciatic nerves of the treated and untreated CCI groups. The CD68 positive macrophage 
infiltration was observed in both treated and untreated CCI groups, thus revealing the presence of 
inflammation at the sciatic nerve in both the CCI groups (Chapter 3, Figure 3-5). The CD68 
fluorescence intensity was not different in individual macrophages, either in the treated or 
untreated CCI rat groups. Therefore, a significant reduction in the mean fluorescence intensity of 
CD68 expression (Chapter 3, Figure 3-6; t test, p<0.0001) was considered as an indirect measure 
of reduced number of the macrophages in the sciatic nerve of the CCI group treated with 
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theranostic nanoemulsion (i.e. containing celecoxib), as compared to the CCI group treated with 
vehicle nanoemulsion (i.e. without celecoxib), and hence the fluorescence differences can-not be 
attributed merely to the staining artifacts. Similarly, there was a significant relative reduction in 
the COX-2 and PGE2 expression (t test, p<0.0001) in discrete macrophages for the CCI group 
treated with theranostic nanoemulsion (i.e. containing celecoxib) as compared to the CCI group 
treated with vehicle nanoemulsion (i.e. without celecoxib) (Chapter 3, Figure 3-5, 3-6). Since the 
CD68 expression in discrete macrophages did not change in both the groups, the ratio of COX-2 
fluorescence intensity to CD68 fluorescence intensity and the ratio of PGE2 fluorescence 
intensity to CD68 fluorescence intensity revealed the relative differences in the expression 
profiles of COX-2 and PGE2 between the two CCI groups. The reduced relative expression of 
COX-2 and PGE2 in the treated CCI group appeared to be due to reduced infiltration of the 
macrophages at the site of injury, as compared to the CCI group injected with the vehicle 
nanoemulsion. Besides reduced macrophage infiltration, the reduced relative expression of PGE2 
in the treated CCI group could also be due to inhibition of COX-2 in the macrophages present at 
the site of injury. Celecoxib has been shown to reduce macrophage infiltration and PGE2 
synthesis during pulmonary inflammation in mice [196]. Hematogenous macrophage recruitment 
at the site of nerve injury occurs due to the release of macrophage inflammatory protein (MIP)-
1α and interleukin (IL)-1β [197]. Therefore, it is feasible that celecoxib affects the 
synthesis/release of cytokines and/or chemokines from the activated macrophages; to impede the 
ongoing macrophage infiltration at the site of sciatic nerve injury, however further 
experimentation is required to test this hypothesis in the CCI rat model of neuropathic pain. 
Possible caveats in this study are that the precise type and number of immune cells that 
endocytose the nanoemulsion and the mechanism of drug release in-vivo, remains elusive. Also, 
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activated macrophages are in a dynamic state at the site of inflammation and some macrophages 
may die at the site of injury and the 19F PFC may get transferred to a new phagocytic cell [175]. 
Hence, further experimentation is required to study the pharmacodynamics and pharmacokinetics 
of the nanoemulsion in-vivo, in the future studies. 
In conclusion, in the current study, we have described the successful implementation of 
celecoxib-containing theranostic nanoemulsion [41, 42] to reduce the hypersensitivity behavior 
due to neuropathic pain in CCI rat model and simultaneously visualize and quantify the 
inflammation in-vivo, with a single dose intravenous injection of celecoxib-containing 
theranostic nanoemulsion in comparison with the CCI rats injected with vehicle nanoemulsion 
without celecoxib that served as a negative control. To the best of our knowledge, this is the first 
study to use theranostic nanoparticles in the setting of neuropathic pain. Recently, PFC labeled 
dendritic cells have been tracked in human colorectal adenocarcinoma patients with no apparent 
side effects noted [175]. Flurbiprofen axetil (NSAID)-containing drug delivery nanoemulsion is 
commercially available along with many other drugs formulated as nanoemulsion [68]. The 
theranostic nanoemulsion used in this study, designed by Dr. Jelena M. Janjic and Sravan K. 
Patel, allowed not only the targeted delivery of celecoxib in the macrophages but also 
simultaneous in-vivo therapeutic evaluation by tracking inflammation at the site of injury.  
5.7 Dynamic Bayesian Network (DBN) Analysis 
As mentioned earlier in Chapter 1 and Chapter 4, various inflammatory mediators are 
involved during neuroinflammation. IL-18 and IL-1β undergo expression, maturation, and 
release via inflammasome assembly and caspase-1 activation by innate immune system [44]. 
Based upon the DBN analysis of the inflammatory mediators at the site of nerve injury in CCI rat 
model of neuropathic pain, the central drivers of inflammation were IL-18 and IL-1β (Chapter 4, 
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Figure 4-3). Both of these mediators, along with their activator enzyme caspase-1, were 
expressed at the site of the nerve injury as determined in the immunofluorescence studies 
(Chapter 4, Figure 4-4). Persistent up regulation of IL-18 has been shown earlier in the spinal 
cord from day 1 to day 18 post-CCI [9]. Potential intervention of these two inflammatory 
mediators by using monoclonal antibodies, IL-18 and IL-1β receptor antagonists or IL-18 and 
IL-1β inhibitors may prove an efficient therapy to manage chronic neuropathic pain.  It is for the 
first time that the computational modeling tool has been used in the field of neuropathic pain 
using CCI rat model with a comprehensive analysis of fourteen different inflammatory mediators 
in the same experimental set up. However, IL-18 and IL-1β as principle drivers of peripheral 
neuropathic pain is only a prediction and needs to be tested in the future studies. 
5.8 Future Directions 
During 19F MRI, besides the presence of the 19F signal at the injured sciatic nerve, the 19F 
signal was also observed in the femur and tibia bones of the CCI and sham rats (Chapter 2, 
Figure 2-4; Chapter 3, Figure 3-4). The 19F signal intensity was less in the ipsilateral femur bones 
of the sham rats as compared to the CCI ipsilateral femur bones (Data not included). As 
mentioned earlier, the presence of 19F signal is an indirect evidence of infiltration of phagocytic 
immune cells (especially monocytes/macrophages). Previously it has been shown that there are 
pathological changes, such as reduction in the bone mineral density (BMD) due to increased 
bone resorption (osteoporosis) induced by a peripheral nerve injury in the vicinity of the bone 
[123, 124].  It is also known that specialized osteoclast cells, which are produced from 
monocyte/macrophage cell lineage precursor cells in bone marrow, cause the bone resorption. 
These precursor cells enter into blood circulation before they differentiate into osteoclasts, and 
the migration of monocytes into bone marrow and their differentiation into osteoclasts is 
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dependent upon the rate of bone resorption [125, 198]. This indicates higher bone resorption 
activity in the CCI femur and tibia bones as compared to the sham rats. Since the 19F signal is 
also found in the femur bones of sham rats, there is a possibility that besides osteoporotic 
changes in the bones of CCI affected rats, the signal is also caused by physiological circulation 
of labeled monocytes through the bone marrow in both sham and CCI rats. Both ipsilateral and 
contralateral femur bones of CCI, sham, and naïve rats (~ 30 total) were collected during the 
tissue dissection from perfusion fixed rats (please refer to appendix) and have been stored in 
0.4% paraformaldehyde solution at 4° C for future studies.  I hypothesize that the 19F signal in 
the femur bones of CCI is caused by osteoporotic (pathological) changes associated with chronic 
constriction injury, along with physiological contribution by the circulating monocytes through 
the bone marrow. Further experiments, especially tissue histology, need to be performed on the 
collected femur bones to substantiate this interesting finding.  
In addition experiments to determine the long-term effects of celecoxib-containing 
nanoemulsion could be performed for longer duration post-CCI. Also, biological 
experimentation is required to verify the conclusions drawn from the computational modeling 
analysis performed in this study. IL-18 and IL-1β inhibitors may be tested in future studies to 
reveal any changes in the hypersensitivity using CCI rat model. Theranostic nanoemulsions 
containing new drugs or different drug combinations may be tried to see their therapeutic effect 
for the treatment of chronic neuropathic pain. 
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Appendix: Detailed Methods 
A.1 Ethics Statement 
The number of animals and the protocols used during the study were approved by the 
Institutional Animal Care and Use Committee (IACUC), Duquesne University (Protocol number 
#1109-10). Also, the study was carried out in strict accordance with the Guide for the care and 
use of the Laboratory Animals of National Institute of Health and American Veterinary Medical 
Association guidelines.     
A.2 Animals 
Male Sprague Dawley rats (Hilltop Lab Animals Inc., Scottdale, PA) weighing 250-350 
grams were used in this study. Upon arrival at the animal care facility, Duquesne University, the 
rats were acclimatized for at least one week, before performing any procedures on them. The rats 
were maintained on regular corncob bedding and were fed regular rat chow during the 
acclimation period. Upon commencement of the study procedures, the rats were shifted on paper 
bedding and were fed purified diet (D10012G Research Diets, Inc. New Brunswick, NJ). Paper 
bedding helps to reduce the discomfort during movement after the CCI surgery, as compared to 
the coarser corncob bedding. Purified diet was preferred to the regular chow because it helps to 
reduce the auto fluorescence during the LiCOR pearl imaging (LiCOR Biosciences). Rats were 
maintained on routine 12:12 hour light dark cycle. Rats had unrestricted access to feed and water 
throughout the study period.  
A.3 Chronic Constriction Injury (CCI) 
The rats were subjected to Chronic Constriction Injury (CCI) surgery as described by 
Bennett and Xie in 1988 (Bennett and Xie, 1988). The surgery was performed under general 
anesthesia using isoflurane. The rats were weighed before the surgery using the manual weigh 
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machine. Immediately after that, the general anesthesia was induced with 5% isoflurane and 
oxygen flow rate of 2 L/minute. The retraction of the eyeball and no response upon tapping of 
the induction chamber were used as indicators of initial induction of anesthesia. Immediately 
after the initial induction of the anesthesia, the rats were transferred to a heated-bed (~38 °C) and 
the facemask was applied to maintain the general anesthesia. The infrared lamp was used at a 
sufficient distance (~2 feet away from rat) to prevent hypothermia in the rats during anesthesia. 
The anesthesia was maintained at ~1.5% isoflurane along with the oxygen flow rate of 
2L/minute throughout the CCI/sham surgery. Rats were observed for the signs of surgical depth 
of anesthesia by examining the retraction of eyeball, no tail flicking upon rolling the tail between 
fingers and no leg withdrawal upon pinching the toe with the tissue forceps, to confirm the 
appropriate depth of anesthesia before beginning the surgical procedures.  
A.4 Rat Preparation Before Surgery   
Rats were shaved at the right hind limb near the thigh region up to the knee joint along 
with the right dorsal lumbar area of the back, using a clipper (Oster) with a size-40 clipper blade. 
The shaving was performed first towards and then against the direction of the hair growth to 
provide a smooth surface for the surgical preparation of the skin. After clipping, Nair hair-
removing cream (for sensitive skin) was applied to the clipped area strictly for no more than 30 
seconds and was wiped off using a gauze pad (2x2 inches) soaked with warm water (wringed 
before use). Nair removing cream removed the fine hairs that were not removed by the clipper. 
The hairless area was then dried with another gauze pad (2x2 inches). To prep of the area for 
surgery, the thigh region was scrubbed with ready-to-use betadine and alcohol gauzes alternately, 
at least three times each, to remove the microorganisms from the surgical area to prevent any 
post-surgical infection. 
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A.5 CCI Surgery   
The surgical instruments were sterilized using the Germinator 500 dry sterilizer where 
glass beads get heated up to 260 °C and the clean surgical instruments get sterilized when placed 
in the beads for about 15 seconds. After wearing surgical gloves, the femur bone was palpated 
(over the skin) with fingertips and a skin incision (~2 cm) was made parallel and right below the 
femur bone, using a scalpel (#3) with a replaceable surgical blade (#10). Under the skin incision, 
the junction between the two thigh muscles (i.e. gluteus superficialis and biceps femoris) was 
seen as a shiny white fibrous tissue. This white fibrous tissue was incised using a scalpel or a 
micro scissors and the two muscles get separated without any muscle tear or bleeding to neatly 
expose the common sciatic nerve. The common sciatic nerve runs closer to the biceps femoris 
muscle due to fascia attachments. Therefore, the common sciatic nerve was liberated from its 
fascia attachments using a micro scissors under the microscope. Microscope must be used to 
prevent any unintended injury to the sciatic nerve itself. When about 1 cm nerve was free from 
its muscle attachments and was dangling in the space between the muscles, a sterile 4-0 chromic 
gut suture was used to tie four square knots, about 1 mm apart on the common sciatic nerve and 
this maneuver was performed under the microscope. Knots were tied with the help of a needle 
holder. Utmost care was taken to ensure that the knots were neither too tight to constrict the 
blood supply at the site of ligation nor too loose to allow the knots to freely move along the 
nerve. The knots were tied in a way to stay put without being too tight or too loose. After the 
CCI surgery, the separated muscles were sutured together using a 4-0 chromic gut suture and the 
simple interrupted suture pattern. Finally, the incised skin was sutured back using 9 mm stainless 
steel autoclips. Throughout the surgery, the rats were checked for peripheral perfusion (capillary 
refill time) by pinching the toes (with the help of an assistant), regular breathing (thoracic 
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movements) and heart rate (by placing the finger tips on ventral chest area, with the help of an 
assistant).   
A.6 Sham Surgery 
Sham surgery was identical to the CCI surgery up to separating the nerve from its 
attachment to the muscles. The common sciatic nerve in the sham rats was handled similar to the 
one in the CCI rats except that no ligatures were placed around the nerve in the sham rats. The 
muscle and skin were sutured back similar to the CCI surgery. Sham rats served as surgical 
controls. Another control used during the study was naïve control where the rats did not 
underwent any anesthesia or surgical protocols. 
A.7 Behavioral Testing (Mechanical Allodynia Testing) 
Mechanical allodynia testing was performed to test for the development of 
hypersensitivity behavior in rats, which is indicative of evoked neuropathic pain post-CCI 
surgery. The mechanical allodynia testing was performed a day before the surgery to obtain the 
baseline levels in the right hind paw of the rats. The testing was repeated on day 11 post-surgery 
to check for the development of hypersensitivity post-CCI or post-sham surgery. The testing was 
performed using the calibrated von Frey filaments ranging from, 0.41 gram-force to 15 gram-
force (Touch test sensory evaluator, size 3.61 to 5.18). The rats were placed into a perspex box 
with a wire mesh bottom and were provided at least 10 minutes of acclimation period before the 
test was started. The von Frey filaments were applied to the plantar surface of both the hind paws 
of the rats through a wire mesh bottom of the cage. The filaments were applied at the plantar 
surface of the hind paw region that is mostly innervated by the sciatic nerve. The filaments were 
applied in an ascending order of their gram-forces (0.4, 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15 g). Each 
filament was applied for a total of ten times for each hind paw and the withdrawal responses 
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were recorded for each application of each of the filaments. To begin with, the smallest gram-
force filament was applied perpendicular to the paw surface for five times, until the filament 
bends at an acute angle. Each application was separated by at least 2-3 seconds to clearly 
distinguish between each response. A time lapse of at least 5 minutes was chosen between any 
two filaments of different gram-forces. Same procedure was followed for all the filaments in the 
ascending order and was repeated for both the hind paws. The testing was complete when either 
all the filaments were tested or if the rat withdrew its hind paw on all ten applications of a given 
filament. 
To determine the gram-force causing 50% withdrawal responses in rats, a linear 
regression analysis was performed with the number of withdrawal responses and the gram-forces 
of the filaments used during the test. The linear regression was performed separately for both the 
hind paws. The following formula was used to determine the normalized 50% withdrawal 
threshold on day 11 post-surgery: 
 Normalized 50% withdrawal threshold (WT) = Post-Surgery (50% WT right paw – 50% WT left 
paw) – Baseline (50% WT right paw – 50% WT left paw).  
The normalized gram-force required for 50% withdrawal response was averaged 
separately for the CCI, sham and naïve control groups and their mean values were compared 
using the Kruskal-Wallis one-way ANOVA by Ranks Test in GraphPad PRSIM version 6.0e. 
The values were considered significant at p ≤ 0.05.  
A.8 Rat Tail-Vein Injection 
The theranostic nanoemulsion (containing celecoxib) and the vehicle nanoemulsion 
(without celecoxib) were injected intravenously through the right or left lateral tail-vein in the 
rats. The injection (0.3 ml) was given under isoflurane anesthesia, on day 8 post-surgery using a 
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1 ml syringe and a 25-gauge over-the-needle catheter. The anesthesia induction and maintenance 
was performed as described earlier under the CCI surgery. At appropriate depth of anesthesia, 
the tail was completely submerged in warm water (~38 º C) for about 1 minute to allow the 
dilation and easy visualization of the lateral tail veins. Immediately after the dilation step, the tail 
was wiped off with clean gauze to remove the moisture and any debris over the tail. Either of the 
lateral tail veins was chosen for the injection based upon easy visualization of the vein. The 
preferred site of the injection was the apical 1/3rd of the tail, about an inch away from the tip of 
the tail. The tail was slightly rolled and held between the forefinger and thumb of the non-
dominant hand with a slight bend of the tail over the forefinger such that the lateral vein was 
facing upwards. An alcohol swab was then used to clean the site of the injection. The needle was 
positioned with its bevel facing upwards, and using the dominant hand, the tip of the needle was 
inserted into the vein followed by rest of the needle. The successful placement into the vein was 
confirmed by seeing blood at the hub of the needle. Immediately thereafter, the syringe 
containing 0.3 ml of the nanoemulsion was attached to the needle, without displacing the needle 
from the vein. The second most important confirmation of correct placement of the needle was 
complete absence of resistance during the injection. The plunger of the syringe was pushed 
slowly, and the nanoemulsion injection was completed in 30 seconds.  
A.9 LiCOR Pearl Imaging 
The in-vivo near-infrared fluorescence imaging was performed using a LiCOR Pearl 
Impulse small animal imaging system (LiCOR Biosciences, Lincoln, NE). The LiCOR Pearl 
imaging was performed at two time-points during a given experiment, one on day 8 post-surgery 
(i.e. immediately after the nanoemulsion injection) to confirm the intravenous delivery of the 
nanoemulsion and the second on day 11 post-surgery to image the site of injury. For the day 8 
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imaging, the rats were imaged under isoflurane anesthesia due to a very short period of imaging 
required, whereas on day 11 post-surgery, the rats were anesthetized with an injectable 
anesthesia (xylazine, 7 mg/kg combined with ketamine, 80 mg/kg) given intraperitoneally to 
maintain a longer duration of anesthesia (~ 20-30 minutes) required for comprehensive imaging. 
   Before capturing the rat images, the imager was set to a focus value of -1 where the rat 
hairs were seen in-focus. All the in-vivo images were captured at a resolution of 170 um. All the 
three wavelengths of light available on the LiCOR pearl imager (i.e. 785 nm, captured as pseudo 
red fluorescence; 820 nm, captured as pseudo green fluorescence, and white light) were used 
during imaging in this study.  
As mentioned earlier, the nanoemulsion injection was given intravenously on day 8 post-
surgery and the rats were maintained on ~1.5% isoflurane anesthesia during the tail vein 
injection. Immediately after the injection and before the transfer of the rat to the LiCOR Pearl 
imager, the anesthetic gas flow was increased to 5% for 1-2 minutes to transiently increase the 
depth of the isoflurane anesthesia. Increase in the isoflurane gas flow was required to maintain 
the anesthesia while taking a tail snapshot in the LiCOR pearl imager, with the site of injection 
in-view. Upon completion of the imaging, the rats were transferred back to their respective 
cages. On day 11 post-surgery, upon completion of the mechanical allodynia testing, the rats 
were anesthetized with the injectable anesthesia mentioned above. At appropriate depth of the 
anesthesia (i.e. absence of corneal reflex and no response to an external stimuli), the rat was 
transferred to the LiCOR pearl imager. On day 11 post-surgery, four views (i.e. dorsal, ventral, 
right lateral and left lateral) of the posterior half of each of the rats were captured and saved in 
the computer for further image analysis. After the imaging was complete, the anesthesia was 
reversed using yohimbine, 2 mg/kg body weight and the rats were monitored until fully 
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awake. Yohimbine was not used if the rats exhibited a positive corneal reflex after the 
completion of the imaging.  
A.10 LiCOR Image Analysis 
All the near-infrared images were analyzed using LiCOR Pearl Impulse software version 
2.0. The dataset to be compared was imported and analyzed using linked look-up feature 
provided in the software. An area was chosen over the right sciatic nerve region as a 
representative of the site of injury (region of interest, ROI) and the same ROI was applied to 
other images in a given dataset to obtain the normalized fluorescence intensity [i.e. total 
fluorescence in ROI/area (pixels)]. The means of the normalized fluorescence intensities of the 
three different conditions (i.e. CCI, sham and naïve control rats) were then compared by one-way 
ANOVA using GraphPad PRISM version 6.0e. The differences were considered significant at p 
< 0.05. 
A.11 Euthanasia  
  On day 12 post-surgery, the rats were injected with ~2 ml of euthasol solution 
(commercially available as fatal plus solution containing sodium pentobarbital, 390 mg/ml) 
intraperitoneally under 1.5% isoflurane anesthesia. The death was confirmed by absence of a 
heartbeat, respiration (thoracic movements), and changing of the eyeball color from pink to 
transparent to opaque white. 
A.12 Intracardiac Perfusion Fixation 
Intracardiac perfusion fixation is mostly used to obtain whole body fixation and is 
performed with 4% paraformaldehyde solution. The paraformaldehyde solution is carried to all 
the body tissues via circulation and thus leads to whole body fixation. Therefore, perfusion 
fixation is highly efficient when started immediately after the intraperitoneal injection of 
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euthasol, when the heart is still functional. A functional circulatory system helps in efficient 
delivery of the paraformaldehyde solution and thus allowing an excellent whole body fixation. 
Immediately after the euthanasia injection, the isoflurane flow rate was increased to 5% and the 
oxygen flow rate was reduced to 0.5 L/minute. The 4% paraformaldehyde solution was made 
fresh (a day before the perfusion fixation) in buffered PBS (pH 7.4) and filtered using Nalgene 
filters (1 L capacity) and stored at 4° C until used. The perfusion fixation apparatus was 
borrowed from Dr. David A. Johnson’s laboratory in the department of Pharmaceutical Sciences 
at Duquesne University.  
  The 60 ml perfusion syringe was filled with buffered PBS (pH 7.4) containing heparin 
(10 U/ml) and was attached with Y tubing and to the perfusion pump. Similarly, another 60 ml 
syringe was filled with 4% PFA solution and was also attached with the Y-tubing and to the 
perfusion pump.  The one-way valves, in the Y-tubing, for both the syringes were kept closed 
until needed. The one-way valve for PBS/heparin was opened and the perfusion pump was 
started to remove any air bubbles from the Y-tubing. Once the perfusion apparatus was ready to 
be used, and the rat was injected with the euthasol, the thoracic cavity of the rat was opened. The 
rat was in supine position with its ventral side facing upwards. To open the thoracic cavity, the 
last rib of the rat was felt and a horizontal incision was made (using a scissors or a scalpel) in the 
skin, muscles and the diaphragm separating the thoracic and the abdominal cavities. Two parallel 
incisions were made on both the sides of the rib cage and the rib cage was reflected towards the 
anterior side of the rat and clamped to keep in-place. The exposed functional heart (a beating 
heart) in the thoracic cavity was grasped with a small artery forceps and a blunt perfusion needle 
was inserted in the left ventricle of the heart and retained in-place with the help of an artery 
forceps holding the needle through its jaws while clamped to the heart. Immediately thereafter, a 
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snip in the right auricle was made with a small scissors, to make an outlet for the circulating fluid 
in the closed circulation system. The perfusion with PBS/heparin was initiated @ 10ml/minute 
and was later increased to 20 ml/minute. The perfusion with PBS/heparin was performed until 
the blood in the circulatory system was replaced with the PBS/heparin solution and this was 
confirmed with oozing of pale straw colored fluid from the auricle. After flushing out blood from 
the circulatory system, the one-way valve for PBS/heparin tubing was closed and the valve for 
4% PFA tubing was opened. Approximately 180 ml (60 ml syringe x 3) were used to perform the 
whole body perfusion fixation of a rat weighing around 350 grams. At the end of the fixation 
protocol, rats were stiff due to rigor mortis and tissue fixation. The surgical instruments used 
during the perfusion fixation procedure were kept separate and never used during the survival rat 
surgeries at any time and vice-versa. 
A.13 Sciatic Nerve And Femur Bone Dissection  
The sciatic nerve dissections were performed on day 12 post-surgery. The approach 
towards the exposure of the common sciatic nerve either during the CCI/sham survival surgery 
or during the dissection was identical. During the nerve dissection, the scar or incision marks 
from the original CCI/sham surgery were followed as landmarks and re-incisions were made at 
exact same sites again. For the naïve rats, the dissection protocol was identical to approaching 
the sciatic nerve during a sham or CCI surgery. The ligations were easily discernible on day 12 
post-surgery and ~1 cm of the common sciatic nerve was transected anterior and posterior to the 
knot ligations using a micro scissors.  The dissected nerve was stored overnight in 4% PFA (pH 
7.4) at 4 °C and then transferred to 0.4% PFA solution next day and stored at 4 °C until further 
processing. The sciatic nerves for both the hind limbs were dissected out from the CCI, sham and 
naïve rats.  
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The femur bone runs parallel and adjacent to the common sciatic nerve.  To prevent any 
damage to the sciatic nerve, the femur bone was always dissected out after the completion of the 
sciatic nerve dissection. The femur bone was palpated with fingers and two parallel incisions 
were made along the margins of the long axis of the bone using a scalpel (#3) with replaceable 
surgical blade (#10). The ligaments joining the femur and tibia/fibula bones were transected and 
the joint was carefully dislodged. Similarly, the ligaments joining the head of the femur and the 
pelvic girdle were transected with circular motion of the blade to set free the femur bone. The 
femur bone was then fixed and stored in 4% PFA (pH 7.4) overnight at 4°C and then transferred 
to 0.4% PFA and stored at 4°C for later use. Both ipsilateral and contralateral femur bones were 
collected from all the CCI, sham and naïve rats.     
A.14 Sciatic Nerve Collection In Live Rats 
The common sciatic nerve was transected under isoflurane anesthesia as the terminal 
procedure and the rats were euthanized thereafter. The tissue collection was performed at four 
time points spanned over a period of 18 days (i.e. 2-3 hours post-surgery and day 8, 11 and 18 
post-surgery) for the CCI and sham rats along with the naïve non-surgical control rats. Four rats 
were used for every given time-point. The common sciatic nerve collection protocol was same as 
described earlier under sciatic nerve dissection. Immediately post-collection, the tissue was 
preserved in RNA later solution (AM7024, Ambion) and stored at 4°C for 24 hours and 
thereafter stored at -20 °C freezer until further processing.  The ipsilateral sciatic nerves were 
collected at the region of injury from all the CCI, sham and naïve rats.    
 A.15 Immunohistochemistry  
The fixed ipsilateral and contralateral sciatic nerves from the CCI, sham and naive 
control rats, stored in 0.4% PFA at 4° C were molded into a block using Optimal Cutting 
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Temperature (OCT) compound (Sakura) at -20° C. Upon freezing, the block containing the 
common sciatic nerve was mounted on the cryostat and was cryosectioned into 20 μm thick 
longitudinal sections. The sections were placed on the superfrost plus gold slides (Fisher 
Scientific, 15-188-48), which provide adequate adhesion of the fixed, frozen tissue section onto 
the slide. The slides containing the cryosections were stored in the slide storage boxes and stored 
at -20° C until used. To proceed with the immunofluorescence protocol, the slides were warmed 
on a slide-warmer at 37 ° C for 30 minutes and then fixed in freshly made 4% 1X PFA (pH 7.4, 
4° C) solution for 15 minutes. After fixation, four washes were performed in 1X PBS for 5 
minutes each at room temperature. After washing, the sections were permeabilized by 
submerging the slides in 0.3% buffered Triton X-100 (1X PBS, pH 7.4) for 30 minutes at room 
temperature. Slides were washed again in 1X PBS for four times, five minutes each, at room 
temperature. Followed by washing, blocking was performed with 50 µL normal donkey serum 
(1:20 in 1X PBS, pH 7.4). The serum was placed covering the section and a coverslip was 
placed over it and the slide was incubated for one hour at room temperature in a moisture 
chamber. After incubation, the coverslip was removed by dipping the slide into 1X PBS solution. 
Immediately after this step, the section was covered with 25 µL primary antibody (working 
dilution) and a coverslip was placed over it and the slide was then incubated in a moisture 
chamber over night at 4 °C. After the incubation, five washes were performed in 1X PBS (pH 
7.4), five minutes each at room temperature. After the washing step, the sections were covered 
with 25 µL secondary antibody (1:200) with a coverslip placed over it. The slide 
was then incubated in the moisture chamber overnight at 4 °C. At the end of the incubation, final 
washes were performed in 1X PBS (pH 7.4), five minutes each at room temperature. The 
sections were mounted in Prolong Gold with DAPI (Molecular Probes) and were incubated over 
138
night at room temperature in dark. For the double immunofluorescence study, the two primary 
antibodies to be used were diluted together and placed over the section. Similarly, the two 
corresponding secondary antibodies were diluted together and placed over the section. Double 
immunofluorescence studies were performed to examine the infiltration of macrophages (CD68) 
along with the presence of caspase-1, IL-18, IL-1β and IL-1α using mouse anti-CD68, 1:100 
(MCA341R, AbD Serotech), rabbit anti-caspse-1, 1:50 (caspse-1 p10 (M20) sc514, Santa Cruz 
Biotechnology), rabbit anti-IL-18, 1:100 (R1186, Acris Antibodies), rabbit anti-IL-1β, 1:100 
(ab9787, abcam) and goat anti-IL-1α, 1:100 (ab9875, abcam) primary antibodies. The double 
immunofluorescence studies were also performed to study the expression of COX-2 and PGE2 in 
the infiltrating macrophages using, rabbit anti-COX-2, 1:100 (ab15191, AbD Serotech) and 
rabbit anti-prostaglandin E2 antibody, 1:100 (ab2318, AbD Serotech) along with mouse CD68, 
1:100 (MCA341R, AbD Serotech) in treated and untreated rat groups. The secondary antibodies 
used were Alexa fluor 488 donkey anti-mouse, 1:200 (A-21202, Invitrogen), Alexa fluor 546 
donkey anti-goat, 1:200 (A-11056, Invitrogen) and Alexa fluor 647 donkey anti-rabbit, 1:200 (A-
31573, Invitrogen). All the antibody dilutions were prepared using 1:20 normal donkey serum in 
1X PBS, pH 7.4.  Antigen retrieval was performed during double immunofluorescence with 
COX-2 and CD68 primary antibodies, using sodium citrate buffer (10 mM sodium citrate, 0.1% 
Tween 20, pH 8.5). Antigen retrieval was also performed during double immunofluorescence 
with caspase-1, IL-18, IL-1β, IL-1α, COX-2 and CD68 primary antibodies, using sodium citrate 
buffer (10 mM sodium citrate, 0.1% Tween 20, pH 6 or pH 8.5). Antigen retrieval was not 
required during double immunofluorescence with PGE2 and CD68 primary antibodies. 
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A.16 Antigen Retrieval  
As mentioned earlier, the antigen retrieval protocol was used for some of the antibodies 
before the double immunofluorescence staining protocol. The protocol was identical to the 
immunohistochemistry protocol described above except for the permeabilization step. The 
permeabilization with Triton X-100 was replaced by a combined permeabilization and antigen 
retrieval step using sodium citrate buffer and Tween-20 solution. For IL-1β and caspase staining, 
the slides were incubated in sodium citrate and Tween-20, pH 6 for 5 minutes at 93°C for the 
permeabilization and antigen retrieval step. For IL-1α staining, the slides were incubated in 
sodium citrate and Tween-20, pH 6 for 3 minutes at 93°C for the permeabilization and antigen 
retrieval step. For IL-18 and COX-2 staining, the slides were incubated in sodium citrate (10 
mM) and Tween-20 (0.1%), pH 8.5 for 1 minute at 93°C for the permeabilization and antigen 
retrieval step. After the permeabilization step, the slides were transferred to deionized water at 
room temperature for 20 minutes and were allowed to cool down to the room temperature. After 
this, the slides were rinsed in 1X buffered PBS (pH 7.4) five times and five minutes were given 
for each rinse. After permeabilization and washing step, the blocking step and the rest of the 
protocol was same as described under immunohistochemistry. 
A.17 Confocal Microscopy and Quantification 
Confocal microscopy was performed on a Leica SP2 spectral Laser Scanning Confocal 
microscope and Leica SP2 spectral Laser Scanning Confocal microscope software was used to 
analyze the confocal images. The quantification analysis was performed for the double 
immunofluorescence slides stained with either COX-2 or PGE2 and CD68 antibodies, in the 
three treated (with celecoxib) and three untreated (vehicle only) CCI rats. Confocal images for a 
comparative set were acquired with the same instrument settings (laser power, PMT voltage, pin 
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hole, etc.).  To determine any changes in the relative number of macrophages in the treated and 
untreated conditions, six regions of interest (ROIs) were chosen in each captured field-of-view of 
the ipsilateral sciatic nerve sections stained for CD68 positive cells for the CCI treated and 
untreated groups. At least two to three field of views (F) were used for each of the rat nerve 
section to obtain ROIs between 12-18 for each of the rats. Since, we had three rats per condition, 
there were between 36-54 ROIs for three rats per condition (i.e. CCI treated or untreated). Mean 
fluorescence intensity (MFI) of CD68 stained sections was averaged from all the ROIs for the 
CCI drug (n=54) and the CCI no drug (n=48) conditions (Table A1, Appendix). No significant 
variation in the mean fluorescence intensity was found among individually identified 
macrophages in the treated or untreated groups (Table A2, A3, Appendix). Therefore, the 
differences in the average mean fluorescence intensity per unit area among treated and untreated 
groups indicates differences in the relative number of macrophages between the two groups.  The 
relative expression of COX-2 and PGE2 in the macrophages was determined by finding the 
ratios of the mean fluorescence intensity of COX-2 to the mean fluorescence intensity of CD68 
in the same macrophage, and separately the ratios of the mean fluorescence intensity PGE2 in a 
given macrophage in both cases in drug and no drug conditions (Table A2, A3, Appendix). The 
CD68 fluorescence intensity in the macrophages did not change in the drug or no drug condition 
and hence was used to normalize the COX-2 or PGE2 fluorescence intensity in the treated or 
untreated CCI conditions. To analyze the COX-2 and PGE2 expression differences, a line was 
drawn across individual macrophages (M) in the field-of-view (F) and mean fluorescence 
intensity for either COX-2 or PGE2 was recorded in the individual cells. For the line analysis, 
the images were captured at a total magnification of 80X (20X objective + 4X zoom). At least 
five macrophages were chosen for each field-of-view and for three rats at least 40 macrophages 
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were analyzed for any given condition. The changes in COX-2: macrophage or PGE2: 
macrophage mean fluorescence intensity ratio in treated or untreated group was indicative of 
relative changes in the COX-2 or PGE2 expression in the macrophages (Table A2, A3, 
Appendix).  
A.18 'Blinded' Experiments 
Aspects of the studies described in this dissertation were carried out under ‘blinded 
condition’. However, under certain circumstances it was not possible to do it as a blind study. 
The nature of several aspect of the work performed would require at least two researchers 
working together at all times to make it a blind study and at the time that these projects were 
initiated that was not feasible. However, some of the experiments were analyzed in a semi-blind 
fashion.  For example, the NIR fluorescence image analysis was performed by an analyzer who 
was blinded to the CCI, sham or naive conditions. Similarly, the histological data was collected 
in a relatively blind fashion as well. The tissue samples collected during dissection were coded 
and the confocal microscopy and image analysis were performed as per the codes which were 
later matched with any given rat condition.  
In the case of the behavioral data collection and analysis, it was not possible to stay blind 
because the signs of a CCI surgery were very robust and the rat conditions were easily 
discernible from the sham or naive rats. 
The semi blind nature of the study would not change the interpretation of the data, due to 
the fact that the behavioral differences, NIR fluorescence intensity differences and histological 
differences observed between the CCI and control groups were robust and would be easily 
distinguishable even if it was a completely blind study. However, for the future studies, when the 
differences between the groups are subtle as may be the case with other experimental drug 
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formulations, a blind study would be very useful and is highly recommended. This is feasible by 
blinding the researcher for the type of nanoemulsion being used during the study.  Furthermore, 
when possible a working group of two should be employed.  For example, one investigator could 
recover the CCI tissue for histology and have a second investigator label the tissue samples for 
their further analysis. There are other opportunities similar to this that can be employed.  
A.19 Statistical Analysis 
The statistical analysis was performed using GraphPad PRISM version 6.0e. as described 
previously in chapter 2, 3 and 4. 
 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
143
Table	A‐1:	Mean	fluorescence	intensity	of	CD68	positive	stained	slides	from	CCI	rats	
injected	with	either	theranostic	nanoemulsion	or	vehicle	nanoemulsion.	
CCI, with theranostic nanoemulsion CD68 mean fluorescence intensity CCI, with vehicle nanoemulsion CD68 mean fluorescence intensity
A1,F1, ROI 1 9.68 C1, R1, 1 14.33
A1,F1, ROI 2 20.06 C1, R1, 2 14.45
A1,F1, ROI 3 10.44 C1, R1, 3 17.05
A1,F1, ROI 4 10.18 C1, R1, 4 12.8
A1,F1, ROI 5 15.06 C1, R1, 5 15.68
A1,F1, ROI 6 15.69 C1, R1, 6 11.68
A1, F2, ROI 1 6.73 C1, R2, 1 10.71
A1, F2, ROI 2 7.43 C1, R2, 2 14.44
A1, F2, ROI 3 7.87 C1, R2, 3 19.16
A1, F2, ROI 4 10.25 C1, R2, 4 14.18
A1, F2, ROI 5 5.42 C1, R2, 5 16.43
A1, F2, ROI 6 5.47 C1, R2, 6 13.52
A1, F3, ROI 1 1.57 C1, R3, 1 14.25
A1, F3, ROI 2 2.68 C1, R3, 2 13.33
A1, F3, ROI 3 2.48 C1, R3, 3 12.27
A1, F3, ROI 4 3.68 C1, R3, 4 14.35
A1, F3, ROI 5 4.18 C1, R3, 5 13.71
A1, F3, ROI 6 3.37 C1, R3, 6 14.05
A3, F1, ROI 1 11.09 C3, R1, 1 9.07
A3, F1, ROI 2 8.53 C3, R1, 2 10.1
A3, F1, ROI 3 8.18 C3, R1, 3 11.58
A3, F1, ROI 4 15.79 C3, R1, 4 9.75
A3, F1, ROI 5 10.74 C3, R1, 5 10.47
A3, F1, ROI 6 8.09 C3, R1, 6 12.47
A3, F2, ROI 1 6.22 C3, R2, 1 26.97
A3, F2, ROI 2 7.19 C3, R2, 2 17.75
A3, F2, ROI 3 4.6 C3, R2, 3 9.98
A3, F2, ROI 4 5.78 C3, R2, 4 7.76
A3, F2, ROI 5 10.93 C3, R2, 5 9.47
A3, F2, ROI 6 5.65 C3, R2, 6 12.75
A3, F3, ROI 1 7 C4, R1, 1 10.59
A3, F3, ROI 2 10.62 C4, R1, 2 8.22
A3, F3, ROI 3 7.1 C4, R1, 3 11.52
A3, F3, ROI 4 4.64 C4, R1, 4 13.78
A3, F3, ROI 5 7.17 C4, R1, 5 10.69
A3, F3, ROI 6 3.63 C4, R1, 6 9.36
A5, F1, ROI 1 5.59 C4, R2, 1 6.94
A5, F1, ROI 2 6.17 C4, R2, 2 5.09
A5, F1, ROI 3 5.93 C4, R2, 3 6.88
A5, F1, ROI 4 8.84 C4, R2, 4 6.89
A5, F1, ROI 5 3.92 C4, R2, 5 8.48
A5, F1, ROI 6 7.37 C4, R2, 6 1.27
A5, F2, ROI 1 4.98 C4, R3, 1 13.05
A5, F2, ROI 2 4.67 C4, R3, 2 4.34
A5, F2, ROI 3 3.27 C4, R3, 3 5.43
A5, F2, ROI 4 2.57 C4, R3, 4 4.43
A5, F2, ROI 5 2.64 C4, R3, 5 12.52
A5, F2, ROI 6 4.39 C4, R3, 6 4.19
A5, F3, ROI 1 1.59
A5, F3, ROI 2 1.35
A5, F3, ROI 3 1.28
A5, F3, ROI 4 4.46
A5, F3, ROI 5 1.85
A5, F3, ROI 6 2.37
A1, A3, A5= three rats n= 54 C1, C3, C4= three rats n=48
F= Field of view F= Field of view
ROI = Region Of Interest ROI = Region Of Interest
n =  total number of ROIs n =  total number of ROIs  
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Table	A‐2:	Mean	fluorescence	intensity	of	PGE2,	CD68	and	normalized	PGE2	intensity	(ratio	
of	PGE2	MFI	and	CD68	MFI)	for	CCI	rats	injected	with	theranostic	and	vehicle	
nanoemulsion.	
CCI, with theranostic nanoemulsion PGE2 MFI CD68 MFI Ratio of PGE2: CD68 MFI CCI, with vehicle nanoemulsion PGE2 MFI CD68 MFI Ratio of PGE2: CD68 MFI
A1, F1, M1 33.56 33.41 1.004 C1, F1, M1 66.89 56.74 1.179
A1, F1, M2 24.09 41.6 0.579 C1, F1, M2 61.79 49.52 1.248
A1, F1, M3 55.12 22.24 2.478 C1, F1, M3 62.45 67.05 0.931
A1, F1, M4 31.75 78.03 0.407 C1, F1, M4 70.35 94.8 0.742
A1, F1, M5 46.58 34.45 1.352 C1, F1, M5 64.42 52.48 1.228
A1, F2, M1 20.01 78.47 0.255 C1, F2, M1 55.43 46.52 1.192
A1, F2, M2 61.5 101.7 0.605 C1, F2, M2 62.37 66.79 0.934
A1, F2, M3 48.25 65.81 0.733 C1, F2, M3 59.99 55.4 1.083
A1, F2, M4 68.82 39.96 1.722 C1, F2, M4 50.01 52.04 0.961
A1, F2, M5 36.26 75.11 0.483 C1, F2, M5 54.19 34.11 1.589
A1, F3, M1 58.59 70.74 0.828 C1, F3, M1 52.1 32.44 1.606
A1, F3, M2 48.84 40.07 1.219 C1, F3, M2 63.32 35.63 1.777
A1, F3, M3 37.98 38.66 0.982 C1, F3, M3 58.57 53.75 1.09
A1, F3, M4 28.94 41.3 0.701 C1, F3, M4 66.53 66.75 0.997
A1, F3, M5 17.53 48.6 0.361 C1, F3, M5 46.95 44.6 1.053
A3, F1, M1 13.38 38.73 0.345 C1, F4, M1 114.98 65.07 1.767
A3, F1, M2 21.86 31.55 0.693 C1, F4, M2 107.15 77.2 1.388
A3, F1, M3 29.75 80.61 0.369 C1, F4, M3 120.11 53 2.266
A3, F1, M4 19.48 37.12 0.525 C1, F4, M4 94.12 73.27 1.285
A3, F1, M5 24.81 58.04 0.427 C1, F4, M5 148.45 94.59 1.569
A3, F2, M1 24.63 26.64 0.925 C1, F5, M1 157.09 97.09 1.618
A3, F2, M2 16.33 48.88 0.334 C1, F5, M2 154.41 139.67 1.106
A3, F2, M3 24.26 58.55 0.414 C1, F5, M3 96.77 53.85 1.797
A3, F2, M4 14.9 53.61 0.278 C1, F5, M4 89.34 52.17 1.712
A3, F2, M5 11.34 23.97 0.473 C1, F5, M5 74.3 52.3 1.421
A3, F3, M1 19.83 41.05 0.483 C3, F1, M1 37.53 85.79 0.437
A3, F3, M2 29.81 69.71 0.428 C3, F1, M2 23.74 32.94 0.721
A3, F3, M3 28.64 39.15 0.732 C3, F1, M3 29.4 65.05 0.452
A3, F3, M4 20.15 35.83 0.562 C3, F1, M4 24.23 103.76 0.234
A3, F3, M5 21.75 54.77 0.397 C3, F1, M5 27.93 54.87 0.509
A5, F1, M1 15.83 29.61 0.535 C3, F2, M1 33.25 74.07 0.449
A5, F1, M2 23.68 38.14 0.621 C3, F2, M2 26.75 46.97 0.57
A5, F1, M3 14.36 37.47 0.383 C3, F2, M3 31.8 60.44 0.526
A5, F1, M4 35.1 102.9 0.341 C3, F2, M4 24.31 46.2 0.526
A5, F1, M5 21.48 38.07 0.564 C3, F2, M5 23.54 82.57 0.285
A5, F2, M1 22.01 25.59 0.86 C4, F1, M1 71.74 41.49 1.729
A5, F2, M2 20.18 45.42 0.444 C4, F1, M2 32.2 46.69 0.69
A5, F2, M3 21.57 34.93 0.618 C4, F1, M3 53.69 93.62 0.573
A5, F2, M4 16.51 37.32 0.442 C4, F1, M4 50.98 30.93 1.648
A5, F2, M5 15.13 47.61 0.318 C4, F1, M5 60.65 49.73 1.22
A5, F3, M1 16.46 62.38 0.264 C4, F2, M1 28.81 56.71 0.508
A5, F3, M2 22.67 94.02 0.241 C4, F2, M2 30.79 42.21 0.729
A5, F3, M3 16.48 36.5 0.452 C4, F2, M3 35.89 39.93 0.899
A5, F3, M4 16.13 42.16 0.383 C4, F2, M4 27.98 57.81 0.484
A5, F3, M5 13.64 27.75 0.492 C4, F2, M5 27.57 34.54 0.798
C4, F3, M1 53.25 54.96 0.969
n = 45 C4, F3, M2 47.49 60.07 0.791
A1, A3, A5 = Three rats C4, F3, M3 52.09 51.01 1.021
F =  Field of view C4, F3, M4 49.72 32.51 1.529
M = Individual macrophages C4, F3, M5 39.42 42.21 0.934
n =  total number of macrophages
MFI= Mean fluorescence intensity n = 50
C1,C3, C4 = Three rats
F =  Field of view
M = Individual macrophages
n =  total number of macrophages
MFI= Mean fluorescence intensity 	
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Table	A‐3:	Mean	fluorescence	intensity	of	COX‐2,	CD68	and	normalized	COX‐2	intensity	
(ratio	of	COX‐2	MFI	and	CD68	MFI)	for	CCI	rats	injected	with	theranostic	and	vehicle	
nanoemulsion.	
CCI with theranostic nanoemulsion COX2 MFI CD68 MFI Ratio of COX2: CD68 MFI CCI with vehicle nanoemulsion COX2 MFI CD68 MFI Ratio of COX2: CD68 MFI
A1, F1, M1 22.57 28.68 0.787 C1, F1, M1 61.05 58.5 1.044
A1, F1, M2 20.23 65.39 0.309 C1, F1, M2 14.34 71.57 0.2
A1, F1, M3 14.28 40.89 0.349 C1, F1, M3 26.88 78.49 0.342
A1, F1, M4 12.42 49.18 0.253 C1, F1, M4 32.16 37.32 0.862
A1, F1, M5 12.03 71.58 0.168 C1, F1, M5 30.4 46.22 0.658
A1, F2, M1 11.41 48.5 0.235 C1, F2, M1 26.2 52.92 0.495
A1, F2, M2 5.8 25.75 0.225 C1, F2, M2 10.64 35.25 0.302
A1, F2, M3 6.15 52.43 0.117 C1, F2, M3 24.78 51.5 0.481
A1, F2, M4 11.61 53.33 0.218 C1, F2, M4 16.96 33.22 0.511
A1, F2, M5 6.14 32.28 0.19 C1, F2, M5 30.85 63.95 0.482
A1, F3, M1 7.09 16.28 0.436 C1, F3, M1 25.45 42.47 0.599
A1, F3, M2 4.74 76.85 0.062 C1, F3, M2 16.62 68.27 0.243
A1, F3, M3 5.72 42.04 0.136 C1, F3, M3 25.28 57.69 0.438
A1, F3, M4 7.71 50.32 0.153 C1, F3, M4 21.55 39.44 0.546
A1, F3, M5 3.62 16 0.226 C1, F3, M5 14.62 46.6 0.314
A3, F1, M1 9.63 64.16 0.15 C3, F2, M1 15.86 24.09 0.658
A3, F1, M2 25.69 48.26 0.532 C3, F2, M2 30.78 42.57 0.723
A3, F1, M3 17.78 59.18 0.3 C3, F2, M3 28.68 26.65 1.076
A3, F1, M4 15.73 128.92 0.122 C3, F2, M4 15.53 46.88 0.331
A3, F1, M5 18.23 98.06 0.186 C3, F2, M5 23.08 49.05 0.471
A3, F2, M1 11.05 39.6 0.279 C3, F1, M1 15.85 78.22 0.203
A3, F2, M2 11.73 37.32 0.314 C3, F1, M2 15.48 59.37 0.261
A3, F2, M3 11.04 35.86 0.308 C3, F1, M3 12.7 49.69 0.256
A3, F2, M4 5.9 33.64 0.175 C3, F1, M4 13.37 59.13 0.226
A3, F2, M5 8 27.82 0.288 C3, F1, M5 18.04 37.15 0.486
A3, F3, M1 4 39.29 0.102 C4, F1, M1 23.95 51.62 0.464
A3, F3, M2 5.73 74.04 0.077 C4, F1, M2 47.86 48.84 0.98
A3, F3, M3 6.27 34.74 0.18 C4, F1, M3 23.7 79.84 0.297
A3, F3, M4 10.4 24.66 0.422 C4, F1, M4 39.55 44.19 0.895
A3, F3, M5 10.77 51.67 0.208 C4, F1, M5 19.5 48.78 0.4
A5, F1, M1 14.95 23.92 0.625 C4, F2, M1 16.52 47.84 0.345
A5, F1, M2 11.09 77.96 0.142 C4, F2, M2 14.01 38.51 0.364
A5, F1, M3 12.78 47.58 0.269 C4, F2, M3 7.86 30.46 0.258
A5, F1, M4 9 57.41 0.157 C4, F2, M4 40.59 70.53 0.575
A5, F1, M5 11.88 38.12 0.312 C4, F2, M5 20.68 84.34 0.245
A5, F2, M1 7.03 41.48 0.169 C4, F3, M1 17.73 33.1 0.536
A5, F2, M2 3.98 26.34 0.151 C4, F3, M2 21.24 45.06 0.471
A5, F2, M3 4.88 46.09 0.106 C4, F3, M3 12.89 24.44 0.527
A5, F2, M4 4.77 20.7 0.23 C4, F3, M4 21.9 22.24 0.985
A5, F2, M5 7.31 35.07 0.208 C4, F3, M5 15.62 23.37 0.668
A5, F3, M1 4.18 20.52 0.204
A5, F3, M2 2.83 16.01 0.177 n = 40
A5, F3, M3 2.28 19.83 0.115
A5, F3, M4 7.97 26.8 0.297
A5, F3, M5 5.14 35.42 0.145
C1,C3, C4 = Three rats
A1, A3, A5 = Three rats n = 45 F =  Field of view
F =  Field of view M = Individual macrophages
M = Individual macrophages n =  total number of macrophages
n =  total number of macrophages MFI= Mean fluorescence intensity
MFI= Mean fluorescence intensity 	
	
 
